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Abstract 
Since their discovery over five decades ago, quinolone antibiotics have found enormous success 
as broad spectrum agents that exert their activity through dual inhibition of bacterial DNA gyrase 
and topoisomerase IV. Increasing rates of resistance, driven largely by target-based mutations in 
the GyrA/ParC Quinolone Resistance Determining Region, have eroded the utility and threaten 
the future use of this vital class of antibiotics. Herein we describe the discovery and optimization 
of a series of 4-(aminomethyl)quinolin-2(1H)-ones, exemplified by 34, that inhibit bacterial DNA 
gyrase and topoisomerase IV and display potent activity against ciprofloxacin-resistant Gram-
negative pathogens. X-ray crystallography reveals that 34 occupies the classical quinolone binding 
site in the topoisomerase IV-DNA cleavage complex, but does not form significant contacts with 
residues in the Quinolone Resistance Determining Region. 
Introduction 
Quinolone antibiotics trace their history to two parallel discovery efforts at Imperial Chemical 
Industries (ICI) and Sterling Drug over 50 years ago.1  From these landmark studies emerged one 
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of the most successful classes of antibacterial agents with nearly 30 analogs approved for clinical 
use, and more still in the pipeline at various pharmaceutical companies.2-8  
Quinolone antibiotics exert their activity by binding to and stabilizing DNA cleavage complexes 
formed by two essential bacterial enzymes: DNA gyrase and topoisomerase IV. This results in 
blockade of DNA replication. Subsequent downstream events lead to induction of the SOS 
response, chromosome fragmentation and cell death.9, 10 Structural characterization of DNA-
enzyme-quinolone ternary complexes has revealed that quinolones intercalate between DNA base 
pairs at two neighboring cleavage sites in the gyrase or topoisomerase IV heterotetramer 
complex.11-13 Additional studies support a binding mode in which the keto-acid functionality of 
bound quinolones is chelated to a Mg2+ cation which in turn forms water mediated hydrogen bonds 
to residues in the quinolone resistance determining region (QRDR) of GyrA and ParC (e.g., Ser83 
and Asp87 in Escherichia coli GyrA).14-18 This interaction appears to be critical for the quinolone 
mechanism of action and may account for the fact that, despite 50 years of medicinal chemistry 
research, the overwhelming majority of quinolone antibiotics retain a carbonyl at C4 and 
carboxylate at C3 (as suggested by Wohlkonig et al).14 In fact, this arrangement of substituents at 
C3 and C4 has been widely regarded as optimal and essential for the antibacterial activity of 
quinolones.19 As with all classes of antibiotics, resistance to quinolones has emerged and continues 
to develop. While several mechanisms have been described, a major driver of high-level resistance 
is amino acid substitutions in DNA gyrase and topoisomerase IV at residues that are responsible 
for mediating the water-metal ion bridge interaction described above.20 As a result, the current and 
long-term utility of quinolones for treatment of many infections caused by both Gram-positive and 
Gram-negative bacteria has already been eroded.21 
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The global problem of antibiotic resistance and the need for new and effective antibiotic drug 
candidates is well-documented.22-28 Bacterial DNA gyrase and topoisomerase IV are clinically 
validated targets for chemotherapy, and quinolone antibiotics possess many attractive features 
including bactericidal activity against a broad spectrum of pathogens, rapid killing kinetics and 
oral bioavailability. As such, there is significant interest in identifying inhibitors of these enzymes 
that are able to overcome target-based resistance to quinolones.29-31 In a series of seminal 
publications and patents Pfizer described the discovery and optimization of 3-
aminoquinazolinediones32-34 (e.g., compound 2, Figure 1) that are capable of binding to and 
stabilizing DNA gyrase/topoisomerase IV cleavage complexes in the absence of the key water-
metal ion bridge interaction that characterizes classical quinolone binding.14-18, 35, 36 Lead 
compounds in this series exhibited little or no cross-resistance with quinolones. Importantly, these 
results demonstrated that the C3 carboxylate/C4 carbonyl arrangement present in nearly all 
quinolone antibiotics (see ciprofloxacin, Figure 1) is not strictly required for antibacterial activity. 
More recently, researchers from the Innovative Medicines Initiative European Gram-Negative 
Antibacterial Engine (IMI-ENABLE) consortium reported a series of imidazopyrazinones (IPYs) 
that target the quinolone binding pocket of bacterial DNA gyrase and topoisomerase IV without 
formation of the water-metal ion bridge.37, 38 Representative compounds from this series showed 
partial cross-resistance with quinolones. Interestingly, the influence of QRDR mutations on the 
activity of IPYs was found to be intermediate between 3-aminoquinazolinediones and quinolone 
antibiotics. 
Within Novartis, antibacterial drug discovery efforts were broadly focused on pathogens and 
resistance phenotypes identified as major threats to human health by the Centers for Disease 
Control and Prevention (CDC) and the World Health Organization (WHO).22, 23 As a part of these 
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efforts, we initiated an early stage medicinal chemistry program around compound 3 (Figure 1), 
which was identified as a hit during phenotypic screening for inhibitors of bacterial cell growth. 
Target identification efforts indicated that compounds in this series were inhibitors of DNA 
gyrase/topoisomerase IV, however the SAR proved to be extremely steep and we were unable to 
improve antibacterial potency to levels sufficient for a lead optimization program. The structural 
similarity to Pfizer’s quinazolinediones, however, led us to consider a scaffold-morphing approach 
with the classical quinolone scaffold (e.g., 1, ciprofloxacin).39  
Structural and biochemical studies with quinazolinediones suggest that while this chemotype is 
incapable of forming a water-metal ion bridge with the target enzymes, it derives potency and 
affinity through additional interactions around the C7 amine moiety and a hydrogen bond between 
the C2 carbonyl oxygen and Arg117 (Streptococcus pneumoniae ParC numbering).12, 35, 36 We 
hypothesized that by simply moving the C4 carbonyl of quinolones such as 1 to the C2 position 
(e.g., 4, Figure 1), we would be able to generate compounds that take advantage of similar 
interactions and thus retain potency against both wild type (WT) and quinolone-resistant bacteria. 
We further postulated that completely removing the C3 carboxylate (e.g., 5, Figure 1) could 
generate compounds that make no binding interactions at all with the GyrA/ParC QRDR region. 
Importantly, if this strategy proved successful it would provide a unique opportunity to explore 
SAR at the C3 and C4 positions of the quinolone scaffold which have remained largely untouched 
over 50 years of research.19  
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Figure 1. Structures of the fluoroquinolone antibiotic ciprofloxacin, quinazolinedione                     
PD 0305970 (Pfizer), Novartis phenotypic hit 3 and initial lead compounds 4 and 5. 
Results and Discussion 
SAR Development of the Quinolin-2(1H)-one Scaffold Our efforts commenced with the 
synthesis and profiling of compounds 4 and 5. Biochemical assays were established that used size-
exclusion chromatography to monitor the introduction of supercoils into relaxed DNA and 
decatenation of kinetoplast DNA by E. coli DNA gyrase and topoisomerase IV respectively (see 
Experimental Section for details). Against DNA gyrase from E. coli, compound 4 was less potent 
than both ciprofloxacin (1) and PD 0305970 (2), while 5 (which lacks the C3 carboxylic acid) 
exhibited potency more comparable to 1 and 2 (Table 1). Against E. coli topoisomerase IV, 
compound 5 was again more potent than 4 and approached the activity seen with compound 2. 
Against a selection of clinically relevant Gram-negative bacteria, compounds 4 and 5 exhibited 
encouraging levels of cell growth inhibition (Table 1). Robust activity was observed, in particular, 
against E. coli and Klebsiella pneumoniae. Importantly, both 4 and 5 exhibited a minimal shift in 
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MIC against an engineered efflux-deficient Pseudomonas aeruginosa strain harboring QRDR 
mutations in gyrase and topoisomerase IV (MIC values increased by 8X for 4 and 2X for 5 
compared to 128X for ciprofloxacin). However, there was clearly a significant loss of intrinsic 
cellular activity for compounds 4 and 5 relative to fluoroquinolones such as ciprofloxacin (1). We 
thus embarked upon a program that was focused upon optimization of activity against Gram-
negative bacteria. 




 1          2  4  5   
Biochemical 
IC50 (µM) 
E. coli Gyrase  0.49 0.20 2.91 0.43 
E. coli Topo IV  2.71 0.22 4.80 0.39 
MIC 
(µg/mL) 
E. coli WT 0.008 1 4 1 
K. pneumoniae WT 0.03 2 8 4 
P. aeruginosa WT 0.125 4 32 16 
P. aeruginosa ΔmexB/ΔmexX 0.03 1 8 4 
P. aeruginosa ΔmexB/ΔmexX FQ-Ra  4 2 64 8 
a GyrA T83I, ParC S87L 
 
Historically, achieving sufficient cellular activity against Gram-negative bacteria has been one 
of the major hurdles limiting the success of many preclinical antibacterial research programs.40-42 
This is due in part to the complexity of the Gram-negative cell envelope which includes an outer 
membrane that restricts permeation of large and/or lipophilic molecules and an inner membrane 
that opposes influx of more polar molecules. These physical barriers work in concert with multi-
drug efflux pumps to create a significant barrier to the accumulation of small molecule drugs in 
Gram-negative microorganisms.43-51 This is a particularly acute problem for inhibitors that must 
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reach targets within the cytoplasm. Simultaneous optimization of cell permeability, efflux, on-
target potency and drug-like properties continues to be a major challenge for the field.52-57  
With this in mind, compound 5 was selected as the starting point for our efforts based on its 
superior baseline cellular activity and reduced impact of QRDR mutations on antimicrobial 
activity relative to 4. Compound 5 also provided a unique opportunity to explore SAR at both the 
C3 and C4 positions of the scaffold. At the time this work was initiated there was scant knowledge 
about the characteristics of this region of the binding pocket in the absence of the water-metal ion 
bridge since the Pfizer quinazolinedione series maintained a C4 carbonyl group. 
Small lipophilic substituents such as chlorine were well tolerated at C4 (e.g., 6, Table 2), 
however compound 7 was substantially less active. The latter may be ascribed to the relatively 
acidic nature and hydration of the hydroxyl (pKa = 5.7), which unlike the carboxylic acid of 4 
cannot be masked by an internal hydrogen bond to the C2 carbonyl and may contribute to poor 
inner membrane permeability. Alternatively, while spectroscopic data for compound 7 was 
qualitatively similar to related C4-O-alkoxy derivatives, we cannot rule out the possibility that the 
C2-hydroxy/C4-carbonyl tautomer of 7 could exist in the bacterial cellular environment, and may 
contribute to the poor antibacterial activity observed. Capping the hydroxyl of 7 with a methyl 
group (8) restored some potency, while the nitrile (9) was 2-4 fold more potent against Gram-
negative bacteria than compound 5. The corresponding aminomethyl analog 10, accessed by 
reduction of the nitrile, proved to be the most potent compound of the series. The introduction of 
a second, weakly basic amine at C4 often served to improve Gram-negative potency, particularly 
against P. aeruginosa (see Table 4 for additional examples of this effect). MIC values for 10 and 
related analogs against E. coli ΔacrB revealed a moderate efflux liability that was later partially 
addressed through modifications at the C7 position (see Table 4 below). Replacing the C4 amine 
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with an alcohol (11) was detrimental to antibacterial activity and appeared to further increase 
susceptibility to efflux in E. coli. The weakly basic amine could, however, be accommodated on a 
longer chain which presumably projects further into the binding pocket without significant loss of 
potency (12). A carboxylic acid (13) was deleterious to antimicrobial activity, possibly due to poor 
inner membrane permeability (carboxylate pKa = 2.2). While smaller substituents at C4 were 
generally preferred for Gram-negative antibacterial activity, some larger groups were tolerated as 
exemplified by 14, which retained some weak activity against E. coli WT. 
 
Table 2. Antibacterial SAR at position 4 of the quinolin-2(1H)-one scaffold.  
 























1 0.06 4 16 4 8 
6  
 
2 0.06 4 8 4 8 
7  
 
>32 16 >32 >32 >32 >32 
8  
 




1 0.03 2 4 1 1 
10  
 
1 0.06 4 2 0.5 2 
11  
 
16 0.25 32 16 4 8 
12  
 
1 - 4 8 4 8 
13  
 
>32 - >32 >32 >32 >32 
14  
 
8 - 32 >32 8 32 
a GyrA T83I, ParC S87L 
 
Upon additional profiling of compound 10 it became apparent that the advantages conveyed by 
the presence of a weakly basic amine at C4 extended beyond an improvement in Gram-negative 
antibacterial potency. Relative to compound 5, 10 displayed improved solubility and a reduction 
in plasma protein binding and hERG inhibition (Table 3). Both compounds exhibited low to 
moderate intrinsic clearance in liver microsomes, however 10 suffered from reduced permeability 
across mammalian cell membranes as gauged by CACO-2 Papp. Despite this, the aminomethyl 
substituent at C4 appeared to provide a good balance of potency and in vitro properties, prompting 






Table 3. In vitro profile of compounds 5 and 10.  
 
5 10 
logD7.4 0.74 -0.29 
Solubility (µg/mL, PBS) 498 >555 
Plasma Protein Binding            
(% bound, mouse/rat/human) 
81/75/90 56/18/17 
hERG IC50 (µM) 48.8
a >300b 
CACO-2 Papp A-B (efflux ratio) 16.7 (1.5) 0.44 (18) 
CLint in Liver Microsomes 
(µL/min/mg, rat/human) 
10 / <7.7 <7.7 / 14 
a Determined using manual patch clamp electrophysiology (see Experimental Section for 
details). b Determined using QPatch automated electrophysiology (see Experimental Section for 
details). 
 
The C7 position of the classical quinolone scaffold is remarkably tolerant of a wide variety of 
substituents. Similarly, we found the C7 position of our scaffold to be more tolerant of structural 
changes than other positions. However, the scope of substituents that provided highly active 
compounds was significantly smaller than that described for quinolone antibiotics.  
In general, substituted pyrrolidines proved to be the most suitable substituents at C7. 3S-
aminopyrrolidine 15 was almost equally active relative to 10, however inversion of the amine 
stereocenter resulted in ≥4-fold loss of in vitro potency (16, Table 4). Hydroxypyrrolidine 17 was 
also well tolerated and provided a boost in potency against E. coli and K. pneumoniae. An 
unsubstituted pyrrolidine at the C7 position provided a compound (18) with comparable potency 
against E. coli and K. pneumoniae but substantially reduced activity against P. aeruginosa.  
Aromatic substituents (e.g., 19) often provided potent compounds but this came at the expense of 
higher logD7.4 and poor solubility (data not shown). Compounds 18 and 19 support the observation 
that compounds with only a single basic amine often exhibited reduced activity against P. 
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aeruginosa compared to compounds with two (e.g., 10) despite equal or better activity against E. 
coli. Six-membered saturated rings (e.g., piperazine, compound 20) offered no improvement in 
antimicrobial activity despite the fact that this group is present in ciprofloxacin. This result 
suggested a divergence in SAR from known quinolone antibiotics. A minor breakthrough was 
realized with the identification of [3.1.0] bicyclic amines 21 and 22, which were the most potent 
compounds of this series against E. coli. Compound 21 also showed reduced susceptibility to 
efflux relative to 10 as evidenced by a 4-fold shift between MIC values against E. coli WT and 
ΔacrB (compared to 16-fold for 10). Further modification of the [3.1.0] azabicyclic moiety 
generally led to loss of antibacterial activity, which was strongly dependent on appropriate 
positioning of the amine. For example, the related [4.1.0] and [3.2.0] bicyclic amines (23 and 24) 
were much less potent, and moving the amine to alternate locations on the [3.1.0] ring system 
provided similar results (25-26). Given the comparable in vitro activity of 21 and 22, we elected 













Table 4. Antibacterial SAR at position 7 of the quinolin-2(1H)-one scaffold.  
 
  MIC (µg/mL) 
























2 0.5 2 4 0.5 2 
16  
 
16 2 8 >32 8 32 
17  
 
0.5 0.03 1 4 0.25 1 
18 
  
1 0.06 2 32 4 8 
19  
 




4 1 2 8 1 2 
21  
 
0.25 0.06 0.5 4 0.5 1 
22  
 
0.125 0.03 0.25 4 1 2 
23  
 
4 1 4 16 4 16 
24  
 
2 0.25 4 8 2 4 
25  
 
8 1 32 32 4 16 
26  
 
1 0.25 4 16 1 2 
a GyrA T83I, ParC S87L 
 
With an optimized C7 moiety established, we explored the C3 and C8 positions in the hope of 
deriving additional antibacterial potency. Removal of the methyl group from the C8 position 
resulted in a 4-fold reduction in potency (27, Table 5), and switching the methyl group for other 
small, polar groups provided similar results (28-30). The C3 position was tolerant of a variety of 
small substituents including CH3, Cl and OH (although activity was lost with groups larger than 
CH3). However, addition of a fluorine substituent led to a further 4 to 8-fold improvement in the 
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MICs against WT E. coli, K. pneumoniae and P. aeruginosa (34). Whether this improvement in 
activity was due to an increase in on-target potency, an increase in intracellular accumulation, or 
a combination of both factors was not immediately clear.  
 
Table 5. Optimization of substitution at positions 3 and 8 of the quinolin-2(1H)-one scaffold.  
 
    MIC (µg/mL) 




















20  H H CH3 0.25 0.06 0.5 4 0.5 1 
27  H H H 1 0.5 4 16 2 4 
28  H H CN 1 0.125 2 16 2 4 
29  CH3 H OCH3 1 0.25 4 32 8 16 
30  H H OCF2H 2 1 8 >32 8 32 
31  H CH3 CH3 0.25 0.125 1 8 1 2 
32    H OH CH3 0.5 0.25 1 2 0.5 2 
33  H Cl CH3 0.25 0.06 0.5 8 1 2 
34  H F CH3 0.06 0.03 0.125 1 0.25 0.5 
a GyrA T83I, ParC S87L 
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Structural Characterization of the Binding Mode of 34 to K. pneumoniae topoisomerase IV 
During the course of the optimization campaign, we developed a co-crystallization system with 
topoisomerase IV from K. pneumoniae. Topoisomerase IV is a tetrameric enzyme formed by two 
ParC and two ParE subunits. For structural studies, we followed a previously employed approach 
to generate a fusion protein, ParE-ParC, from the respective subunits of K. pneumoniae.18 The 
resulting single polypeptide is a fusion protein from the C-terminal portion of the ParE (residues 
390-631) and N-terminal portion of the ParC (residues 1-490) subunits of K. pneumoniae 
topoisomerase IV.18 This enabled us to solve several co-crystal structures with inhibitor and DNA 
bound, including compound 34 (Figure 2 and Supplementary Figures 1 and 2). The DNA duplex 
was an uninterrupted 26-mer of the symmetrized E-site DNA.18 Because of the size and inherent 
flexibility of the complex, achieving near-atomic level diffraction proved very challenging and 
most data sets had diffraction limits between 3-3.50 Å.   
The complex formed between the ParE-ParC fusion protein, the homoduplex DNA and 
compound 34 resulted in crystals that diffracted to 3.20 Å resolution and contained two copies of 
a ParE-ParC fusion protein dimer in the asymmetric unit, each bound to one homoduplex DNA. 
Unbiased electron density for compound 34 was observed in all four compound binding sites 
(Supplementary Figure 1). The following description is based on observations made of the 
compound binding site with the best electron density. Only small variations in the binding mode 
are observed in the other copies present in the asymmetric unit.   
Inspection of the electron density revealed that 34 occupies the quinolone binding site as 
expected with the compound intercalating between base pairs and stabilizing the cleaved DNA. A 
covalent phosphotyrosine bond was observed between the catalytic Tyr120 of ParC and the 5′-
phosphate of the bound DNA at the break site, thus affording a view of the biologically relevant 
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cleavage complex (in contrast to structures of ternary complexes formed with pre-cut DNA; see 
D. A. Veselkov et al.18 for a comparison of structures solved with intact and pre-cut DNA). Binding 
affinity for compound 34 is driven in part by π-stacking interactions with the base pairs located 
above and below the ligand. A number of suboptimal intermolecular interactions between 34 and 
neighboring residues of topoisomerase IV are also present, generally characterized by relatively 
large interatomic distances. The C2 carbonyl oxygen is posed to interact with the side chain of 
Arg119 (ParC subunit), similar to the reported S. pneumoniae topoisomerase IV-DNA co-structure 
with  PD 0305970.12 In this case, however, the interatomic distance is too long to invoke a 
productive interaction. The C4 aminomethyl substituent occupies a relatively open portion of the 
binding pocket that would normally accommodate the water-metal ion bridge interaction involved 
in classical fluoroquinolone binding. Only poor electron density is observed for the C4 
aminomethyl substituent, which does not permit placing this group accurately and therefore no 
direct intermolecular interactions can be postulated. No specific interactions were observed 
between the nearby C3 fluorine atom and the protein, however its close proximity to Ser80 of ParC 
could explain the detrimental effect of a larger substituent at this position. It is possible that the 
fluorine atom contributes to an improved stacking interaction with DNA through electronic effects 
on the quinolin-2(1H)-one core, which would explain the boost in potency conveyed by that 
substituent. With respect to the crucial C7 amine, the moderate resolution of the structure (3.2 Å) 
meant that the preferred stereochemistry and precise orientation was difficult to determine. Finally, 
the primary amine is positioned to form weak interactions with the backbone carbonyl of K442 
and the side chain of E461 (ParE subunit). The boost in potency observed for the [3.1.0] bicyclic 
group (as compared to a simple aminopyrrolidine such as 15, for example) is potentially driven by 
a conformational preference that places the primary amine in an optimal location for binding. 
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However, improved bacterial inner membrane permeability due to the reduced pKa of the amine 
may also have a significant impact.  
 
Figure 2. Binding site view of the topoisomerase IV cleavage complex from K. pneumoniae with 
compound 34 bound (PDB ID: 6WAA). DNA nucleotides of the cleavage site are shown in gray. 
ParC and ParE residues of one ParE-ParC fusion protein are shown in green and cyan, respectively. 
ParC residues from the second ParE-ParC fusion protein, which provide the catalytic tyrosine, are 
shown in magenta. Residues further out from the binding site were omitted for clarity. 
In Vitro ADMET Profile of Compound 34 Further in vitro profiling data for 34 is shown in 
Table 6. Biochemical activity against DNA gyrase and topoisomerase IV from E. coli was 
comparable to ciprofloxacin and well balanced (IC50 = 1.25 and 0.81 µM respectively). The two 
amines proved to be weakly basic as expected with experimentally determined pKa values of 8.0 
and 7.6. Over the course of our optimization effort, this pKa range was generally associated with 
good Gram-negative antibacterial potency. Solubility and plasma protein binding values were 
comparable to clinically used fluoroquinolone antibiotics. Importantly, 34 displayed CACO-2 
permeability that was significantly higher than starting point 10, likely driven by a reduction in the 
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amine pKa of the C7 moiety and an associated increase in logD7.4. Unfortunately, it appeared that 
this increase in lipophilicity was also associated with a reduction in microsomal stability 
(particularly in rat microsomes) and a marginal in vitro safety profile.  
Compound 34 was found to exhibit moderate levels of cytotoxicity against three human cell 
lines (EC50 = 82, 40 and 29 µM respectively against HepG2, K562 and MT4 cells). Further in vitro 
evaluation of 34 for phototoxicity potential using the 3T3 neutral red uptake (NRU) test produced 
a photo-irritation factor (PIF) value of 621. The measured cellular IC50 in the presence of 
irradiation with simulated sunlight was 1.61 µM, while in the absence of irradiation the IC50 
exceeded the solubility limit of the compound (1000 µM). The solubility limit was thus used in 
lieu of a measured IC50 in the absence of irradiation to calculate the PIF (PIF = IC50(-irr)/ IC50(+irr)). 
While a PIF value of 621 was considered high, it also reflected the very high solubility of 
compound 34. Although 34 was not evaluated in vivo for phototoxicity, Schümann et al. have 
demonstrated that for a range of systemic drug candidates, the probability of in vivo phototoxicity 
correlates well with the magnitude of the PIF value obtained from the 3T3 NRU assay.58 Notably, 
this study made use of the fluoroquinolone sparfloxacin as a positive control. Sparfloxacin 
produced an in vitro PIF value of >82 and was found to produce significant and dose-dependent 
phototoxicity in mice. Phototoxicity has also been observed clinically with a number of 
fluoroquinolones, and has severely limited the use of certain members of this class (e.g., 
clinafloxacin, sparfloxacin).59, 60  
Fluoroquinolones exhibit a range of photochemical activation and degradation pathways that 
depend strongly on substitution pattern and on the reaction medium.61 It has been suggested that 
fluoroquinolone phototoxicity may be caused by toxic photochemical degradation products, the 
generation of reactive oxygen species, or reactive intermediates such as aryl cations (arising from 
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dehalogenation) and/or radicals (arising from oxidation reactions induced by fluoroquinolones in 
the triplet state).62-64 Compared with quinolones that have a single fluorine at the C6 position, 
difluorinated quinolones (i.e. fluorine at C6 and C8) are markedly more photolabile, with 
unimolecular defluorination constituting a major photodegradation pathway. The pendant alkyl 
groups at C7 and N1 can also participate in secondary intramolecular reactions with excited state 
species and reactive intermediates, thereby influencing the photochemical fate of quinolones.  
Without further experimental data it is not possible to confirm if compound 34 exhibits 
comparable photochemical reactivity patterns. However, in order to derive additional SAR around 
phototoxicity for this series, compounds 15 and 21 were evaluated in the 3T3 NRU test. Compound 
21, which lacks the C3 fluorine atom present in 34, produced a PIF value of 104. Like 34, the IC50 
of 21 in the absence of irradiation exceeded the solubility limit of the compound (316 µM). In the 
presence of irradiation, however, compound 21 produced an IC50 of 3.03 µM, only marginally 
higher than 34 (IC50(+irr) = 1.61 µM). Interestingly, compound 15, which lacks the C3 fluorine and 
features a simple 3-aminopyrrolidine at C7, produced a PIF value of 1.7 (IC50(+irr) = 288 µM). Thus, 
it appears that phototoxicity of this series (as assessed by the 3T3 NRU test) is strongly influenced 
by the nature of the C7 substituent and to a lesser extent by halogenation at C3. 
Compound 34 also exhibited increased hERG channel inhibition relative to 10 (IC50 = 114 µM 
compared to >300 µM).65 Like the in vitro phototoxicity results, the observed in vitro hERG 
inhibition data was viewed with some concern given the clinical history of certain members of the 
quinolone class. Moxifloxacin, for example, has a similar reported hERG IC50 and produces QT 
prolongation in humans at therapeutic doses.66-68 Based on reported data for fluoroquinolones, we 
anticipated that the plasma free Cmax for an efficacious gyrase/topoisomerase IV inhibitor would 
be roughly 5-10 µM. A hERG IC50 of 114 µM would thus fall significantly short of the preferred 
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100-fold safety margin.69 Many compounds in this series (including compound 34), feature a basic 
amine flanked by a lipophilic aromatic group, which broadly fits the accepted hERG 
pharmacophore model for channel blockers. The reduced hERG inhibition exhibited by compound 
10 is likely driven by reduced lipophilicity (logD7.4 = -0.29 for 10, compared with 1.1 for 34). 
Increasing polarity represents a reasonable strategy for addressing hERG inhibition in future 
analogs, and one which has been applied successfully in the context of many drug discovery 
efforts.70 Other well-known strategies, including removal of basic amines and aromatic groups, 
reduction of amine pKa, and introduction of acidic groups (c.f. fluoroquinolones) may also be 
successful in reducing hERG inhibition, but come with the risk of undesirable effects on other 
compound properties (e.g. antibacterial activity, solubility, lipophilicity and fluoroquinolone 
cross-resistance). Although analogs with improved ADMET properties were identified during the 
course of the optimization effort, we were unable to identify compounds that combined these 












Table 6. In vitro ADMET profile of 34.  
Assay 34 
E. coli Gyrase IC50 (µM) 1.25 
E. coli Topo IV IC50 (µM) 0.81 
logD7.4 1.1 
pKa 8.0, 7.6 
Solubility (µg/mL, PBS) 1276 
CLint in Liver Microsomes 
(µL/min/mg, 
mouse/rat/human) 
40 / 117 / 18 
Plasma Protein Binding       
(% bound, mouse/rat/human) 
32 / 58 / 35 
CACO-2 Papp A-B          
(cm/sec) [efflux ratio] 
10.4 [1.8] 
hERG IC50 (µM) 114a 
Cytotoxicity EC50             
(µM, HepG2 / K562 / MT4) 
82 / 40 / 29 
PIF (3T3 NRU) 621 
a Determined using QPatch automated electrophysiology with a long incubation protocol (see 
Experimental Section for details). 
Microbiological Profile Of Compound 34  Table 7 shows the microbiological profile of 34 
and ciprofloxacin against a panel of 126 clinical isolates, 70% of which were resistant to 
ciprofloxacin.71 Against Enterobacteriaceae (n = 96) 34 displayed a MIC90 of 8 µg/mL, whereas 
the ciprofloxacin MIC90 was >32 µg/mL. Against isolates of E. coli (n = 30) and K. pneumoniae 
(n = 30) MIC90 values were 2 and 16 µg/mL, respectively. This level of in vitro activity was again 
substantially better than ciprofloxacin (MIC90 = >32 µg/mL against E. coli and K. pneumoniae). 
As expected, 34 was less active against P. aeruginosa (MIC90 = 32 µg/mL). The frequency of 
single step mutant selection was low; no resistant mutants were selected when >1010 cells of E. 
coli ATCC 25922 were plated on Mueller-Hinton agar containing 2X (0.12 µg/mL), 4X (0.25 
µg/mL) or 8X (0.5 µg/mL) multiples of the MIC of compound 34 (mutant frequency <10-10). The 
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low frequency of single step resistance for 34 may reflect balanced targeting of both DNA gyrase 
and topoisomerase IV in E. coli, consistent with similar levels of activity against both enzymes in 
the biochemical assay (Table 6).72  
Table 7. Microbiological profile of 34: performance against a Gram-negative challenge panel (126 
clinical isolates, 70% ciprofloxacin-resistant).  
  MIC (µg/mL) 
Organism # isolates 
1 (ciprofloxacin) 34  
Range MIC50 MIC90 Range MIC50 MIC90 
Enterobacteriaceae* 
All species       
(96) 
≤0.03->32 8 >32 0.06->32 1 8 
E. coli             
(30) 
≤0.03->32 >32 >32 0.06-8 1 2 
K. pneumoniae 
(30) 
≤0.03->32 8 >32 0.25-32 4 16 
P. aeruginosa  30 0.125->32 8 >32 1->32 8 32 
* 6 Citrobacter spp., 10 Enterobacter spp., 30 E. coli, 30 K. pneumoniae, 5 Klebsiella oxytoca, 
4 Morganella morganii, 5 Proteus mirabilis, 6 Serratia marcescens 
 
Given the promising potency of 34 against Enterobacteriaceae, we anticipated that a primary 
indication for a putative clinical candidate would be in complicated urinary tract infections (cUTI). 
It has been shown previously that in vitro antibacterial activity of some fluoroquinolone antibiotics 
is influenced by the pH of the test medium.73 It therefore became a priority to assess the 
antibacterial activity of 34 at a slightly acidic pH in order to mimic the environment in the urinary 
tract. As shown in Table 8, ciprofloxacin is 16-fold less active against E. coli WT at pH 5.8 
compared to pH 7.4 (MIC = 0.125 µg/mL vs 0.008 µg/mL respectively). Analogs such as 5 and 
17, which feature a single basic amine, displayed a similar loss of activity at pH 5.8. Compounds 
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with two basic amines, however, were affected to a greater extent. The pH-dependent reduction of 
activity was particularly severe for 34, which was 512-fold less active against E. coli WT at pH 
5.8 compared to pH 7.4 (MIC = 32 µg/mL vs 0.06 µg/mL). Although monobasic compounds were 
more tolerant of acidic pH, such compounds had insufficient antibacterial potency and spectrum 
to be progressed further. 
Table 8. Effect of pH on antimicrobial activity of selected compounds. 
 E. coli WT MIC (µg/mL) MIC Fold 
Shift Compound pH 7.4  pH 5.8  
1 
(ciprofloxacin) 
0.008 0.125 16 
5  1 16 16 
10 1 >32 ≥64 
15 2 >32 ≥32 
17 0.5 8 16 
21 0.25 32 128 
34 0.06 32 512 
 
In Vivo Profile of Compound 34 The in vivo PK and efficacy of compound 34 is shown in 
Table 9. In both rat and mouse PK studies compound 34 exhibited moderate to high CL, consistent 
with in vitro microsomal stability results. This likely drives the low oral bioavailability observed 
with 34. However, dose-normalized oral exposure was broadly similar to ciprofloxacin, and was 
somewhat higher in mice. In a neutropenic mouse thigh infection model using fluoroquinolone-
sensitive E. coli ATCC 25922, the static dose was determined. At the initiation of therapy, mice 
had a cfu/thigh of approximately log10 6 which increased to >log10 9.5 cfu/thigh 24 hours later in 
vehicle treated animals (see Supplementary Figure 3). 34 resulted in a static dose of 45.5 
mg/kg/day compared to 6.4 mg/kg/day for ciprofloxacin. This closely parallels the difference in in 
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vitro potency (MIC) between the two compounds and demonstrates that compounds in this series 
are capable of achieving in vivo efficacy against Gram-negative bacteria.  
 
Table 9. PK and in vivo efficacy of 34 in comparison to ciprofloxacin (1).  
Pharmacokinetics (PK) 
 
1 (ciprofloxacin) 34 
Mousea Ratb Mousec Ratd 
CL (mL/min·kg) 63 40 50 71 
Vss (L/kg) 2.2 3.4 5.1 24.1 
T1/2 term. i.v. (h) 0.46 1.2 1.7 8.2 
AUC (µM·h) / dose (mg/kg) p.o. 0.13 0.29 0.31 0.10 
Cmax (µM) / dose (mg/kg) p.o. 0.06 0.14 0.10 0.01 
Tmax p.o. (h) 0.25 0.5 0.5 1.3 
Oral BA (%F) 19 23 36 15 
Neutropenic Murine Thigh Infection Model 
 1e 34f 
MIC (E. coli ATCC 25922, µg/mL) 0.008 0.06 
Static Dose (mg/kg/day) 6.4 45.5 
Compounds were administered as hydrochloride salts in solution using the following vehicles 
and doses: a Vehicle = 0.9% NaCl; dose = 5 mg/kg I.V. and 10 mg/kg P.O. b Vehicle = DI water; 
dose = 5 mg/kg I.V. and 10 mg/kg P.O. c Vehicle = 20% PEG300 + 5% Solutol in D5W; dose = 5 
mg/kg I.V. and P.O. d Vehicle = 20% PEG300 + 5% Solutol in D5W; dose = 5 mg/kg I.V. and 10 
mg/kg P.O. e Vehicle = DI water; multiple dose levels, subcutaneous route of administration. f 
Vehicle = 40% PEG300 + 10% Solutol HS-15 in D5W; multiple dose levels, subcutaneous route 





Chemistry A detailed description of the synthesis of compounds 4 and 5 is provided in the 
Experimental Section, and followed synthetic routes similar to those described below. Initial SAR 
exploration at C4 was enabled by the synthesis of key intermediate 43, equipped with an oxidative 
handle for further functionalization (Scheme 1). Starting from commercially available arene 35, 
standard protocols were employed to effect sequential esterification, nitration, reduction, and 
halogenation to provide iodide 37 in four steps and 57% overall yield. The methyl group at C8 was 
next installed by Suzuki reaction with methyl boronic acid, while the aniline in 38 was engaged in 
a Chan–Lam coupling to provide cyclopropylamine 39.74-76 Following acetylation, bromide 40 was 
leveraged to append functionalized pyrrolidine 41 at C7 via Buchwald–Hartwig coupling, 
catalyzed by the combination of Pd2(dba)3 and Xantphos in toluene at 110 °C.77-80  Construction 
of the quinolin-2(1H)-one core was then accomplished by subjection of 42 to base-mediated 
cyclization, delivering 43 in an overall 9-step sequence.  
Scheme 1. Synthesis of key intermediate toward C4-substituted analogs.   
 
With a robust route to access 43, analogs containing oxidation at C4 were prepared in short order 
as shown in Scheme 2. Boc deprotection gave hydroxy derivative 7, while treatment with POCl3 
effected chlorination and concomitant deprotection to provide 6. Ethers 8 and 12 were accessed 
via alkylations with methyl iodide and 2-dimethylaminoethyl chloride, respectively.  
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Scheme 2. Direct functionalization of C4-OH. 
 
The divergent synthesis of analogs with carbon-based functionality at C4 is illustrated in Scheme 
3. Conversion of 43 to triflate 44 enabled installation of an ethyl ester (45, obtained as a partially 
de-protected mixture) via palladium-catalyzed carbonylation,81, 82 or a nitrile (46) via a Negishi-
type cyanation reaction.83 Reduction of the deprotected ester (45, R = H) afforded hydroxymethyl 
derivative 11. Alternatively, heating the protected ester with hydrazine in EtOH provided the acyl 
hydrazide 47, which was cyclized with CDI in dioxane at 90 °C to give oxadiazolone 14 after Boc 
deprotection. The versatile nitrile 46 was used to access 10 (via deprotection and hydrogenation) 








Scheme 3. Generation of C4-carbon-based analogs via triflate functionalization.  
 
Having established the C4 aminomethyl substituent as optimal, attention turned to adapting the 
synthetic route to facilitate rapid SAR exploration at the C7 position by introducing the amine at 
a later stage in the synthesis (Scheme 4). To this end, N-acetylated bromide 40 was cyclized to 
form the quinolin-2(1H)-one core as before, followed by treatment with N-phenyl triflamide to 
give 48 in 77% yield over the two steps. Triflate 48 underwent chemoselective Negishi cyanation, 
leaving the bromide in 49 intact and poised for subsequent Buchwald–Hartwig coupling. A variety 
of C7 amine derivatives were prepared in this manner as exemplified by 50, obtained in 60% yield 
after reaction with tert-butyl (S)-pyrrolidin-3-ylcarbamate. The reaction conditions shown in 
Scheme 4 were slightly modified as necessary to accommodate more difficult amine substrates 
(see Experimental Section for details).79, 84, 85 Next, the aminomethyl substituent at C4 was 
revealed upon hydrogenation of the cyano group, for which the best results were consistently 
obtained when ammonia/methanol was used as solvent. A final Boc deprotection efficiently 
generated a series of differentially functionalized C7 analogs 15-26 (see Table 4). Compound 19 
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was prepared via Suzuki coupling with the appropriate arylboronic acid.86, 87 The requisite 
azabicyclic amines for compounds 22-23 were prepared using an intramolecular Kulinkovich-style 
reaction reported by Laroche et al.88 (see Experimental Section for details). 
Scheme 4. Divergent synthesis of C7 analogs.  
 
Whereas the C7 position was ultimately amenable to SAR exploration in a divergent fashion, 
the preparation of compounds with alternative substituents at C3 and C8 required multiple 
adaptations at an earlier point in the synthetic route. However, efforts directed at developing new 
sequences also provided an opportunity to improve upon the previously established strategy. For 
instance, an alternative 2-step procedure was identified to afford 55 by conversion of aniline 52 
(see Scheme 1, intermediate not drawn) to iodide 53 via Sandmeyer reaction,89, 90 followed by 
Buchwald–Hartwig coupling with cyclopropylamine, which proved higher yielding and generally 
more reliable than the previously utilized Chan–Lam reaction (Scheme 5a). Likewise, it was found 
that Suzuki reaction with triflate 57 and N-Boc aminomethyl potassium trifluoroborate proceeded 
smoothly to afford 58 in 53% yield, thus establishing a more convenient protocol for direct 
introduction of the aminomethyl group at C4.91 Compound 27 lacking the C8 methyl group was 
then obtained by coupling with pyrrolidine 59 and double Boc deprotection.  
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Scheme 5. Adapted synthetic routes toward C8 analogs.  
 
The synthetic routes toward C8 analogs 28 and 29 diverge at an early stage. Aryl cyanide 60 was 
produced in 77% yield by exposure of iodide 37 to CuCN in DMSO at elevated temperature 
(Scheme 5b). In this case, Chan–Lam coupling was utilized, albeit in low yield to access 
intermediate 61, which was elaborated to 28 through a sequence analogous to that described in 
Scheme 1 (see Experimental Section for details). Aryl iodide 37 was also used to prepare C8-
methoxy intermediate 62, which was converted to cyclopropylamine 64 using the same strategy 
employed for 27. Compound 29 was then accessed by carrying 64 through the 7-step synthetic 
sequence outlined in Scheme 4. Fortunately, iodide 63 could also be leveraged toward the synthesis 
of analog 30; demethylation and SEM protection gave 65, which was elaborated to 66 in 7 steps 
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(Scheme 5c). The free phenol was then reacted with difluorocarbene generated from PhCOCF2Cl 
to produce 67 in serviceable yield.92 Finally, coupling with pyrrolidine 59 under our standard 
conditions and double Boc deprotection delivered C8 difluoromethoxy analog 30.  
The syntheses of C3 analogs 31 and 33 are shown in Scheme 6. Pyrrolidine 59 was coupled to 
aryl bromide 49 in 85% yield, followed by conversion of the C4 cyano group to the corresponding 
aminomethyl via hydrogenation in NH3/MeOH with subsequent Boc protection to give 69. This 
common intermediate was chlorinated at C3 upon exposure to NCS in acetonitrile, leading to 33. 
Alternatively, 69 could be brominated and subjected to a Suzuki reaction with methyl boronic acid, 
affording 31 after deprotection.  
Scheme 6. Synthesis of C3-Cl and Me analogs.  
 
 
Incorporation of either OH or F substituents at C3 required yet another synthetic route 
modification to build in an additional oxidation state prior to formation of the quinolin-2(1H)-one 
core; this was accomplished from cyclopropylamine 39 via acylation with either 2-benzyloxy or 
2-fluoroacetyl chloride to generate 71 and 75, respectively (Scheme 7a/b). Each of these 
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intermediates was progressed through the established 4-step sequence involving cyclization, 
triflation, Suzuki, and Buchwald–Hartwig coupling reactions to yield advanced intermediates 74 
(C3-OH) and 79 (C3-F) respectively. Fluoride 34 was obtained after Boc deprotection of 79, while 
hydrogenolysis was required to remove the benzyl group from 74, thus providing 32 after Boc 
deprotection. 
Scheme 7. Synthesis of C3-OH and C3-F analogs 32 and 34.  
 
Conclusions 
After decades of clinical success quinolone antibiotics remain a crucial component of our 
antibacterial armamentarium. Unfortunately, resistance—driven by target-based QRDR mutations 
that disrupt quinolone binding—poses a serious threat to their continued use. In an effort to address 
this situation we elected to prioritize the discovery of small molecules that target WT and QRDR 
mutant forms of bacterial DNA gyrase and topoisomerase IV. Based on a scaffold-morphing 
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approach we were ultimately able to identify inhibitors that lacked both the C3 carboxylate and 
the C4 carbonyl responsible for engaging in the key water-metal ion bridge that anchors classical 
quinolones in the gyrase/topoisomerase IV cleavage complex. Compounds in this series displayed 
minimal cross-resistance with quinolones in spite of an intrinsic loss of potency. Through a 
concerted SAR exploration effort we were successful in optimizing activity against Gram-negative 
bacteria en route to 34, which demonstrated promising activity against Gram-negative bacteria and 
in vivo efficacy against E. coli. Unfortunately, however, further optimization of antibacterial 
potency proved extremely challenging. A number of in vitro safety issues were subsequently 
identified for compound 34, including hERG inhibition, cytotoxicity, and phototoxicity. 
Compound 34, and related analogs, also suffered from a severe loss of antibacterial potency at pH 
5.8, suggesting that clinical utility in the cUTI setting would be compromised. Although some of 
these issues were resolved in other analogs from this series, we were ultimately unable to identify 
compounds that married such properties with sufficient antibacterial potency and spectrum of 
activity. These challenges prompted us to halt further development of the series. It is our hope, 
however, that these studies may point the way toward development of more efficacious inhibitors 











General: Unless otherwise noted, all key compounds possess a purity of at least 95% as assessed 
by analytical reversed phase HPLC and/or LC/MS.  
Typical conditions for analytical HPLC: High performance liquid chromatography (HPLC) 
using a Waters UPLC instrument (Milford, MA). HPLC solvent A was 100% Water with 0.1% 
trifluoroacetic acid (TFA) and solvent B was 100% acetonitrile with 0.1% TFA from EMD 
Chemicals Inc.  The instrument was a Waters ACQUITY UPLC system with 1.2 mL/min flow 
rate; column Kinetex-C18, 2.6 µm, 2.1 x 50 mm from Phenomenex, column temperature:  50 °C; 
gradient:  2-88% solvent B over 9.79 min. Compounds were detected by ultraviolet light (UV) 
absorption at either 220 or 254 nm.  
Typical conditions for LC/MS analysis: HPLC/mass spectrometric analysis (LC/MS) was 
performed on a Waters ACQUITY UPLC system equipped with a ZQ 2000 or SQD MS system; 
Column: Kinetex by Phenomenex, 2.6 µm, 2.1 x 50mm, column temperature:  50 °C; 
gradient:  2-88% (or 0-45%, or 65-95%) solvent B over a 1.29 min or 9.79 min period; flow rate 
1.2 mL/min.  Compounds were detected by a Waters Photodiode Array Detector.  All masses were 
reported as those of the protonated parent ions, molecular weight range 150-850; cone Voltage 
20 V. For select bromine-containing intermediates, MS data is reported as [M+2]+, reflecting the 
mass of the heavier isotope [M+H]+. 
Alternative LC/MS method (compounds 27, 30, 32): BEH 1.7µm C18 50x2.1mm; column 
temperature: ambient; mobile phase: 5mM ammonium acetate in 0.1% formic acid in water 
(solvent A) and 0.1% formic acid in MeCN (solvent B); gradient:  5%-100% solvent B over 2.5 
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minutes and holding at 100% for 0.8 minutes with a flow rate of 0.55 mL/min. Compounds were 
detected by ESI-MS in positive ion mode and UV absorption at 254 nm. 
High resolution ESI-MS data were recorded using a LTQ Orbitrap mass spectrometer (Thermo 
Fisher Scientific) with electrospray ionization source. The resolution of the MS system was 
approximately 30000. The analyte compound was infused into the mass spectrometer by UPLC 
(Acquity, Waters) from sample probe. The separation was performed on Acquity UPLC BEH C18 
1x50 mm column at 0.15 mL/min flow rate with the gradient from 5% to 95% in 2.8 min. Solvent 
A was Water with 0.1% Trifluoroacetic acid and solvent B was 75% Methanol and 25% Isopropyl 
alcohol with 0.1% Trifluoroacetic acid. The mass accuracy of the system was found to be <5 ppm.  
NMR spectra were run on Varian 400 or Bruker 400 and 500 MHz NMR spectrometers. Spectra 
were measured at 298K and were referenced using the solvent peak. 
Preparative separations were carried out using a Combiflash Rf system (Teledyne Isco, Lincoln, 
NE) with RediSep silica gel cartridges (Teledyne Isco, Lincoln, NE) or SiliaSep silica gel 
cartridges (Silicycle Inc., Quebec City, Canada) or by flash column chromatography using silica 
gel (230-400 mesh) packing material, or by HPLC using a Waters 2767 Sample Manager, C-18 
reversed phase Sunfire column, 30X50 mm, flow 75 mL/min. Typical solvents employed for the 
Combiflash Rf system and flash column chromatography were dichloromethane, methanol, ethyl 
acetate, hexane, heptane, acetone, aqueous ammonia (or ammonium hydroxide), and triethyl 
amine. Typical solvents employed for the reverse phase HPLC are varying concentrations of 






2-oxo-1,2-dihydroquinoline-3-carboxylic acid hydrochloride (4) 
 
3-Bromo-4-fluoro-2-methylbenzoic acid (S2) 
 
To a stirred solution of n-butyllithium (1024 mL, 2560 mmol, 2.5M in hexanes) was added 
2,2,6,6-tetramethylpiperidine (436.0 mL, 2560 mmol) in THF (2300 mL) at −5 °C. After stirring 
for 15 min the mixture was cooled to −60 °C. A solution of 3-bromo-4-fluorobenzoic acid (255.0 
g, 1160 mmol) in THF (700 mL) was added dropwise and the mixture was stirred at this 
temperature for 2.5 h. The mixture was then treated with MeI (291.0 mL, 4640 mmol) at −70 °C. 
The resulting solution was allowed to warm to 20 °C within 30 mins. Water was added to quench 
the reaction, and the resulting solution was washed with EtOAc and then acidified with 4M HCl. 
The resulting mixture was extracted with EtOAc, the organic layer dried over anhydrous Na2SO4, 
filtered and concentrated to give the crude benzoic acid, which was re-crystallized from toluene to 
give the title compound (114 g, 42% yield) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 
7.81 (dd, J = 8.8, 5.6 Hz, 1H), 7.28 (t, J = 8.4 Hz, 1H), 2.60 (s, 3H). 
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tert-Butyl (3-bromo-4-fluoro-2-methylphenyl)carbamate (S3) 
 
To a solution of 3-bromo-4-fluoro-2-methylbenzoic acid (6.00 g, 25.8 mmol) in t-BuOH (49 
mL) was added TEA (7.20 mL, 51.6 mmol) and DPPA (6.30 mL, 28.4 mmol) at 15 °C. The mixture 
was then allowed to reflux for 1 h. After the reaction was complete, the reaction mixture was 
concentrated to give the crude product, which was purified by chromatography on silica gel (10% 
EtOAc/PE) to afford the title compound (6.20 g, 79% yield) as a white solid. LCMS (m/z): 248.0 
[M–55]. 1H NMR (400 MHz, DMSO-d6) δ 8.82 (br s, 1H), 7.27 (dd, J = 9.2, 5.6 Hz, 1H), 7.16 (t, 
J = 8.4 Hz, 1H), 2.26 (s, 3H), 1.43 (s, 9H). 
3-Bromo-4-fluoro-2-methylaniline (S4) 
 
To a mixture of tert-butyl (3-bromo-4-fluoro-2-methylphenyl)carbamate (6.20 g, 20.4 mmol) in 
MeOH (5.00 mL) was added HCl (4M in MeOH, 25.5 mL, 102 mmol) at 0 °C. The reaction 
mixture was stirred at rt for 30 min. The reaction mixture was quenched with saturated aqueous 
NaHCO3 (20 mL). The slurry was extracted with EtOAc, the organic layer dried with Na2SO4, 
filtered and concentrated to give the title compound (3.80 g, 91% yield) as a white solid. LCMS 
(m/z): 204.0 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 6.91 (t, J = 8.4 Hz, 1H), 6.63 (dd, J = 8.8, 




A solution of 3-bromo-4-fluoro-2-methylaniline (2.30 g, 11.3 mmol) in EtOH (15 mL) was 
added dropwise to a mixture of I2 (2.90 g, 11.3 mmol) and Ag2SO4 (3.50 g, 11.3 mmol) in EtOH 
(35 mL) at rt. The resulting solution was then stirred at rt for 2 h. After completion the reaction 
mixture was filtered and the filtrate was concentrated. The residue was re-dissolved in DCM. The 
organic phase was washed with 5% aq. NaOH and water, dried over Na2SO4, filtered and 
concentrated to give a residue, which was purified by column chromatography on silica gel (0-
10% EtOAc/PE), providing the title compound (2.10 g, 56% yield) as a black solid. LCMS (m/z): 
329.9 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 7.34 (d, J = 7.6 Hz, 1H), 4.02 (br s, 2H), 2.36 (s, 
3H). 
Methyl 2-amino-4-bromo-5-fluoro-3-methylbenzoate (38) 
 
To a solution of 3-bromo-4-fluoro-6-iodo-2-methylaniline (2.00 g, 6.10 mmol) in MeOH (20 
mL) was added Pd(PPh3)4 (36.0 mg, 0.031 mmol) and TEA (1.70 mL, 12.2 mmol). The mixture 
was stirred under a CO (40 psi) atmosphere for 30 mins. After completion the reaction mixture 
was concentrated to give a crude product which was purified by chromatography on silica gel (0-
5% EtOAc/PE) affording the title compound (1.40 g, 84% yield). 1H NMR (400 MHz, CDCl3) δ 
7.53 (d, J = 9.6 Hz, 1H), 5.83 (br s, 2H), 3.87 (s, 3H), 2.32 (s, 3H). 
(2-Amino-4-bromo-5-fluoro-3-methylphenyl)methanol (S6) 
 
To a solution of methyl 2-amino-4-bromo-5-fluoro-3-methylbenzoate (1.47 g, 5.61 mmol) in 
THF (10 mL) was added LAH (234 mg, 6.17 mmol) at 0 °C. After stirring at 0 °C for 20 mins, 
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another batch of LAH (117 mg, 3.09 mmol) was added. The reaction mixture was further stirred 
at 0 °C for 30 mins. After completion of the reaction, water was added, the resulting suspension 
dried over anhydrous Na2SO4 and the solid filtered. The filtrate was concentrated to give the 
desired product (1.32 g, quantitative yield). 1H NMR (400 MHz, DMSO-d6) δ 6.99 (d, J = 9.6 Hz, 
1H), 5.29 (t, J = 5.6 Hz, 1H), 4.83 (br s, 2H), 4.38 (d, J = 9.6 Hz, 1H), 2.23 (s, 3H). 
2-Amino-4-bromo-5-fluoro-3-methylbenzaldehyde (S7) 
 
To a solution of (2-amino-4-bromo-5-fluoro-3-methylphenyl)methanol (1.32 g, 5.64 mmol) in 
DCM (60 mL) was added MnO2 (3.68 g, 42.3 mmol) at 0 °C. After stirring at 10 °C for 30 mins, 
another batch of MnO2 (1.84 g, 21.2 mmol) was added. The reaction mixture was further stirred at 
0 °C for 30 mins. The suspension was filtered and the filtrate was concentrated to give the desired 
product (1.17 g, 89% yield). 1H NMR (400 MHz, DMSO-d6) δ 9.80 (s, 1H), 7.52 (d, J = 8.8 Hz, 
1H), 7.15 (br s, 2H), 2.23 (s, 3H). 
4-Bromo-2-(cyclopropylamino)-5-fluoro-3-methylbenzaldehyde (S8) 
 
To a solution of 2-amino-4-bromo-5-fluoro-3-methylbenzaldehyde (1.70 g, 7.30 mmol) in DCE 
(30 mL) was added cyclopropylboronic acid (1.25 g, 14.6 mmol), Cu(OAc)2 (1.33 g, 7.30 mmol), 
bipyridine (1.14 g, 7.30 mmol) and Na2CO3 (1.55 g, 14.6 mmol). The mixture was stirred at 80 °C 
for 40 mins. After completion the mixture was filtered and the filtrate was concentrated to give the 
crude product, which was purified by flash chromatography (5% EtOAc/PE), providing the title 
compound as a yellow oil (400 mg, 20% yield). 1H NMR (400 MHz, DMSO-d6) δ 10.02 (s, 1H), 
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7.49 (d, J = 8.8 Hz, 1H), 7.31 (br s, 1H), 2.95–2.85 (m, 1H), 2.50 (s, 3H), 0.75–0.70 (m, 2H), 0.50–




To a solution of 4-bromo-2-(cyclopropylamino)-5-fluoro-3-methylbenzaldehyde (1.40 g, 5.20 
mmol) in EtOH (30 mL) was added diethyl malonate (1.67 g, 10.4 mmol) and piperidine (1.77 g, 
20.8 mmol). The mixture was refluxed at 100 °C for 16 h. The mixture was concentrated to give 
the crude product, which was purified by flash chromatography (20% EtOAc/PE) to give the title 
compound as a yellow solid (840 mg, 44% yield). 1H NMR (400 MHz, CDCl3) δ 8.13 (s, 1H), 7.17 
(d, J = 7.2 Hz, 1H), 4.40 (q, J = 7.2 Hz, 2H), 3.52–3.45 (m, 1H), 2.78 (s, 3H), 1.41 (t, J = 7.2 Hz, 




To a solution of ethyl 7-bromo-1-cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2- dihydroquinoline-
3-carboxylate (250 mg, 0.68 mmol) in toluene (50 mL) was added tert-butyl ((S)-1-((R)-pyrrolidin-
3-yl)ethyl)carbamate (291 mg, 1.36 mmol), Cs2CO3 (666 mg, 2.04 mmol), xantphos (59.0 mg, 
0.10 mmol) and Pd2(dba)3 (31.1 mg, 0.03 mmol) at rt. The reaction mixture was stirred at 110 °C 
for 12 h. After completion the mixture was dissolved in water (20 mL) and extracted with EtOAc. 
The organic layer was dried over Na2SO4 and concentrated to give a crude product, which was 
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purified by column chromatography on silica gel (0-50% EtOAc/PE) affording the desired product 
(280 mg, 82% yield). 1H NMR (400 MHz, CDCl3) δ 8.16 (s, 1H), 7.05 (d, J = 12.4 Hz, 1H), 4.51 
(br s, 1H), 4.41 (q, J = 7.2 Hz, 2H), 3.80–3.70 (m, 1H), 3.68–3.60 (m, 1H), 3.54–3.45 (m, 4H), 
2.45 (s, 3H), 2.12–2.10 (m, 1H), 2.11–2.07 (m, 1H), 1.80–1.70 (m, 1H), 1.47–1.40 (m, 12H), 1.30–
1.26 (m, 5H), 0.60–0.56 (m, 2H). 
7-((R)-3-((S)-1-((tert-Butoxycarbonyl)amino)ethyl)pyrrolidin-1-yl)-1-cyclopropyl-6-
fluoro-8-methyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid (S11) 
 
To a solution of ethyl 7-((R)-3-((S)-1-((tert-butoxycarbonyl)amino)ethyl)pyrrolidin-1-yl)-1-
cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-dihydroquinoline-3-carboxylate (200 mg, 0.40 mmol) 
in THF/H2O (8 mL, 1:1) was added NaOH (32.0 mg, 0.80 mmol). The reaction mixture was stirred 
at 45 °C for 4 h. After the reaction was complete, the reaction mixture was acidified to pH = 5 and 
extracted with EtOAc. The organic phase was dried over Na2SO4 and concentrated to give the 
desired product (175 mg, 93% yield). 1H NMR (400 MHz, DMSO-d6) δ 8.64 (s, 1H), 7.64 (d, J = 
13.6 Hz, 1H), 7.20–7.17 (m, 1H), 4.48–4.40 (m, 2H), 4.20–4.10 (m, 2H), 3.69–3.60 (m, 1H), 3.35–
3.25 (m, 2H), 2.89–2.75 (m, 1H), 2.60–2.50 (m, 1H), 2.38 (s, 3H), 1.50–1.40 (s, 11H), 1.30–1.24 
(m, 3H), 0.70–0.62 (m, 2H). 
7-((R)-3-((S)-1-Aminoethyl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-
dihydroquinoline-3-carboxylic acid hydrochloride (4) 
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To a solution of 7-((R)-3-((S)-1-((tert-butoxycarbonyl)amino)ethyl)pyrrolidin-1-yl)-1-
cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid (180 mg, 0.38 
mmol) in EtOAc (10 mL) was added HCl (1M in EtOAc, 10 mL) at 0 °C. The reaction mixture 
was stirred at rt for 3 h. After completion of the reaction, the organic layer was concentrated to 
give a crude product which was purified by reverse phase HPLC, affording the product (140 mg, 
99% yield). HRMS (ESI) calc’d for C20H25FN3O3 [M+H]+ 374.1874, found 374.1869. 1H NMR 
(400 MHz, DMSO-d6) δ 8.67 (s, 1H), 8.25 (br s, 3H), 7.66 (d, J = 13.6 Hz, 1H), 3.78–3.70 (m, 
1H), 3.60–3.40 (m, 4H), 3.30–3.20 (m, 1H), 2.45–2.35 (m, 4H), 2.20–2.10 (m, 1H), 1.80–1.70 (m, 
1H), 1.30–1.20 (m, 5H), 0.62–050 (m, 2H). 
Synthesis of 7-((R)-3-((S)-1-Aminoethyl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-





To a solution of ethyl 7-bromo-1-cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2- dihydroquinoline-
3-carboxylate (300 mg, 0.81 mmol) in MeOH (12 mL) and H2O (3 mL) was added KOH (91.4 
mg, 1.63 mmol) at 10 °C. The resulting mixture was stirred at 40 °C for 2 h. After completion the 
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reaction mixture was acidified to pH 4 by the addition of 2N HCl. The resulting solution was 
extracted with DCM, and the organic layer was washed with brine, dried over anhydrous Na2SO4, 
filtered and concentrated to give the title compound (230 mg, 83% yield). 1H NMR (400 MHz, 
CDCl3) δ 14.16 (br s, 1H), 8.68 (s, 1H), 7.33 (d, J = 6.4 Hz, 1H), 3.65–3.60 (m, 1H), 2.86 (s, 3H), 
1.40–1.30 (m, 2H), 0.70–0.60 (m, 2H). 
7-Bromo-1-cyclopropyl-6-fluoro-8-methylquinolin-2(1H)-one (S13)  
 
To a solution of 7-bromo-1-cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-dihydroquinoline-3-
carboxylic acid (230 mg, 0.68 mmol) in quinoline (2 mL) was added Cu (42.9 mg, 0.68 mmol) at 
10 °C. The resulting mixture was stirred at 240 °C for 30 mins. The reaction mixture was cooled 
to 10 °C and water was added. The resulting suspension was extracted with EtOAc, the organic 
layer was washed with brine, dried over Na2SO4, filtered and concentrated. The crude product was 
purified by column chromatography on silica gel (0-50% EtOAc/PE) to give the title compound 
as a yellow solid (120 mg, 60% yield). 1H NMR (400 MHz, CDCl3) δ 7.44 (d, J = 9.6 Hz, 1H), 
7.08 (d, J = 7.6 Hz, 1H), 6.61 (d, J = 9.6 Hz, 1H), 3.53–3.48 (m, 1H), 2.78 (s, 3H), 1.30–1.20 (m, 




To a solution of 7-bromo-1-cyclopropyl-6-fluoro-8-methylquinolin-2(1H)-one (50.0 mg, 0.17 
mmol) in toluene (3 mL) was added tert-butyl ((S)-1-((R)-pyrrolidin-3-yl)ethyl)carbamate (45.4 
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mg, 0.21 mmol) and Cs2CO3 (138.0 mg, 0.42 mmol), followed by xantphos (12.3 mg, 0.021 mmol) 
and Pd2(dba)3 (6.5 mg, 0.007 mmol). The resulting mixture was stirred at 110 °C under nitrogen 
for 16 h. The reaction mixture was concentrated, the residue was dissolved in water, and the slurry 
was extracted with DCM. The organic layer was dried over anhydrous Na2SO4, filtered and 
concentrated to afford a crude product, which was purified by preparative TLC to give the title 
compound (35.0 mg, 48% yield). 1H NMR (400 MHz, CDCl3) δ 7.38 (d, J = 9.2 Hz, 1H), 6.94 (d, 
J = 12.4 Hz, 1H), 6.45 (d, J = 9.6 Hz, 1H), 4.63 (d, J = 8.0 Hz, 1H), 3.80–3.73 (m, 1H), 3.60–3.35 
(m, 5H), 2.76–2.68 (m, 1H), 2.49 (s, 3H), 2.32–2.27 (m, 1H), 2.10–2.00 (m, 1H), 1.43 (s, 9H), 
1.22 (d, J = 6.8 Hz, 3H), 1.25–1.15 (m, 2H), 0.60–0.50 (m, 2H). 
7-((R)-3-((S)-1-Aminoethyl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-methylquinolin-
2(1H)-one hydrochloride (5) 
 
To a solution of tert-butyl ((S)-1-((R)-1-(1-cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2- 
dihydroquinolin-7-yl)pyrrolidin-3-yl)ethyl)carbamate (35.0 mg, 0.08 mmol) in MeOH (2 mL) was 
added HCl (4M in MeOH, 2 mL) at 10 °C. The resulting mixture was stirred at rt for 1 h. The 
reaction mixture was concentrated, and the residue was purified by reverse phase HPLC to give 
the title compound (10.9 mg, 37% yield). HRMS (ESI) calc’d for C19H25FN3O [M+H]+ 330.1976, 
found 330.1972. 1H NMR (400 MHz, D2O) δ 7.63 (d, J = 9.2 Hz, 1H), 7.25 (d, J = 12.0 Hz, 1H), 
6.49 (d, J = 9.2 Hz, 1H), 3.90–3.83 (m, 1H), 3.82–3.75 (m, 2H), 3.70–3.60 (m, 1H), 3.55–3.40 (m, 
2H), 2.90–2.80 (m, 1H), 2.56 (s, 3H), 2.40–2.30 (m, 1H), 2.07–1.96 (m, 1H), 1.40 (d, J = 6.4 Hz, 
3H), 1.20–1.15 (m, 2H), 0.50–0.40 (m, 2H). 
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Preparation of compounds 6–15.  
Compounds 6–15 were prepared from intermediate 43, which was synthesized according to the 
scheme below:  
 
Methyl 4-bromo-3-fluorobenzoate (S15) 
 
A solution of 4-bromo-3-fluorobenzoic acid (350 g, 1.60 mol) in HCl (4M in MeOH, 2 L) was 
stirred at 50 °C for 3 h. The reaction mixture was concentrated to give the title compound (372 g, 
quant. yield) as a gray solid. 1H NMR (400 MHz, CDCl3) δ 7.78–7.64 (m, 3H), 3.93 (s, 3H). 
Methyl 4-bromo-5-fluoro-2-nitrobenzoate (36) 
 
To a solution of methyl 4-bromo-3-fluorobenzoate (372 g, 1.60 mol) in H2SO4 (1000 mL) was 
added KNO3 (170 g, 1.68 mol) at 0 °C. The mixture was then stirred at rt for 2 h. The reaction 
mixture was quenched with ice water and then extracted with EtOAc. The organic layer was dried 
over anhydrous Na2SO4 and concentrated to give the crude product, which was purified by column 
chromatography on silica gel (5% EtOAc/PE) affording the title compound (380 g, 86% yield) as 
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a yellow solid. 1H NMR (400 MHz, CDCl3) δ 8.21 (d, J = 5.6 Hz, 1H), 7.45 (d, J = 7.6 Hz, 1H), 
3.94 (s, 3H). 
Methyl 2-amino-4-bromo-5-fluorobenzoate (S16) 
 
To a solution of methyl 4-bromo-5-fluoro-2-nitrobenzoate (95.0 g, 0.34 mol) in MeOH (1000 
mL) was added AcOH (102 g, 1.70 mol). Fe power (95.4 g, 1.70 mol) was added slowly at 0 °C. 
After stirred at rt for 1 h, the reaction mixture was filtered. The filtrate was concentrated, and the 
residue was purified by column chromatography on silica gel (5% EtOAc/PE) to give the title 
compound (62.5 g, 74% yield) as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.59 (d, J = 9.6 Hz, 
1H), 6.88 (d, J = 5.6 Hz, 1H), 5.62 (br s, 2H), 3.88 (s, 3H). 
Methyl 2-amino-4-bromo-5-fluoro-3-iodobenzoate (37) 
 
To a solution of methyl 2-amino-4-bromo-5-fluorobenzoate (50.0 g, 0.20 mol) in MeOH (480 
mL) was added water (400 mL) and Ag2SO4 (100 g, 0.32 mol). A solution of I2 (81.2 g, 0.32 mol) 
in THF (480 mL) was added at rt. After stirring at rt for 30 min, the solvent was evaporated and 
the resulting suspension was filtered. The filtrate was extracted with EtOAc, the organic phase was 
dried over anhydrous Na2SO4 and concentrated to give the crude product, which was purified by 
column chromatography on silica gel (5% EtOAc/PE) affording the title compound (68.0 g, 90% 
yield) as a yellow solid. 1H NMR (400 MHz, CDCl3) δ 7.75 (d, J = 9.6 Hz, 1H), 6.55 (br s, 2H), 
3.90 (s, 3H). 
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Methyl 2-amino-4-bromo-5-fluoro-3-methylbenzoate (38) 
 
To a solution of methyl 2-amino-4-bromo-5-fluoro-3-iodobenzoate (80.0 g, 214 mmol) in DME 
(1170 mL) was added water (200 mL), CH3B(OH)2 (77.0 g, 1.28 mol), K2CO3 (59.0 g, 428 mmol) 
and Pd(PPh3)2Cl2 (15.0 g, 2.14 mol). The reaction mixture was stirred at 60 °C for 18 h and then 
at 90 °C for 6 h. The reaction was quenched with water and extracted with EtOAc. The organic 
phase was dried over Na2SO4, concentrated and then purified by column chromatography on silica 
gel (2% EtOAc/PE), followed by recrystallization with PE/EtOAc to give the title compound (29.0 
g, 52% yield) as a yellow solid. LCMS (m/z): 262.0 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 7.52 
(d, J = 9.6 Hz, 1H), 5.83 (br s, 2H), 3.87 (s, 3H), 2.32 (s, 3H). 
Methyl 4-bromo-2-(cyclopropylamino)-5-fluoro-3-methylbenzoate (39) 
 
To a solution of methyl 2-amino-4-bromo-5-fluoro-3-methylbenzoate (5.00 g, 19.2 mmol) in 
DCE (50 mL) was added Na2CO3 (4.07 g, 38.4 mmol), 2,2'-bipyridine (2.90 g, 19.2 mmol), 
Cu(OAc)2 (3.50 g, 19.2 mmol) and cyclopropylboronic acid (3.50 g, 19.2 mmol) at 10 °C. The 
reaction mixture was stirred at 10 °C for 20 min and then at 70 °C for 5 h. The reaction mixture 
was filtered and concentrated. The residue was purified by column chromatography on silica gel 
(2% EtOAc/PE) to give the title compound (2.40 g, 42% yield) as a yellow oil. LCMS (m/z): 302.2 
[M+H]+. 1H NMR (400 MHz, CDCl3) δ 7.52 (d, J = 9.0 Hz, 1H), 7.22 (br s, 1H), 3.85 (s, 3H), 2.71 
(tt, J = 6.8, 3.5 Hz, 1H), 2.57 (s, 3H), 0.68–0.62 (m, 2H), 0.49–0.45 (m, 2H). 
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Methyl 4-bromo-2-(N-cyclopropylacetamido)-5-fluoro-3-methylbenzoate (40) 
 
To a solution of methyl 4-bromo-2-(cyclopropylamino)-5-fluoro-3-methylbenzoate (13.0 g, 43.0 
mmol) in DCM (260 mL) was added DIPEA (27.8 g, 215 mmol) and acetyl chloride (33.8 g, 430 
mmol). The reaction mixture was stirred at rt for 20 minutes. The reaction mixture was poured into 
ice water and the phases were separated. The organic layer was washed with brine, dried over 
Na2SO4, filtered, and concentrated. The residue was purified by column chromatography on silica 
gel (0-50% EtOAc/PE) to give the title compound (10.5 g, 71% yield) as a brown oil. 1H NMR 
(400 MHz, CDCl3) δ 7.63–7.53 (m, 1H), 3.90–3.80 (m, 3H), 3.15–3.01 (m, 1H), 2.41 (s, 2H), 2.34 




To a suspension of methyl 4-bromo-2-(N-cyclopropylacetamido)-5-fluoro-3-methylbenzoate 
(6.00 g, 17.5 mmol) in toluene (180 mL) was added tert-butyl ((S)-1-((R)-pyrrolidin-3-yl)ethyl) 
carbamate (6.72 g, 31.5 mol), Cs2CO3 (11.4 g, 35.0 mmol), xantphos (3.00 g, 5.25 mmol) and 
Pd2(dba)3 (1.60 g, 1.75 mmol) at 10 °C. The resulting mixture was purged with nitrogen for 5 min 
and heated to 110 °C for 24 h. The reaction mixture was filtered and the filtrate was concentrated. 
The residue was purified by column chromatography on silica gel (50% EtOAc/PE) to give the 
title compound (5.00 g, 60% yield) as a brown oil. 1H NMR (400 MHz, CDCl3) δ 7.54–7.45 (m, 
1H), 4.61 (br s, 1H), 3.85–3.80 (m, 3H), 3.75–3.65 (m, 1H), 3.40–3.26 (m, 3H), 3.12–3.05 (m, 
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1H), 2.44–2.37 (m, 2H), 2.29–2.23 (m, 1H), 2.13 (s, 2H), 2.08–2.02 (m, 3H), 1.79–1.72 (m, 2H), 





To a solution of methyl 4-((R)-3-((S)-1-((tert-butoxycarbonyl)amino)ethyl)pyrrolidin-1-yl)-2- 
(N-cyclopropylacetamido)-5-fluoro-3-methylbenzoate (5.00 g, 10.5 mmol) in THF (150 mL) was 
added NaHMDS (52.4 mL, 52.4 mmol, 1M in THF) at 10 °C followed by stirring for 20 min. The 
mixture was quenched with water and acidified to pH 4 with 1M HCl. The resulting suspension 
was extracted with EtOAc, and the organic layer was washed with brine, dried over Na2SO4, 
filtered and concentrated. The residue was purified by HPLC to give the title compound (2.30 g, 
49% yield) as a yellow solid. LCMS (m/z): 447.2 [M+H]+. 1H NMR (400 MHz, CD3OD) δ 7.40 
(d, J = 13.6 Hz, 1H), 6.71 (d, J = 8.8 Hz, 1H), 5.79 (s, 1H), 3.62 (d, J = 6.5 Hz, 2H), 3.48–3.38 
(m, 4H), 2.54 (s, 3H), 2.40–2.29 (m, 1H), 2.11 (ddd, J = 11.4, 7.3, 3.9 Hz, 1H), 1.80–1.68 (m, 1H), 
1.45 (s, 9H), 1.25–1.10 (m, 5H), 0.55–0.44 (m, 2H). 
7-((R)-3-((S)-1-Aminoethyl)pyrrolidin-1-yl)-4-chloro-1-cyclopropyl-6-fluoro-8-
methylquinolin-2(1H)-one trifluoroacetic acid (6) 
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A solution of tert-butyl ((S)-1-((R)-1-(1-cyclopropyl-6-fluoro-4-hydroxy-8-methyl-2-oxo-1,2-
dihydroquinolin-7-yl)pyrrolidin-3-yl)ethyl)carbamate (65.0 mg, 0.15 mmol) and phosphoryl 
trichloride (0.03 mL, 0.15 mmol) in dioxane (2 mL) was stirred at room temperature for 2 minutes 
and then heated to 120 °C via microwave for 20 minutes. The reaction was cooled to room 
temperature and treated with ice and 6N NaOH. The reaction was extracted with ethyl acetate, the 
organic phase was collected, dried over MgSO4, filtered, concentrated, and purified by prep HPLC 
to afford the title compound (16.0 mg, 18% yield). HRMS (ESI) calc’d for C19H24ClFN3O [M+H]+ 
364.1586, found 364.1582. 1H NMR (400 MHz, DMSO-d6) δ 7.83 (br s, 2H), 7.39 (d, J = 13.6 Hz, 
1H), 6.67 (s, 1H), 3.58 (q, J = 8.2 Hz, 1H), 3.51–3.35 (m, 4H), 3.32–3.25 (m, 1H), 2.44 (s, 3H), 
2.38 (q, J = 8.6, 8.5 Hz, 1H), 2.15–2.05 (m, 1H), 1.80–1.68 (m, 1H), 1.27 (d, J = 6.4 Hz, 3H), 
1.19–1.07 (m, 2H), 0.46–0.38 (m, 2H).  
7-((R)-3-((S)-1-Aminoethyl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-hydroxy-8-
methylquinolin-2(1H)-one trifluoroacetic acid (7) 
 
To a solution of tert-butyl ((S)-1-((R)-1-(1-cyclopropyl-6-fluoro-4-hydroxy-8-methyl-2-oxo-
1,2-dihydroquinolin-7-yl)pyrrolidin-3-yl)ethyl)carbamate (50.0 mg, 0.11 mmol) in MeOH (1.1 
mL) was added HCl (4M in dioxane, 1.1 mL) and the solution was stirred at rt for 16 h. The 
reaction solution was concentrated and purified by reverse phase HPLC to give the desired product 
(42.0 mg, 64% yield). HRMS (ESI) calc’d for C19H25FN3O2 [M+H]+ 346.1925, found 346.1922. 
1H NMR (500 MHz, DMSO-d6) δ 11.27 (s, 1H), 7.82 (s, 3H), 7.28 (d, J = 13.3 Hz, 1H), 5.65 (s, 
1H), 3.51–3.39 (m, 2H), 3.36–3.29 (m, 3H), 3.29–3.21 (m, 1H), 2.43 (s, 3H), 2.41–2.32 (m, 1H), 
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2.12–2.04 (m, 1H), 2.07 (s, 3H), 1.80–1.66 (m, 1H), 1.26 (d, J = 6.6 Hz, 3H), 1.13–1.00 (m, 2H), 
0.34 (p, J = 4.8 Hz, 2H).  
7-((R)-3-((S)-1-Aminoethyl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-methoxy-8-
methylquinolin-2(1H)-one trifluoroacetic acid (8)  
 
A mixture of tert-butyl ((S)-1-((R)-1-(1-cyclopropyl-6-fluoro-4-hydroxy-8-methyl-2-oxo-1,2-
dihydroquinolin-7-yl)pyrrolidin-3-yl)ethyl)carbamate (17.0 mg, 0.04 mmol), iodomethane (10.9 
mg, 0.08 mmol), potassium carbonate (10.6 mg, 0.08 mmol) and 18-crown-6 (41.0 mg, 0.15 mmol) 
in DMA (1 mL) was stirred at rt overnight. The reaction was poured into brine and extracted with 
ethyl acetate. The organic phase was collected, dried over MgSO4, filtered and concentrated. The 
crude material was diluted with dichloromethane (1 mL) and treated with trifluoroacetic acid (1 
mL) for 30 minutes. The reaction was concentrated and purified by prep HPLC to afford the 
desired material (6.0 mg, 34% yield). HRMS (ESI) calc’d for C20H27FN3O2 [M+H]+ 360.2082, 
found 360.2077. 1H NMR (400 MHz, DMSO-d6) δ 7.79 (br s, 2H), 7.29 (d, J = 13.5 Hz, 1H), 5.83 
(s, 1H), 3.86 (s, 3H), 3.53–3.45 (m, 2H), 3.44–3.23 (m, 4H), 2.55 (p, J = 2.0 Hz, 2H), 2.44 (s, 3H), 
2.42–2.31 (m, 1H), 2.13–2.01 (m, 1H), 1.79–1.66 (m, 1H), 1.26 (d, J = 6.5 Hz, 3H), 1.14–0.99 (m, 







Preparation of compounds 9–10.  
 
7-((R)-3-((S)-1-((tert-Butoxycarbonyl)amino)ethyl)pyrrolidin-1-yl)-1-cyclopropyl-6-
fluoro-8-methyl-2-oxo-1,2-dihydroquinolin-4-yl trifluoromethanesulfonate (44) 
 
To a ice-cold solution of tert-butyl ((S)-1-((R)-1-(1-cyclopropyl-6-fluoro-4-hydroxy-8-methyl-
2-oxo-1,2-dihydroquinolin-7-yl)pyrrolidin-3-yl)ethyl)carbamate (170 mg, 0.38 mmol) and 
triethylamine (160 µL, 1.15 mmol) in DMF (1.2 mL) was added dropwise 1,1,1-trifluoro-N-
phenyl-N-((trifluoromethyl)sulfonyl)methanesulfonamide (164 mg, 0.46 mmol) in DMF (1 mL). 
The reaction was stirred for 1 hour and then poured into water, extracted with ethyl acetate and 
washed with brine. The organic phase was collected, dried over MgSO4, filtered, and concentrated. 
The crude material was purified by silica gel column chromatography (0-100% EtOAc/heptane) 
to afford the desired material (202 mg, 92% yield). LCMS (m/z): 478.2 [M-Boc+H]. 1H NMR 
(400 MHz, CDCl3) δ 7.16 (d, J = 12.9 Hz, 1H), 6.49 (s, 1H), 4.48 (d, J = 7.1 Hz, 1H), 3.84–3.70 
(m, 1H), 3.65 (q, J = 8.8 Hz, 1H), 3.55–3.39 (m, 4H), 2.47 (s, 3H), 2.33–2.23 (m, 1H), 2.09 (dtd, 
J = 14.0, 6.8, 2.8 Hz, 1H), 1.80–1.69 (m, 1H), 1.44 (s, 9H), 1.30–1.24 (m, 2H), 1.23 (d, J = 6.7 
Hz, 3H), 1.19–1.10 (m, 1H), 0.66–0.52 (m, 2H). 
 53 
tert-Butyl ((S)-1-((R)-1-(4-cyano-1-cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-
dihydroquinolin-7-yl)pyrrolidin-3-yl)ethyl)carbamate (46)  
 
A solution of 7-((R)-3-((S)-1-((tert-butoxycarbonyl)amino)ethyl)pyrrolidin-1-yl)-1-
cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-dihydroquinolin-4-yl trifluoromethanesulfonate (113 
mg, 0.20 mmol), tetrakis(triphenylphosphine)palladium (2.25 mg, 1.95 µmol) and dicyanozinc 
(13.7 mg, 0.12 mmol) in DMF (650 µl) was heated at 80 °C for 2 days. The reaction was cooled 
to room temperature and partitioned between brine and ethyl acetate. The organic phase was 
collected, dried over MgSO4, filtered, concentrated and purified by silica gel chromatography (0-
100% EtOAc/heptane) to afford the desired material (54.5 mg, 60% yield). 1H NMR (400 MHz, 
CDCl3) δ 7.31 (d, J = 12.7 Hz, 1H), 6.85 (s, 1H), 4.48 (d, J = 9.2 Hz, 1H), 3.81–3.70 (m, 1H), 3.65 
(q, J = 7.1 Hz, 1H), 3.54–3.40 (m, 4H), 2.46 (s, 3H), 2.29 (q, J = 8.3 Hz, 1H), 2.14–3.05 (m, 1H), 
1.75 (dq, J = 12.0, 8.9 Hz, 1H), 1.44 (s, 9H), 1.32–1.24 (m, 2H), 1.23 (d, J = 6.6 Hz, 3H), 0.62–
0.48 (m, 2H). 
7-((R)-3-((S)-1-Aminoethyl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-
dihydroquinoline-4-carbonitrile trifluoroacetic acid (9) 
 
A solution of tert-butyl ((S)-1-((R)-1-(4-cyano-1-cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-
dihydroquinolin-7-yl)pyrrolidin-3-yl)ethyl)carbamate (26.4 mg, 0.06 mmol) in dichloromethane 
(1 mL) was treated with trifluoroacetic acid (1 mL) and stirred for 30 minutes at room temperature. 
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The reaction was concentrated and purified by prep HPLC to afford the title compound (13.0 mg, 
60% yield). HRMS (ESI) calc’d for C20H24FN4O [M+H]+ 355.1929, found 355.1924. 1H NMR 
(400 MHz, DMSO-d6) δ 7.84 (br s, 2H), 7.24 (d, J = 12.9 Hz, 1H), 7.12 (s, 1H), 3.65–3.56 (m, 
1H), 3.54–3.44 (m, 3H), 3.39 (t, J = 9.0 Hz, 1H), 3.33–3.24 (m, 1H), 2.43 (s, 3H), 2.43–2.31 (m, 
2H), 2.15–2.07 (m, 1H), 1.81–1.68 (m, 1H), 1.27 (d, J = 6.5 Hz, 3H), 1.21–1.10 (m, 1H), 0.44 
(ddd, J = 10.5, 6.2, 4.5 Hz, 2H). 
7-((R)-3-((S)-1-Aminoethyl)pyrrolidin-1-yl)-4-(aminomethyl)-1-cyclopropyl-6-fluoro-8-
methylquinolin-2(1H)-one trifluoroacetic acid (10) 
 
A mixture of 7-((R)-3-((S)-1-aminoethyl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-methyl-2-
oxo-1,2-dihydroquinoline-4-carbonitrile (13.7 mg, 0.020 mmol), Pd/C (10%, 50% in water, 10.0 
mg), and acetic acid (100 µL) in methanol (2.00 mL) was sparged with H2 (g) for 5 minutes and 
then left under an atmosphere of H2 (g) for 4 hours. The suspension was filtered over Celite, 
concentrated, and purified by prep HPLC to give the title compound (3.0 mg, 32% yield). LCMS 
(m/z): 359.5 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.33 (br s, 2H), 7.86 (br s, 2H), 7.38 (d, 
J = 14.1 Hz, 1H), 6.44 (s, 1H), 4.23 (dd, J = 5.4, 4.7 Hz, 2H), 3.55 (dd, J = 8.6, 7.5 Hz 1H), 3.50–
3.24 (m, 6H), 2.45 (s, 3H), 2.43–2.35 (m, 1H), 2.14–2.05 (m, 1H), 1.79–1.68 (m, 1H), 1.27 (d, J = 










A solution of 7-((R)-3-((S)-1-((tert-butoxycarbonyl)amino)ethyl)pyrrolidin-1-yl)-1-
cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-dihydroquinolin-4-yl trifluoromethanesulfonate (193 
mg, 0.34 mmol), palladium acetate (7.50 mg, 0.03 mmol), dppf (18.5 mg, 0.03 mmol), 
molybdenum hexacarbonyl (44.0 mg, 0.17 mmol), EtOH (1.00 mL) and pyridine (0.250 mL) was 
heated at 150 °C via microwave for 20 minutes. The reaction was concentrated, diluted with ethyl 
acetate, and washed with water. The organic phase was collected, dried over MgSO4, filtered, 
concentrated, and purified by silica gel column chromatography (0-100% EtOAc/heptane, then 0-
10% MeOH/DCM) to afford deprotected ester 45 (34.0 mg, 25% yield) along with the 






methylquinolin-2(1H)-one trifluoroacetic acid (11)  
 
A solution of the ester (cmpd 45, 34.0 mg, 0.08 mmol) in i-PrOH (0.7 mL)/water (0.15 mL) was 
treated with sodium borohydride (11.3 mg, 0.30 mmol) and stirred at rt for 4 hours. The reaction 
was quenched with acetic acid, concentrated under reduced pressure and purified by reverse phase 
prep HPLC to afford the title compound (4.0 mg, 8% yield). LCMS (m/z): 360.4 [M+H]+. 1H NMR 
(400 MHz, DMSO-d6) δ 7.79 (br s, 2H), 7.24 (d, J = 13.9 Hz, 1H), 6.42 (s, 1H), 4.59 (s, 2H), 3.53–
3.22 (m, 6H), 3.17 (s, 1H), 2.45 (s, 3H), 2.43–2.33 (m, 1H), 2.09 (ddt, J = 14.9, 7.4, 3.0 Hz, 1H), 
1.78–1.68 (m, 1H), 1.26 (d, J = 6.5 Hz, 3H), 1.11 (tq, J = 10.1, 5.1 Hz, 2H), 0.40–0.29 (m, 2H). 
7-((R)-3-((S)-1-Aminoethyl)pyrrolidin-1-yl)-1-cyclopropyl-4-(2-(dimethylamino)ethoxy)-
6-fluoro-8-methylquinolin-2(1H)-one trifluoroacetic acid (12) 
 
A suspension of tert-butyl ((S)-1-((R)-1-(1-cyclopropyl-6-fluoro-4-hydroxy-8-methyl-2-oxo-
1,2-dihydroquinolin-7-yl)pyrrolidin-3-yl)ethyl)carbamate (59.4 mg, 0.133 mmol), 2-chloro-N,N-
dimethylethanamine hydrochloride (19.2 mg, 0.13 mmol), potassium carbonate (55.3 mg, 0.40 
mmol), and 18-crown-6 (211 mg, 0.80 mmol) in DMA (444 µl) was heated at 85 °C and stirred 
overnight. The reaction was poured into brine and extracted with ethyl acetate. The organic phase 
was collected, dried over MgSO4, filtered, and concentrated. The crude residue was dissolved in 
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DCM (0.5 mL) and treated with TFA (1 mL). The reaction was stirred 1 hour and then concentrated 
under reduced pressure. The crude residue was purified by prep HPLC to afford the title compound 
(45.2 mg, 45% yield). LCMS (m/z): 417.1 [M+H]+.  1H NMR (400 MHz, CD3OD) δ 7.61 (d, J = 
13.3 Hz, 1H), 5.95 (s, 1H), 4.47 (dd, J = 5.6, 4.0 Hz, 2H), 3.74–3.68 (m, 2H), 3.65–3.54 (m, 2H), 
3.50–3.40 (m, 3H), 3.40–3.33 (m, 1H), 3.01 (s, 6H), 2.56 (s, 3H), 2.49 (q, J = 8.5 Hz, 1H), 2.28–
2.18 (m, 1H), 1.89–1.78 (m, 1H), 1.40 (d, J = 6.6 Hz, 3H), 1.27–1.14 (m, 2H), 0.55–0.41 (m, 2H).  
Preparation of 7-((R)-3-((S)-1-Aminoethyl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-
methyl-2-oxo-1,2-dihydroquinoline-4-carboxylic acid trifluoroacetic acid (13) 
 
A solution of tert-butyl ((S)-1-((R)-1-(4-cyano-1-cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-
dihydroquinolin-7-yl)pyrrolidin-3-yl)ethyl)carbamate (27.7 mg, 0.06 mmol) in 10% aqueous 
ethanol (2.00 mL) was treated with sodium hydroxide (12.2 mg, 0.30 mmol) and stirred at 120 °C 
for 30 minutes. The reaction was concentrated under reduced pressure, dissolved in DCM (1.00 
mL) and treated with TFA (1.00 mL). After 30 minutes, the reaction was concentrated and the 
desired product was isolated by prep HPLC (4.0 mg, 19% yield, purity = 87%) along with the 
corresponding primary amide (8.0 mg, 38% yield). LCMS (m/z) for 13: 374.0 [M+H]+. 1H NMR 
(400 MHz, DMSO-d6) δ 7.83 (br s, 2H), 7.73 (d, J = 14.7 Hz, 1H), 6.74 (s, 1H), 3.60–3.51 (m, 
1H), 3.53–3.44 (m, 2H), 3.43–3.30 (m, 2H), 3.30–3.20 (m, 1H), 2.44 (s, 3H), 2.42–2.34 (m, 2H), 











A solution of ethyl 7-((R)-3-((S)-1-((tert-butoxycarbonyl)amino)ethyl)pyrrolidin-1-yl)-1-
cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-dihydroquinoline-4-carboxylate (48.1 mg, 0.096 mmol) 
and hydrazine (0.015 mL, 0.479 mmol) in ethanol (2 mL) was stirred for 12 hours at 60 °C. The 
reaction cooled to room temperature and was concentrated under reduced pressure to afford the 
desired material, which was used without further purification. LCMS (m/z): 488.1 [M+H]+.   
7-((R)-3-((S)-1-aminoethyl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-methyl-4-(5-oxo-4,5-
dihydro-1H-1,2,4-triazol-3-yl)quinolin-2(1H)-one trifluoroacetic acid (14) 
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A solution of 47 (51.6 mg, 0.106 mmol) and carbonyldiimidazole (34.32 mg, 0.212 mmol) in 
dioxane (1 mL) was stirred for 2 days at 90 °C. The reaction was concentrated and then diluted 
with dichloromethane (1 mL) and treated with trifluoroacetic acid  (1 mL) and aged for 30 minutes. 
The reaction was concentrated under reduced pressure and then purified by prep HPLC to afford 
the title compound (4.9 mg, 6% yield, 2 steps, purity = 90%). LCMS (m/z): 414.1 [M+H]+. 1H 
NMR (400 MHz, DMSO-d6) δ 13.03 (s, 1H), 8.08 (d, J = 15.0 Hz, 1H), 7.80 (bs, 2H), 6.72 (s, 
1H), 3.68 - 3.16 (m, 6H), 2.45 (s, 3H), 2.42 - 2.34 (m, 1H), 2.10 (m, 1H), 1.75 (m, 1H), 1.27 (d, J 
= 6.5 Hz, 3H), 1.15 (m, 2H), 0.42 (m, 2H). 
Preparation of (S)-4-(Aminomethyl)-7-(3-aminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-




To an ice-cold solution of methyl 4-bromo-2-(N-cyclopropylacetamido)-5-fluoro-3-
methylbenzoate (595 mg, 1.73 mmol) in THF (12 mL) was added dropwise NaHMDS (8.64 mL, 
8.64 mmol, 1M in THF). After 30 minutes of stirring, 1N HCl was added dropwise until pH 2 was 
reached. A solid precipitated, was filtered and washed with water. The aqueous phase was 
extracted with ethyl acetate and the organic phase collected, dried over MgSO4, filtered, and 
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concentrated under reduced pressure. The extracted material was combined with the solid filtrate 
to give the title compound (461 mg, 85% yield). LCMS (m/z): 313.9 [M+H]+. 1H NMR (400 MHz, 
DMSO-d6) δ 11.60 (br s, 1H), 7.50 (d, J = 8.6 Hz, 1H), 5.78 (s, 1H), 3.39 (tt, J = 6.8, 4.0 Hz, 1H), 




A ice-cold mixture of 7-bromo-1-cyclopropyl-6-fluoro-4-hydroxy-8-methylquinolin-2(1H)-one 
(287 mg, 0.92 mmol) and triethylamine (384 µl, 2.76 mmol) in DMF (2.5 mL) was treated 
dropwise with 1,1,1-trifluoro-N-phenyl-N-((trifluoromethyl)sulfonyl)methanesulfonamide (394 
mg, 1.10 mmol) in DMF (1 mL) followed by stirring for 1 hour. The reaction was poured into 
water, extracted with ethyl acetate and washed with brine. The organic phase was collected, dried 
over MgSO4, filtered, and concentrated. The crude material was purified by silica gel column 
chromatography (0-100% EtOAc/heptane) to afford the desired material (369 mg, 90% yield). 
LCMS (m/z): 446.0 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 7.32 (d, J = 7.8 Hz, 1H), 6.68 (s, 1H), 
3.51 (tt, J = 6.8, 4.0 Hz, 1H), 2.81 (s, 3H), 1.30–1.22 (m, 2H), 0.63–0.56 (m, 2H). 
7-Bromo-1-cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-dihydroquinoline-4-carbonitrile (49) 
 
 A solution of 7-bromo-1-cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-dihydroquinolin-4-yl 
trifluoromethanesulfonate (238 mg, 0.54 mmol), tetrakis(triphenylphosphine)palladium (31.0 mg, 
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0.03 mmol), and dicyanozinc (33.0 mg, 0.28 mmol) in DMF (1.8 mL) was heated at 85 °C for 18 
hours. The reaction was treated with water and extracted with ethyl acetate. The organic phase was 
collected, washed with brine, dried over MgSO4, filtered, concentrated, and purified by silica gel 
column chromatography (0-100% EtOAc/heptane) to afford the desired material (125 mg, 72% 




A solution of 7-bromo-1-cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-dihydroquinoline-4-
carbonitrile (159 mg, 0.50 mmol), xantphos (43.0 mg, 0.07 mmol), (S)-tert-butyl pyrrolidin-3-
ylcarbamate (138 mg, 0.74 mmol), tris(dibenzylideneacetone)dipalladium(0) (22.7 mg, 25.0 mol) 
and cesium carbonate (323 mg, 0.99 mmol) in toluene (1.65 mL) was heated at 110 °C overnight. 
The reaction was poured into water and extracted with ethyl acetate. The organic phase was washed 
with brine, dried over MgSO4, filtered, concentrated, and purified by silica gel column 
chromatography (0-80% EtOAc/heptane) to afford the desired compound (126 mg, 60% yield). 
LCMS (m/z): 427.1 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 7.34 (d, J = 12.5 Hz, 1H), 6.87 (s, 
1H), 4.75 (s, 1H), 4.35 (s, 1H), 3.81–3.73 (m, 1H), 3.61 (q, J = 8.0 Hz, 1H), 3.49 (tt, J = 7.4, 4.2 
Hz, 2H), 3.30 (dd, J = 10.0, 4.3 Hz, 1H), 2.48 (s, 3H), 2.33 (dq, J = 13.5, 6.9 Hz, 1H), 1.92 (td, J 





methylquinolin-2(1H)-one hydrochloride (15) 
 
A mixture of (S)-tert-butyl (1-(4-cyano-1-cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-
dihydroquinolin-7-yl)pyrrolidin-3-yl)carbamate (126 mg, 0.30 mmol) in 2M NH3 in EtOH (5 mL) 
was treated with Pd/C (10% dry wt, 50% water, 95.0 mg, 0.09 mmol) and sparged with hydrogen 
for 5 minutes. The reaction was left under an atmosphere of H2 for 2 hours. The reaction was 
filtered over Celite, concentrated under reduced pressure, diluted with DCM (1 mL) and treated 
with TFA (2 mL). After 1 hour, the reaction was concentrated under reduced pressure and purified 
by reverse phase HPLC to give the title compound (44.0 mg, 33% yield, 2 steps). Re-lyophilizing 
with 1N HCl provided the HCl salt. HRMS (ESI) calc’d for C18H24FN4O [M+H]+ 331.1929, found 
331.1925. 1H NMR (400 MHz, CD3OD) δ 7.38 (d, J = 13.5 Hz, 1H), 6.54 (s, 1H), 4.34 (s, 2H), 
3.99 (p, J = 5.7 Hz, 1H), 3.82 (ddd, J = 10.8, 6.3, 1.8 Hz, 1H), 3.63 (q, J = 8.1, 7.5 Hz, 1H), 3.53 
(dt, J = 10.2, 3.4 Hz, 3H), 2.60 (s, 3H), 2.49 (dtd, J = 13.6, 7.9, 5.9 Hz, 1H), 2.09 (ddt, J = 13.3, 
8.0, 5.5 Hz, 1H), 1.27–1.15 (m, 2H), 0.51–0.42 (m, 2H). 
(R)-4-(Aminomethyl)-7-(3-aminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-
methylquinolin-2(1H)-one trifluoroacetic acid (16) 
 
16 (0.09 g, 10% yield, 2 steps) was prepared from 7-bromo-1-cyclopropyl-6-fluoro-8-methyl-2-
oxo-1,2-dihydroquinoline-4-carbonitrile 49 (105 mg, 0.33 mmol) and (R)-tert-butyl pyrrolidin-3-
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ylcarbamate (91.0 mg, 0.49 mmol) according to the procedure used for compound 15. LCMS 
(m/z): 331.2 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.35 (br s, 2H), 8.10 (br s, 2H), 7.41 (d, 
J = 14.1 Hz, 1H), 6.46 (s, 1H), 4.23 (q, J = 6.9 Hz, 2H), 3.95–3.87 (m, 1H), 3.71–3.65 (m, 1H), 
3.56–3.44 (m, 4H), 2.50 (s, 3H), 2.37–2.30 (m, 1H), 2.02–1.96 (m, 1H), 1.18–1.11 (m, 2H), 0.34–
0.30 (m, 2H). 
(S)-4-(Aminomethyl)-1-cyclopropyl-6-fluoro-7-(3-hydroxypyrrolidin-1-yl)-8-
methylquinolin-2(1H)-one hydrochloride (17) 
 
17 (62.2 mg, 18% yield, 2 steps) was prepared from 7-bromo-1-cyclopropyl-6-fluoro-8-methyl-
2-oxo-1,2-dihydroquinoline-4-carbonitrile 49 (300 mg, 0.93 mmol) and (S)-3-((tert-
butyldimethylsilyl)oxy)pyrrolidine (376 mg, 1.87 mmol) according to the procedure used for 
compound 15 (omitting the Boc deprotection step). HRMS (ESI) calc’d for C18H23FN3O2 [M+H]+ 
332.1769, found 332.1767. 1H NMR (400 MHz, CD3OD) δ 7.30 (d, J = 13.9 Hz, 1H), 6.46 (s, 1H), 
4.53 (tt, J = 5.1, 2.8 Hz, 1H), 4.36–4.28 (m, 2H), 3.84 (p, J = 6.3, 5.2 Hz, 2H), 3.58–3.35 (m, 2H), 
2.53 (s, 3H), 2.27–2.12 (m, 1H), 1.99 (ddd, J = 11.6, 6.8, 3.6 Hz, 1H), 1.34–1.17 (m, 2H), 0.54–





18 (17.8 mg, 14% yield, 2 steps) was prepared from 7-bromo-1-cyclopropyl-6-fluoro-8-methyl-
2-oxo-1,2-dihydroquinoline-4-carbonitrile 49 (75 mg, 0.23 mmol) and pyrrolidine (39 µL, 0.47 
mmol) according to the procedure used for compound 15 (omitting the Boc deprotection step). 
HRMS (ESI) calc’d for C18H23FN3O [M+H]+ 316.1820, found 316.1820. 1H NMR (500 MHz, 
DMSO-d6) δ 8.33 (br s, 3H), 7.35 (d, J = 14.2 Hz, 1H), 6.41 (s, 1H), 4.26 - 4.17 (m, 2H), 2.42 (s, 
3H), 1.98 - 1.88 (m, 4H), 1.21 - 1.09 (m, 2H), 0.35 - 0.28 (m, 2H). 
Preparation of 7-(4-Amino-2,5-difluorophenyl)-4-(aminomethyl)-1-cyclopropyl-6-fluoro-






A mixture of 7-bromo-1-cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-dihydroquinoline-4-
carbonitrile (85.0 mg, 0.20 mmol), 2,5-difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)aniline (68.0 mg, 0.26 mmol), tetrakis(triphenylphosphine)palladium (92.0 mg, 0.08 mmol), 
and sodium carbonate (84.0 mg, 0.80 mmol) in toluene (1 mL)/water (0.35 mL)/ethanol (0.35 mL) 
was sealed and maintained at 110 °C for 18 hours. The reaction was cooled to room temperature, 
diluted with water, ethyl acetate, and the phases separated. The organic phase was washed with 
brine, dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was 
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purified by silica gel column chromatography (0-100% EtOAc/heptane) to afford the product (16.0 
mg, 21% yield) along with an equimolar amount of the dehalogenated starting material. LCMS 
(m/z): 369.9 [M+H]+. 
7-(4-Amino-2,5-difluorophenyl)-4-(aminomethyl)-1-cyclopropyl-6-fluoro-8-
methylquinolin-2(1H)-one trifluoroacetic acid (19) 
 
A mixture of 7-(4-amino-2,5-difluorophenyl)-1-cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-
dihydroquinoline-4-carbonitrile (41.0 mg, 0.05 mmol) in 2M NH3 in EtOH (4 mL) was treated 
with Pd/C (10% dry wt, 50% water, 17.4 mg, 0.02 mmol) and sparged with hydrogen for 5 minutes. 
The reaction was left under an atmosphere of H2 for 2 hours. The reaction was then filtered over 
Celite and concentrated under reduced pressure. The residue was purified by reverse phase HPLC 
to give the desired compound (6.0 mg, 30% yield). LCMS (m/z): 374.1 [M+H]+. 1H NMR (400 
MHz, CD3OD) δ 7.46 (d, J = 9.6 Hz, 1H), 6.93 (dd, J = 11.1, 6.4 Hz, 1H), 6.69 (dd, J = 11.1, 7.5 
Hz, 1H), 6.65 (s, 1H), 4.41 (s, 2H), 3.58 (dq, J = 6.8, 3.4 Hz, 1H), 2.52 (s, 3H), 1.36–1.17 (m, 2H), 
0.60–0.49 (m, 2H). 
4-(Aminomethyl)-1-cyclopropyl-6-fluoro-8-methyl-7-(piperazin-1-yl)quinolin-2(1H)-one 
trifluoroacetic acid (20) 
 
20 (7.5 mg, 6% yield, 2 steps) was prepared from 7-bromo-1-cyclopropyl-6-fluoro-8-methyl-2-
oxo-1,2-dihydroquinoline-4-carbonitrile 49 (81 mg, 0.25 mmol) and benzyl piperazine-1-
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carboxylate (83 mg, 0.38 mmol) according to the procedure used for compound 15. LCMS (m/z): 
331.1 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.84 (br s, 1H), 8.36 (br s, 2H), 7.45 (d, J = 13.1 
Hz, 1H), 6.49 (s, 1H), 4.22 (s, 2H), 3.53–3.42 (m, 4H), 3.30–3.17 (m, 5H), 2.58 (s, 3H), 1.20–1.10 
(m, 2H), 0.35–0.22 (m, 2H).  
7-(1-Amino-3-azabicyclo[3.1.0]hexan-3-yl)-4-(aminomethyl)-1-cyclopropyl-6-fluoro-8-
methylquinolin-2(1H)-one trifluoroacetic acid (21) 
 
21 (7.0 mg, 6% yield, 2 steps) was prepared from 7-bromo-1-cyclopropyl-6-fluoro-8-methyl-2-
oxo-1,2-dihydroquinoline-4-carbonitrile 49 (60.0 mg, 0.30 mmol) and tert-butyl (3-
azabicyclo[3.1.0]hexan-1-yl)carbamate (75.0 mg, 0.23 mmol) according to the procedure used for 
compound 15. HRMS (ESI) calc’d for C19H24FN4O [M+H]+ 343.1929, found 343.1929. 1H NMR 
(500 MHz, DMSO-d6) δ 8.65 (br s, 2H), 8.37 (br s, 2H), 7.43 (d, J = 13.6 Hz, 1H), 6.55 (br s, 2H), 
4.23 (s, 2H), 3.73 (d, J = 8.9 Hz, 1H), 3.69–3.60 (m, 1H), 3.54 (d, J = 9.1 Hz, 1H), 3.50–3.42 (m, 
1H), 3.23–3.19 (m, 1H), 2.43 (s, 3H), 1.94 (ddd, J = 8.5, 4.6, 3.4 Hz, 1H), 1.24 (dd, J = 8.8, 5.7 
Hz, 1H), 1.18–1.07 (m, 3H), 0.36–0.27 (m, 2H). 
rac-7-((1S,5R)-1-Amino-5-methyl-3-azabicyclo[3.1.0]hexan-3-yl)-4-(aminomethyl)-1-
cyclopropyl-6-fluoro-8-methylquinolin-2(1H)-one trifluoroacetic acid (22) 
 
22 (9.0 mg, 5% yield, 2 steps) was prepared from 7-bromo-1-cyclopropyl-6-fluoro-8-methyl-2-
oxo-1,2-dihydroquinoline-4-carbonitrile 49 (80.0 mg, 0.22 mmol), BINAP (21 mg, 0.03 mmol) as 
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ligand instead of xantphos, and tert-butyl rac-((1S,5R)-5-methyl-3-azabicyclo[3.1.0]hexan-1-
yl)carbamate (66.0 mg, 0.31 mmol) according to the procedure used for compound 15. tert-butyl 
rac-((1S,5R)-5-methyl-3-azabicyclo[3.1.0]hexan-1-yl)carbamate was prepared using procedures 
analogous to those described for 23 below. LCMS (m/z): 357.4 [M+H]+. 1H NMR (400 MHz, 
CD3OD) δ 7.32 (d, J = 13.5 Hz, 1H), 6.55 (s, 1H), 4.13 (s, 2H), 3.63 (d, J = 9.0 Hz, 1H), 3.59–
3.47 (m, 3H), 3.38 (d, J = 9.2 Hz, 1H), 2.53 (s, 3H), 1.32 (s, 3H), 1.25–1.17 (m, 2H), 1.13 (d, J = 




tert-butyl (3-benzyl-3-azabicyclo[4.1.0]heptan-1-yl)carbamate (S22) 
 
A solution of 2-(benzyl(but-3-en-1-yl)amino)acetonitrile (500 mg, 2.50 mmol) and titanium 
(IV) isopropoxide (1.48 ml, 4.99 mmol) in ether (15 ml) was slowly treated with a 2M solution 
of  cyclohexylmagnesium chloride (9.99 ml, 9.99 mmol) over 1 hour. The reaction mixture was 
then stirred at rt for 1 more hour. The crude product was then cooled to 0 °C and treated with 2M 
NaOH (15 mL) and allowed to stir for 1 hour. Inorganic precipitates were filtered off through a 
pad of Celite, and the filter cake was washed thoroughly with ether. The combined filtrates were 
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washed with brine and dried with MgSO4. The solvent was removed under reduced pressure. The 
residue was dissolved in dioxane (2.5 mL) then treated 1N NaOH (2 mL) and di-tert-butyl 
dicarbonate (1079 mg, 4.94 mmol) and stirred at room temperature overnight.  The reaction was 
diluted with ethyl acetate and water. Phases were separated and the organic phase collected, dried 
(MgSO4), filtered, concentrated, and purified by silica gel column chromatography eluting with a 
linear gradient of 0-60% ethyl acetate in heptane to afford the desired product (157 mg, 21% yield, 
2 steps).  LCMS (m/z): 303.1 [M+H]+. 
tert-butyl (3-azabicyclo[4.1.0]heptan-1-yl)carbamate (S23) 
 
A mixture of tert-butyl (3-benzyl-3-azabicyclo[4.1.0]heptan-1-yl)carbamate (155 mg, 0.513 
mmol) and 10% Pd/C (54.5 mg, 0.051 mmol) in MeOH (5 mL) was sparged with H2  for 5 minutes 
and then left under an atmosphere (balloon) of H2 overnight. The reaction was then filtered over 
an acrodisc filter and concentrated under reduced pressure to give the desired amine, which was 




A microwave vial was charged with 49 (100 mg, 0.311 mmol), tert-butyl (3-
azabicyclo[4.1.0]heptan-1-yl)carbamate (99 mg, 0.467 mmol), cesium carbonate (304 mg, 0.934 
mmol), Pd2(dba)3 (57.0 mg, 0.062 mmol) and BINAP (78 mg, 0.125 mmol). The vial was placed 
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under vaccum and backfilled with N2 3 times, then toluene (2 mL) was added. The mixture was 
stirred at 90 °C overnight. The crude reaction mixture was filtered through a disposable filter 
funnel and volatiles were evaporated under reduced pressure. SiO2 flash chromatography (0-100% 
EtOAc/heptane) provided the desired product (46.3 mg, 33 % yield, 2 steps) as a yellow dense oil. 




A mixture of tert-butyl (3-(4-cyano-1-cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-
dihydroquinolin-7-yl)-3-azabicyclo[4.1.0]heptan-1-yl)carbamate (45 mg, 0.099 mmol) in 2M 
NH3 in MeOH (2 mL) was treated with Pd/C (10% dry wt, 50% water, 63.5 mg, 0.030 mmol). The 
flask was partially evacuated and back-filled with H2 5 times, then stirred under a balloon of 
hydrogen for ~60 minutes. The flask was partially evacuated and back-filled with N2 5 times, then 
the reaction mixture was passed through a 1 µm syringe filter and concentrated under reduced 
pressure to give the desired product (45 mg, 99 % yield) as a yellow oil, which was used without 
further purification. LCMS (m/z): 457.3 [M+H]+. 
7-(1-amino-3-azabicyclo[4.1.0]heptan-3-yl)-4-(aminomethyl)-1-cyclopropyl-6-fluoro-8-
methylquinolin-2(1H)-one trifluoroacetic acid (23) 
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A mixture of tert-butyl (3-(4-(aminomethyl)-1-cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-
dihydroquinolin-7-yl)-3-azabicyclo[4.1.0]heptan-1-yl)carbamate (45.7 mg, 0.1 mmol) in DCM (1 
mL) and TFA (1 mL) was stirred for 30 minutes. Volatiles were evaporated under reduced 
pressure. The residue was dissolved in water/H2O and purified by preparative RP-HPLC (0.1% 
TFA in MeCN/H2O) to give the desired product (11 mg, 23% yield). HRMS (ESI) calc’d for 
C20H25FN4O [M+H]+ 357.2085, found 357.2080. 1H NMR (400 MHz, Methanol-d4) δ 7.40 (d, J 
= 12.8 Hz, 1H), 6.56 (s, 1H), 4.35 (s, 2H), 3.73 – 3.60 (m, 2H), 3.60 – 3.52 (m, 1H), 3.10 – 3.02 
(m, 1H), 2.65 (s, 3H), 2.27 – 2.16 (m, 1H), 2.05 – 1.92 (m, 1H), 1.61 – 1.51 (m, 1H), 1.35 – 1.18 
(m, 4H), 0.50 – 0.42 (m, 2H).  
rac-7-((1S,5R)-1-Amino-3-azabicyclo[3.2.0]heptan-3-yl)-4-(aminomethyl)-1-cyclopropyl-
6-fluoro-8-methylquinolin-2(1H)-one trifluoroacetic acid (24) 
 
24 (13.5 mg, 7% yield, 2 steps) was prepared from 7-bromo-1-cyclopropyl-6-fluoro-8-methyl-
2-oxo-1,2-dihydroquinoline-4-carbonitrile 49 (80.0 mg, 0.22 mmol), BINAP (21.0 mg, 0.03 
mmol) as ligand instead of xantphos and benzyl rac-((1S,5R)-3-azabicyclo[3.2.0]heptan-1-
yl)carbamate (55.0 mg, 0.22 mmol) according to the procedure used for compound 15. HRMS 
(ESI) calc’d for C20H26FN4O [M+H]+ 357.2085, found 357.2080. 1H NMR (400 MHz, CD3OD) δ 
7.41 (d, J = 13.3 Hz, 1H), 6.57 (s, 1H), 4.37 (d, J = 1.2 Hz, 2H), 3.78–3.71 (m, 1H), 3.71–3.55 (m, 
5H), 3.54–3.45 (m, 1H), 3.11–3.00 (m, 1H), 2.77 (s, 3H), 2.45–2.36 (m, 3H), 1.93 (dd, J = 10.5, 
3.6 Hz, 1H), 1.29–1.20 (m, 2H), 0.56–0.44 (m, 2H). 
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rac-4-(Aminomethyl)-7-(1-(aminomethyl)-3-azabicyclo[3.1.0]hexan-3-yl)-1-cyclopropyl-6-
fluoro-8-methylquinolin-2(1H)-one trifluoroacetic acid (25) 
 
25 (4.0 mg, 3% yield, 2 steps) was prepared from 7-bromo-1-cyclopropyl-6-fluoro-8-methyl-2-
oxo-1,2-dihydroquinoline-4-carbonitrile 49 (80.0 mg, 0.22 mmol), BINAP (21.0 mg, 0.03 mmol) 
as ligand instead of xantphos and tert-butyl ((3-azabicyclo[3.1.0]hexan-1-yl)methyl)carbamate 
hydrochloride (78.0 mg, 0.31 mmol) according to the procedure used for compound 15. HRMS 
(ESI) calc’d for C20H26FN4O [M+H]+ 357.2085, found 357.2080. 1H NMR (400 MHz, CD3OD) δ 
7.34 (d, J = 13.3 Hz, 1H), 6.52 (s, 1H), 4.34 (d, J = 1.2 Hz, 2H), 3.72 (d, J = 9.6 Hz, 1H), 3.68–
3.57 (m, 2H), 3.57–3.50 (m, 1H), 3.46–3.36 (m, 2H), 3.08 (d, J = 13.6 Hz, 1H), 2.54 (s, 3H), 1.70 
(dt, J = 7.8, 3.9 Hz, 1H), 1.30–1.19 (m, 2H), 1.10 (t, J = 4.7 Hz, 1H), 0.93 (dt, J = 8.1, 4.2 Hz, 2H), 
0.52–0.42 (m, 2H). 
rac-7-((1R,5S,6s)-6-Amino-3-azabicyclo[3.1.0]hexan-3-yl)-4-(aminomethyl)-1-
cyclopropyl-6-fluoro-8-methylquinolin-2(1H)-one trifluoroacetic acid (26) 
 
26 (14.3 mg, 11% yield, 2 steps) was prepared from 7-bromo-1-cyclopropyl-6-fluoro-8-methyl-
2-oxo-1,2-dihydroquinoline-4-carbonitrile 49 (75.0 mg, 0.22 mmol), BINAP (58.0 mg, 0.09 
mmol) as ligand instead of xantphos and tert-butyl 3-azabicyclo[3.1.0]hexan-1-ylcarbamate (70.0 
mg, 0.35 mmol) according to the procedure used for compound 15. HRMS (ESI) calc’d for 
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C19H24FN4O [M+H]+ 343.1929, found 343.1923. 1H NMR (400 MHz, CD3OD) δ 7.38 (d, J = 13.2 
Hz, 1H), 6.56 (s, 1H), 4.37 (d, J = 1.2 Hz, 2H), 3.70 (d, J = 9.4 Hz, 2H), 3.62–3.52 (m, 3H), 2.86 
(t, J = 2.2 Hz, 1H), 2.57 (s, 3H), 2.08 (q, J = 1.9 Hz, 2H), 1.30–1.17 (m, 2H), 0.56–0.42 (m, 2H). 
Preparation of 7-(1-Amino-3-azabicyclo[3.1.0]hexan-3-yl)-4-(aminomethyl)-1-
cyclopropyl-6-fluoroquinolin-2(1H)-one hydrochloride (27) 
 
Methyl 4-bromo-5-fluoro-2-iodobenzoate (53) 
 
Methyl 2-amino-4-bromo-5-fluorobenzoate (2.37 g, 9.54 mmol) was dissolved in acetonitrile 
(15 mL) and 6M HCl (48 mL). To the heterogeneous yellow mixture at 0 °C was added dropwise 
a solution of sodium nitrite (0.69 g, 10.0 mmol) in water (20 mL). The resulting mixture was stirred 
for 1 hour at 0 °C to give an almost clear, yellow solution. A solution of potassium iodide (3.17 g, 
19.1 mmol) in water (20 mL) was added dropwise and the mixture was allowed to warm slowly to 
rt overnight. The reaction mixture was diluted with water and extracted with EtOAc. The combined 
organic extracts were washed with saturated aqueous Na2S2O3, brine, dried over MgSO4, filtered 
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and concentrated under reduced pressure. The desired product was purified silica gel column 
chromatography (0-5% EtOAc/heptane) to give the desired product (2.40 g, 70% yield).  
Methyl 4-bromo-2-(cyclopropylamino)-5-fluorobenzoate (55) 
 
To methyl 4-bromo-5-fluoro-2-iodobenzoate (5.00 g, 13.9 mmol) in dioxane (50 mL) were 
added Cs2CO3 (9.05 g, 27.8 mmol), xantphos (1.21 g, 2.01 mmol), Pd2(dba)3 (0.64 g, 0.70 mmol), 
cyclopropylamine (1.59 g, 27.8 mmol) and the reaction mixture was stirred at 85 °C for 7 hours. 
The reaction mixture was cooled to room temperature, diluted with water and extracted with 
EtOAc. The organic layer was washed with brine, dried over Na2SO4 and concentrated to afford a 
crude residue. The crude residue was purified by silica gel column chromatography (0-5% 
EtOAc/hexanes) to afford the desired product (2.75 g, 69% yield). LCMS (m/z): 290.3 [M+2]+. 
Methyl 4-bromo-2-(N-cyclopropylacetamido)-5-fluorobenzoate (S26) 
 
Methyl 4-bromo-2-(cyclopropylamino)-5-fluorobenzoate (2.75 g, 9.55 mmol) was dissolved in 
toluene (30 mL) at room temperature. Acetyl chloride (1.49 g, 19.1 mmol) was added and the 
reaction mixture was stirred at 110 °C for 3 hours. The reaction mixture was cooled to room 
temperature, diluted with water and extracted with EtOAc. The organic layer was washed with 
brine, dried over sodium sulfate and concentrated to afford a crude residue. The crude residue was 
purified by silica gel column chromatography (0-5% EtOAc/hexanes) to afford the desired product 





Methyl 4-bromo-2-(N-cyclopropylacetamido)-5-fluorobenzoate (1.00 g, 3.03 mmol) was 
dissolved in dry THF (10 mL) and the reaction mixture was cooled to –78 °C. LiHMDS (1.0 M 
solution in THF, 6.06 mL, 6.06 mmol) was added dropwise and the reaction mixture was stirred 
at –78 °C for 1 hour. The reaction mixture was quenched with water at 0 °C, acidified with HCl 
and extracted with EtOAc. The organic layer was washed with water and concentrated to afford 
the desired product (0.62 g, 69% yield). LCMS (m/z): 299.9 [M+2]+. 1H NMR (400 MHz, DMSO-
d6) δ 11.67 (s, 1H), 8.05 (d, J = 6.0 Hz, 1H), 7.67 (d, J = 9.0 Hz, 1H), 5.84 (s, 1H), 2.85 (ddd, J = 




7-Bromo-1-cyclopropyl-6-fluoro-4-hydroxyquinolin-2(1H)-one (0.62 g, 2.08 mmol) and TEA 
(0.63 g, 6.25 mmol) were dissolved in DMF (8 mL) and the reaction mixture was stirred at 0 °C 
for 30 minutes. A solution of N-phenyl-bis(trifluoromethanesulfonimide) (0.59 g, 1.66 mmol) in 
DMF (1 mL) was added dropwise and the reaction mixture was stirred at room temperature for 2 
hours. The reaction mixture was quenched with water and extracted with EtOAc. The organic layer 
was washed with brine, dried over sodium sulfate and concentrated to afford the product (0.57 g, 





A mixture of 7-Bromo-1-cyclopropyl-6-fluoro-2-oxo-1,2-dihydroquinolin-4-yl 
trifluoromethane sulfonate (0.47 g, 1.09 mmol), potassium (((tert-
butoxycarbonyl)amino)methyl)trifluoroborate (0.52 g, 2.19 mmol) and Na2CO3 (0.35 g, 3.28 
mmol) in toluene (10 mL) and water (0.5 mL) was degassed with nitrogen for 5 minutes. 
PdCl2(dppf) (0.08 g, 0.11 mmol) was added and the reaction mixture was stirred at 110 °C for 5 
hours. The reaction mixture was diluted with water and extracted with EtOAc. The organic layer 
was washed with brine, dried over sodium sulfate and concentrated to afford the crude residue. 
The crude residue was purified by silica gel column chromatography (45-60% EtOAc/hexanes) to 
afford the desired product (0.24 g, 53% yield). LCMS (m/z): 413.5 [M+2]+. 1H NMR (400 MHz, 
CDCl3) δ 8.10 (d, J = 6.1 Hz, 1H), 7.45 (d, J = 9.1 Hz, 1H), 6.67 (s, 1H), 4.93 (s, 1H), 4.47 (d, J = 
6.0 Hz, 2H), 2.97–2.88 (m, 1H), 1.48 (d, J = 11.7 Hz, 9H), 1.44 –1.37 (m, 2H), 0.91 (q, J = 7.3 
Hz, 2H). 
7-(1-Amino-3-azabicyclo[3.1.0]hexan-3-yl)-4-(aminomethyl)-1-cyclopropyl-6-
fluoroquinolin-2(1H)-one hydrochloride (27) 
 
tert-Butyl ((7-bromo-1-cyclopropyl-6-fluoro-2-oxo-1,2-dihydroquinolin-4-
yl)methyl)carbamate (0.210 g, 0.51 mmol), tert-butyl (3-azabicyclo[3.1.0]hexan-1-yl)carbamate 
 76 
(0.20 g, 1.02 mmol), cesium carbonate (0.50 g, 1.53 mmol), Pd2dba3 (0.09 g, 0.10 mmol) and 
BINAP (0.13 g, 0.20 mmol) were combined in a sealed tube, which was evacuated and back-filled 
with nitrogen. Previously degassed toluene (5 mL) was added and the reaction mixture was stirred 
at 110 °C for 5 hours in a sealed tube. The reaction mixture was quenched with water and extracted 
with EtOAc. The organic layer was washed with brine, dried over sodium sulfate and concentrated 
to afford a crude residue. The crude product was purified by silica gel column chromatography 
(45-60% EtOAc/Hexane) to afford the desired protected amine. The Boc protected material was 
dissolved in DCM (5 mL) and cooled to 0 °C. HCl (4M in dioxane, 1.0 mL) was added and the 
reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was 
concentrated to afford a crude product, which was triturated with diethyl ether to afford the title 
compound (0.140 g, 69% yield, 2 steps). HRMS (ESI) calc’d for C18H22FN4O [M+H]+ 329.1772, 
found 329.1771. 1H NMR (400 MHz, CD3OD) δ 7.53 (d, J = 14.8 Hz, 1H), 7.22 (d, J = 8.0 Hz, 
1H), 6.47 (s, 1H), 4.38 (s, 2H), 4.26 (dd, J = 9.5, 2.8 Hz, 1H), 3.87 (d, J = 8.1 Hz, 1H), 3.76–3.67 
(m, 2H), 3.04–2.97 (m, 1H), 2.18 (dt, J = 8.9, 4.4 Hz, 1H), 1.48–1.35 (m, 3H), 1.18–1.10 (m, 1H), 










cyclopropyl-6-fluoro-2-oxo-1,2-dihydroquinoline-8-carbonitrile trifluoroacetic acid (28) 
 
Methyl 2-amino-4-bromo-3-cyano-5-fluorobenzoate (60) 
 
To methyl 2-amino-4-bromo-5-fluoro-3-iodobenzoate (5.00 g, 13.4 mmol) in DMSO (50 mL) 
was added CuCN (2.40 g, 26.7 mmol) followed by stirring at 90 °C overnight. The reaction mixture 
was diluted with cold water, filtered through Celite and extracted with EtOAc. The organic layer 
was washed with brine, dried over sodium sulfate and concentrated. The crude residue was purified 
by silica gel column chromatography (2.5% EtOAc/hexanes) to afford the desired product (2.80 
g, 77% yield). LCMS (m/z): 273.1 [M+H]+.  
Methyl 4-bromo-3-cyano-2-(cyclopropyl amino)-5-fluorobenzoate (61) 
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To methyl 2-amino-4-bromo-3-cyano-5-fluorobenzoate (2.80 g, 10.2 mmol) in DCM (60 mL) 
was added cyclopropyl boronic acid (1.80 g, 20.4 mmol), 2,2’-bipyridine (3.20 g, 20.4 mmol), 
Cu(OAc)2 (3.70 g, 20.4 mmol) and Na2CO3 (3.2 g, 30.7 mmol). Oxygen (gas) was purged 
continuously and the reaction mixture was stirred at room temperature for 3 days. The reaction 
mixture was filtered through celite, washed with DCM and the filtrate was concentrated. The crude 
residue was purified by silica gel column chromatography (0-5% EtOAc/hexanes) to afford the 
desired product (0.50 g, 16% yield). 1.5 g of starting material was recovered. LCMS (m/z): 313.1 
[M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.36 (s, 1H), 7.98 (d, J = 9.1 Hz, 1H), 3.83 (d, J = 3.9 




A suspension of methyl 4-bromo-3-cyano-2-(cyclopropyl amino)-5-fluorobenzoate (280 mg, 
0.89 mmol), Cs2CO3 (870 mg, 2.68 mmol), tert-butyl (azabicyclo[3.1.0]hexan-1-yl)carbamate 
(354 mg, 1.79 mmol) in toluene (6 mL) was degassed for 5 minutes. Pd2(dba)3 (163 mg, 0.18 
mmol) and BINAP (222 mg, 0.36 mmol) were added and the reaction mixture was stirred at 110 
°C for 15 hours. The reaction mixture was quenched with cold water and extracted with EtOAc. 
The combined organic layers were washed with brine, dried over sodium sulfate and concentrated 
to afford a crude residue, which was purified by silica gel column chromatography (0-10% 
EtOAc/hexanes) giving the desired product (210 mg, 51% yield). LCMS (m/z): 431.6 [M+H]+. 1H 
NMR (400 MHz, CDCl3) δ 8.44 (s, 1H), 7.61 (d, J = 15.2 Hz, 1H), 5.06 (s, 1H), 4.03–4.00 (m, 
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2H), 3.84–3.80 (m, 5H), 3.14–3.10 (m, 1H), 1.74–1.71 (m, 1H), 1.50 (s, 9H), 1.05–1.02 (m, 2H), 





(cyclopropylamino)-5-fluorobenzoate (190 mg, 0.44 mmol) was dissolved in toluene (2 mL), 
acetyl chloride (0.06 mL, 0.88 mmol) was added and the reaction mixture was stirred at 110 °C 
for 4 hours. The reaction mixture was quenched with water and extracted with EtOAc. The organic 





NaHMDS (1M in THF, 0.31 mL, 0.31 mmol) was added dropwise to a solution of methyl 4-(1-
((tert-butoxycarbonyl)amino)-3-azabicyclo[3.1.0]hexan-3-yl)-3-cyano-2-(N-
cyclopropylacetamido)-5-fluorobenzoate (48.0 mg, 0.10 mmol) in THF (2 mL) at –78 °C. After 3 
hours at this temperature, the reaction mixture was allowed to warm to –20 °C over the next 45 
minutes. The reaction was quenched by dropwise addition of saturated aqueous NH4Cl at –78 °C. 
Upon warming to rt, the mixture was diluted with water and extracted with EtOAc. The combined 
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organic layers were washed with brine, dried over Na2SO4 and concentrated under reduced 
pressure. LCMS (m/z): 441.2 [M+H]+. 
7-(1-((tert-Butoxycarbonyl)amino)-3-azabicyclo[3.1.0]hexan-3-yl)-8-cyano-1-cyclopropyl-
6-fluoro-2-oxo-1,2-dihydroquinolin-4-yl trifluoromethanesulfonate (S30) 
 
tert-Butyl (3-(8-cyano-1-cyclopropyl-6-fluoro-4-hydroxy-2-oxo-1,2-dihydroquinolin-7-yl)-3-
azabicyclo[3.1.0]hexan-1-yl)carbamate (92.0 mg, 0.21 mmol) and Et3N (63.0 mg, 0.63 mmol) 
were dissolved in DMF (1 mL) and the reaction mixture was stirred at 0 °C for 10 minutes. A 
solution of N-phenyl-bis(trifluoromethanesulfonimide) (89.0 mg, 0.25 mmol) in DMF (1 mL) was 
added dropwise and the reaction mixture was stirred at room temperature for 1 hour. The reaction 
mixture was quenched with water and extracted with EtOAc. The organic layer was washed with 
brine, dried over sodium sulfate and concentrated. The crude residue was purified by silica gel 
column chromatography (0-100% EtOAc/hexanes) to afford the desired product (69.0 mg, 58% 
yield, 3 steps). LCMS (m/z): 573.1 [M+H]+.  
7-(1-Amino-3-azabicyclo[3.1.0]hexan-3-yl)-4-(aminomethyl)-1-cyclopropyl-6-fluoro-2-
oxo-1,2-dihydroquinoline-8-carbonitrile trifluoroacetic acid (28) 
 
A mixture of 7-(1-((tert-Butoxycarbonyl)amino)-3-azabicyclo[3.1.0]hexan-3-yl)-8-cyano-1-
cyclopropyl-6-fluoro-2-oxo-1,2-dihydroquinolin-4-yl trifluoromethanesulfonate (69.0 mg, 0.12 
mmol), potassium (((tert-butoxycarbonyl)amino)methyl)trifluoroborate (57.0 mg, 0.24 mmol) and 
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Na2CO3 (38.0 mg, 0.36 mmol) in toluene (1.2 mL) and water (0.05 mL) was degassed with 
nitrogen for 5 minutes. PdCl2(dppf) (20.0 mg, 0.02 mmol) was added and the reaction mixture was 
stirred at 70 °C overnight. The reaction mixture was diluted with water and extracted with EtOAc. 
The organic layer was washed with brine, dried over sodium sulfate and concentrated to afford the 
crude residue. The crude residue was purified by silica gel column chromatography (0-100% 
EtOAc/heptane) to afford the protected amine. The Boc protected material was dissolved in DCM 
(1 mL) and TFA (0.5 mL) was added. The reaction mixture was stirred at room temperature for 20 
minutes. The reaction mixture was concentrated to afford a crude product, which was purified by 
prep-HPLC to afford the title compound (14.0 mg, 19% yield, 2 steps). HRMS (ESI) calc’d for 
C19H21FN5O [M+H]+ 354.1725, found 354.1722. 1H NMR (400 MHz, CD3OD) δ 7.76 (d, J = 14.1 
Hz, 1H), 6.60 (s, 1H), 4.36 (d, J = 0.9 Hz, 2H), 4.16 (d, J = 10.1 Hz, 1H), 4.04 (d, J = 9.8 Hz, 2H), 
3.90 (d, J = 10.5 Hz, 1H), 3.55–3.47 (m, 1H), 2.11–2.04 (m, 1H), 1.48–1.39 (m, 2H), 1.37–1.30 
(m, 1H), 1.27–1.20 (m, 1H), 0.78–0.70 (m, 2H). 
Preparation of 7-(1-Amino-5-methyl-3-azabicyclo[3.1.0]hexan-3-yl)-4-(aminomethyl)-1-




Methyl 2-amino-4-bromo-5-fluoro-3-methoxybenzoate (62) 
 
Methyl 2-amino-4-bromo-5-fluoro-3-iodobenzoate (1.00 g, 2.65 mmol) was dissolved in 
methanol (15 mL) and CuI (0.10 g, 0.53 mmol) was added, followed by stirring for 5 minutes. 
NaOMe (1.43 g, 26.5 mmol) and pyridine (2 mL) were added and the reaction mixture was stirred 
at 110 °C for 1 hour under microwave irradiation. The reaction mixture was quenched with cold 
water, acidified to pH 2 by the addition of 1N HCl and the suspension was extracted with EtOAc. 
The organic layer was washed with brine, dried over sodium sulfate and concentrated to afford the 
corresponding acid which was triturated with pentane:diethyl ether (1:1). The acid was dissolved 
in methanol (120 mL), concentrated H2SO4 (12 mL) was added and the reaction mixture was stirred 
at 85 °C for 24 hours. The reaction mixture was quenched with ice-water and extracted with DCM. 
The organic layer was washed with brine, dried over sodium sulfate and concentrated to give a 
crude residue, which was purified by column chromatography (0-20% EtOAc/hexanes), affording 
the desired product (4.50 g, 71% yield). LCMS (m/z): 279.9 [M+H]+. 1H NMR (400 MHz, DMSO-
d6) δ 7.41 (d, J = 9.7 Hz, 1H), 6.69 (s, 2H), 3.82 (s, 3H), 3.75 (s, 3H). 
Methyl 4-bromo-5-fluoro-2-iodo-3-methoxybenzoate (63) 
 
Methyl 2-amino-4-bromo-5-fluoro-3-methoxybenzoate (4.50 g, 16.2 mmol) was dissolved in 
acetonitrile (27 mL), 6M HCl (58.5 mL) was added and the reaction mixture was stirred at room 
temperature for 10 minutes. The reaction mixture was cooled to 0 °C and NaNO2 (1.17 g, 17.0 
mmol) in water (18 mL) was added followed by stirring at 0 °C for 1 hour. KI (5.37 g, 32.4 mmol) 
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in water (36 mL) was added dropwise and the reaction mixture was stirred at 0 °C for 30 minutes. 
The reaction mixture was quenched with cold water and extracted with EtOAc. The organic layer 
was washed with saturated aqueous sodium thiosulfate solution, dried over sodium sulfate and 
concentrated to afford a crude residue. The crude residue was purified by silica gel column 
chromatography (10% EtOAc/hexanes) to afford the desired product (1.80 g, 29% yield). 1H NMR 
(400 MHz, DMSO-d6) δ 7.55 (d, J = 8.5 Hz, 1H), 3.87 (s, 3H), 3.83 (s, 3H). 
Methyl 4-bromo-2-(cyclopropylamino)-5-fluoro-3-methoxybenzoate (64) 
 
Methyl 4-bromo-5-fluoro-2-iodo-3-methoxybenzoate (6.00 g, 15.4 mmol) and Cs2CO3 (15.0 g, 
46.3 mmol) were suspended in dioxane (60 mL) and degassed with nitrogen for 10 minutes. 
Pd2dba3 (0.70 g, 0.70 mmol), xantphos (1.30 g, 2.30 mmol) and cyclopropyl amine (2.20 mL, 30.8 
mmol) were added and the reaction mixture was stirred at 100 °C for 16 hours. The reaction 
mixture was quenched with water and extracted with EtOAc. The organic layer was washed with 
brine, dried over sodium sulfate and concentrated to afford a crude residue, which was purified by 
silica gel column chromatography (0-10% EtOAc/hexanes), providing the desired product (4.20 
g, 86% yield). LCMS (m/z): 320.13 [M+2]+. 1H NMR (400 MHz, CDCl3) δ 7.48 (d, J = 9.2 Hz, 
1H), 3.86 (s, 3H), 3.83 (s, 3H), 3.03–3.00 (m, 1H), 0.74–0.69 (m, 2H), 0.52–0.48 (m, 2H).  
Methyl 4-bromo-2-(N-cyclopropylacetamido)-5-fluoro-3-methoxybenzoate (S31) 
 
Methyl 4-bromo-2-(cyclopropylamino)-5-fluoro-3-methoxybenzoate (2.90 g, 9.10 mmol) was 
dissolved in DCM (45 mL) and cooled to 0 °C. DIPEA (7.92 mL, 45.5 mmol) and acetyl chloride 
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(6.50 mL, 91.1 mmol) were added and the reaction mixture was stirred at room temperature for 1 
hour. The reaction mixture was quenched with saturated NaHCO3 solution and extracted with 
DCM. The combined organic layers were washed with brine, dried over sodium sulfate and 
concentrated to afford a crude residue, which was purified by silica gel column chromatography 
(25-40% EtOAc/hexanes) providing the desired product (2.60 g, 79% yield). LCMS (m/z): 362.4 
[M+2]+. 1H NMR (400 MHz, CDCl3) δ 7.54 (d, J = 6.8 Hz, 1H), 3.88 (s, 3H), 3.85 (s, 3H), 3.19–




Methyl 4-bromo-2-(N-cyclopropylacetamido)-5-fluoro-3-methoxybenzoate (2.30 g, 6.30 mmol) 
was dissolved in THF (25 mL) and cooled to –78 °C. NaHMDS (1.0 M in THF, 19.2 mL, 19.2 
mmol) was added dropwise and the reaction mixture was stirred at –78 °C for 1 hour. The reaction 
mixture was quenched with ice-water, acidified to pH 2 by the addition of 1N HCl and extracted 
with 5% MeOH in DCM solution. The combined organic layer was dried over sodium sulfate and 
concentrated to afford the desired cyclized product. The quinolone was dissolved in DMF (20 mL) 
and cooled to 0 °C. TEA (2.56 mL, 18.3 mmol), PhNTf2 (2.61 g, 7.31 mmol) were added and the 
reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was quenched 
with cold water and extracted with EtOAc. The organic layer was washed with cold water, brine, 
dried over sodium sulfate and concentrated to give a crude residue, which was purified by silica 
gel column chromatography (0-15% EtOAc/hexanes) providing the desired product (1.50 g, 50% 
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yield, 2 steps). LCMS (m/z): 462.3 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 7.69 (d, J = 8.4 Hz, 




A solution of 7-bromo-1-cyclopropyl-6-fluoro-8-methoxy-2-oxo-1,2-dihydroquinolin-4-yl 
trifluoromethanesulfonate (0.80 g, 1.74 mmol) and Zn(CN)2 (0.22 g, 1.91 mmol) in DMF (12 mL) 
was degassed with nitrogen for 10 minutes. Pd(PPh3)4 (0.10 g, 0.09 mmol) was added and the 
reaction mixture was stirred at 100 °C for 16 hours. The reaction mixture was quenched with cold 
water and extracted with EtOAc. The combined organic layers were washed with brine, dried over 
sodium sulfate and concentrated to give a crude residue, which was purified by silica gel column 
chromatography (0-15% EtOAc/hexanes), affording the desired product (0.58 g, 58% yield). 
LCMS (m/z): 339.3 [M+2]+. 1H NMR (400 MHz, DMSO-d6) δ 7.48 (d, J = 7.6 Hz, 1H), 7.10 (s, 




A vial containing 7-bromo-1-cyclopropyl-6-fluoro-8-methoxy-2-oxo-1,2-dihydroquinoline-4-
carbonitrile (100 mg, 0.30 mmol), tert-butyl (5-methyl-3-azabicyclo[3.1.0]hexan-1-yl)carbamate 
(94.0 mg, 0.45 mmol), BINAP (74.0 mg, 0.12 mmol), tris(dibenzylideneacetone)dipalladium(0) 
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(54.3 mg, 0.06 mmol) and cesium carbonate (290 mg, 0.89 mmol) was sealed, evacuated and back-
filled with N2. Toluene (3 mL) was added and the mixture was heated to 100 °C for 6 hours. Upon 
cooling to room temperature the mixture was filtered and volatiles were evaporated under reduced 
pressure. Silica gel flash chromatography (0-100% EtOAc/heptane) provided the desired product 
(200 mg). LCMS (m/z): 469.4 [M+H]+. 
7-(1-Amino-5-methyl-3-azabicyclo[3.1.0]hexan-3-yl)-4-(aminomethyl)-1-cyclopropyl-6-
fluoro-8-methoxyquinolin-2(1H)-one trifluoroacetic acid (29) 
 
A mixture of tert-butyl (3-(4-cyano-1-cyclopropyl-6-fluoro-8-methoxy-2-oxo-1,2-
dihydroquinolin-7-yl)-5-methyl-3-azabicyclo[3.1.0]hexan-1-yl)carbamate (200 mg, 0.43 mmol) 
in 2M NH3 in MeOH (8.5 mL) was treated with Pd/C (10%, 50% in water, 136 mg, 0.06 mmol). 
The flask was partially evacuated and backfilled with H2 several times, then stirred under a balloon 
of H2 for 1 hour. The reaction mixture was then filtered and volatiles were evaporated under 
reduced pressure. The crude product was dissolved in a mixture of DCM (2 mL) and TFA (2 mL) 
and stirred at room temperature for 45 minutes. Volatiles were evaporated under reduced pressure. 
The residue was concentrated twice from MeOH-toluene. Preparative prep-HPLC provided the 
product (14.9 mg, 7% yield, 3 steps) as a dark yellow powder. HRMS (ESI) calc’d for 
C20H26FN4O2 [M+H]+ 373.2034, found 373.2030. 1H NMR (500 MHz, DMSO-d6) δ 8.72 (s, 3H), 
8.37 (s, 3H), 7.37 (d, J = 13.9 Hz, 1H), 6.45 (s, 1H), 4.25–4.17 (m, 2H), 3.80 (d, J = 9.4 Hz, 1H), 
3.71 (d, J = 9.3 Hz, 1H), 3.64 (d, J = 9.8 Hz, 1H), 3.48 (s, 3H), 3.42 (d, J = 8.8 Hz, 1H), 3.36–3.29 
(m, 1H), 1.36 (s, 3H), 1.10–0.98 (m, 4H), 0.42–0.31 (m, 2H). 
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Synthesis of 7-(1-Amino-3-azabicyclo[3.1.0]hexan-3-yl)-4-(aminomethyl)-1-cyclopropyl-8-
(difluoromethoxy)-6-fluoroquinolin-2(1H)-one hydrochloride (30) 
 
Methyl 4-bromo-5-fluoro-2-iodo-3-((2- (trimethylsilyl)ethoxy)methoxy) benzoate (65) 
 
Methyl 4-bromo-5-fluoro-2-iodo-3-methoxybenzoate (1.80 g, 4.60 mmol) was dissolved in 
DCM (20 mL) and cooled to –78 °C. BBr3 (1M in DCM, 36.8 mL, 36.8 mmol) was added and the 
reaction mixture was stirred at room temperature for 18 hours. The reaction mixture was quenched 
with ice-water and extracted with EtOAc. The organic layer was washed with brine, dried over 
sodium sulfate and concentrated to afford the crude residue. The crude residue was purified by 
silica gel column chromatography (0-10% EtOAc/hexanes) to afford the demethylated product. 
The corresponding phenol was dissolved in acetonitrile (6 mL). K2CO3 (0.73 g, 5.30 mmol) and 
SEM-Cl (0.42 g, 2.50 mmol) were added and the reaction mixture was stirred at 100 °C for 1 hour. 
The reaction mixture was filtered, washed with EtOAc, and concentrated to afford the crude 
desired product (0.90 g, 39% yield, 2 steps). The crude product was used in the next step without 
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further purification. 1H NMR (400 MHz, CDCl3) δ 7.37 (d, J = 8.6 Hz, 1H), 5.30 (s, 2H), 4.11–




Methyl 4-bromo-5-fluoro-2-iodo-3-((2-(trimethylsilyl)ethoxy)methoxy) benzoate (0.90 g, 1.78 
mmol), Cs2CO3 (0.86 g, 2.65 mmol) and xantphos (0.15 g, 0.27 mmol) were suspended in dioxane 
(28 mL). Pd2(dba)3 (0.08 g, 0.09 mmol) and cyclopropyl amine (0.20 g, 3.50 mmol) were added 
and the reaction mixture was stirred at 110 °C for 8 hours. The reaction mixture was quenched 
with water and extracted with EtOAc. The organic layer was washed with brine, dried over sodium 
sulfate and concentrated. The crude residue was purified by silica gel column chromatography (0-
5% EtOAc/hexanes) affording the cyclopropyl aniline. The aniline was dissolved in DCM (10 mL) 
and cooled to 0 °C. DIPEA (0.44 g, 3.46 mmol) and acetyl chloride (0.27 g, 3.46 mmol) were 
added and the reaction mixture was stirred at room temperature for 4 hours. The reaction mixture 
was quenched with water and extracted with DCM. The organic layer was washed with brine, dried 
over sodium sulfate and concentrated to afford the crude residue. The crude residue was purified 
by silica gel column chromatography (20-30% EtOAc/hexanes) to afford the desired product (0.30 
g, 35% yield, 2 steps). LCMS (m/z): 346.2 [M–SEM+H]+. 1H NMR (400 MHz, CDCl3) δ 7.55 (d, 
J = 8.6 Hz, 1H), 5.10 (d, J = 5.0 Hz, 1H), 5.02 (d, J = 5.0 Hz, 1H), 3.90 (d, J = 1.9 Hz, 2H), 3.85 
(s, 3H), 3.22–3.19 (m, 1H), 2.41 (s, 3H), 1.28 (d, J = 2.8 Hz, 2H), 1.03 (d, J = 3.3 Hz, 2H), 0.84–




dihydroquinolin-4-yl trifluoromethanesulfonate (S37) 
 
Methyl 4-bromo-2-(N-cyclopropylacetamido)-5-fluoro-3-((2-(trimethylsilyl)ethoxy)methoxy) 
benzoate (0.30 g, 0.63 mmol) was dissolved in THF (10 mL) and cooled to –78 °C. NaHMDS (1.0 
M in THF, 1.90 mL, 1.90 mmol) was added dropwise and the reaction mixture was stirred at –78 
°C for 1 hour. The reaction mixture was quenched with ice-water, acidified to pH 2 by the addition 
of 1N HCl and extracted with EtOAc. The organic layer was washed with brine, dried over sodium 
sulfate and concentrated to afford the desired cyclized product. The crude heterocycle was 
dissolved in DMF (5 mL) and cooled to 0 °C. Et3N (0.10 g, 1.00 mmol) and PhNTf2 (0.19 g, 0.50 
mmol) were added and the reaction mixture was stirred at room temperature for 1.5 hours. The 
reaction mixture was quenched with cold water and extracted with EtOAc. The organic layer was 
washed with cold water, brine, dried over sodium sulfate and concentrated to afford a crude 
residue. The crude residue was purified by silica gel column chromatography (0-20% 
EtOAc/hexanes) to afford the desired product (0.19 g, 94% yield, 2 steps). LCMS (m/z): 578.4 
[M+2]+. 1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 8.6 Hz, 1H), 6.72 (s, 1H), 5.12 (s, 2H), 3.87–






dihydroquinolin-4-yl trifluoromethanesulfonate (0.59 g, 10.2 mmol), potassium (((tert-
butoxycarbonyl)amino)methyl)trifluoroborate (0.49 g, 20.5 mmol) and Na2CO3 (0.27 g, 2.56 
mmol) were suspended in toluene (18 mL) and water (0.1 mL) and the reaction mixture was 
degassed with nitrogen for 5 minutes. PdCl2(dppf) (0.04 g, 0.51 mmol) was added and the reaction 
mixture was stirred at 110 °C for 9 hours. The reaction mixture was diluted with water and 
extracted with EtOAc. The organic layer was washed with brine, dried over sodium sulfate and 
concentrated to afford a crude residue, which was purified silica gel column chromatography (20-





1,2-dihydroquinolin-4-yl)methyl)carbamate (0.12 g, 9.55 mmol) was dissolved in DCM (2 mL) at 
room temperature. HCl (4M in dioxane, 1 mL) was added and the reaction mixture was stirred at 
room temperature for 2 hours. The reaction mixture was concentrated to afford a crude residue, 
which was purified by trituration with pentane, affording the desired product (65.0 mg, 93% yield). 







4-(Aminomethyl)-7-bromo-1-cyclopropyl-6-fluoro-8-hydroxyquinolin-2(1H)-one (65.0 mg, 
0.20 mmol) was dissolved in DCM (2 mL) and the reaction mixture was cooled to 0 °C. Et3N (0.12 
g, 1.22 mmol) and (Boc)2O (59.0 mg, 0.27 mmol) were added and the reaction mixture was stirred 
at room temperature for 2 hours. The reaction mixture was concentrated to afford a crude residue 
which was purified by trituration with pentane, affording the desired product (80.0 mg, 94% yield). 





yl)methyl)carbamate (100 mg, 0.23 mmol) was dissolved in acetonitrile at room temperature. 
K2CO3 (1.29 g, 9.36 mmol) in water (3 mL) and 2-chloro-2,2-difluoro-1-phenylethan-1-one (178 
mg, 0.94 mmol) were added and the reaction mixture was stirred at 120 °C for 24 hours. The 
reaction mixture was quenched with cool water and extracted with EtOAc. The organic layer was 
washed with brine, dried over sodium sulfate and concentrated to afford a crude residue, which 
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was purified by silica gel column chromatography (15-20% EtOAc/Hexane), providing the desired 






4-yl)methyl)carbamate (30.0 mg, 0.06 mmol), tert-butyl (3-azabicyclo[3.1.0]hexan-1-
yl)carbamate (25.0 mg, 0.13 mmol), cesium carbonate (61.0 mg, 0.19 mmol), Pd2(dba)3 (11.0 mg, 
0.01 mmol) and BINAP (16.0 mg, 0.03 mmol) were combined in a sealed tube which was 
evacuated and back-filled with nitrogen. Toluene (0.6 mL) was added and the reaction mixture 
was stirred at 110 °C for 12 hours. The reaction mixture was quenched with water and extracted 
with EtOAc. The organic layer was washed with brine, dried over sodium sulfate and concentrated 
to afford a crude residue, which was purified by prep TLC (50% EtOAc/hexanes), affording the 
desired product (15.0 mg, 40% yield). LCMS (m/z): 595.9 [M+H]+.  
7-(1-Amino-3-azabicyclo[3.1.0]hexan-3-yl)-4-(aminomethyl)-1-cyclopropyl-8-




8-(difluoromethoxy)-6-fluoro-2-oxo-1,2-dihydroquinolin-4-yl)methyl) carbamate (15.0 mg, 0.03 
mmol) was dissolved in DCM (1 mL) and cooled at 0 °C. HCl (4M in dioxane, 0.5 mL) was added 
and the reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was 
concentrated to afford the crude product, which was triturated with diethyl ether, providing the 
desired product (10.0 mg, 85% yield, purity = 82%). HRMS (ESI) calc’d for C19H22F3N4O2 
[M+H]+ 395.1689, found 395.1682. 1H NMR (400 MHz, CD3OD) δ 7.53 (d, J = 13.6 Hz, 1H), 
6.57 (s, 1H), 4.38 (s, 2H), 4.00 (d, J = 9.6 Hz, 1H), 3.88–3.80 (m, 2H), 3.73 (d, J = 10.1 Hz, 1H), 
3.47 (s, 1H), 2.03 (d, J = 4.2 Hz, 1H), 1.35–1.27 (m, 2H), 1.23–1.18 (m, 2H), 0.57 (d, J = 2.9 Hz, 
2H). 
Preparation of 7-(1-Amino-3-azabicyclo[3.1.0]hexan-3-yl)-4-(aminomethyl)-1-





A mixture of tert-butyl ((7-(1-((tert-butoxycarbonyl)amino)-3-azabicyclo[3.1.0]hexan-3-yl)-1-
cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-dihydroquinolin-4-yl)methyl)carbamate (100 mg, 0.18 
mmol) in MeCN (1 mL) was treated with N-bromosuccinimide (49.0 mg, 0.24 mmol). After 
stirring 30 minutes at rt, the reaction was concentrated and the crude material was purified by silica 
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gel flash chromatography (0-100% EtOAc/heptane) to provide the desired product (27.0 mg, 24% 
yield) as a yellow oil. LCMS (m/z): 623.4 [M+2]+. 
7-(1-Amino-3-azabicyclo[3.1.0]hexan-3-yl)-4-(aminomethyl)-1-cyclopropyl-6-fluoro-3,8-
dimethylquinolin-2(1H)-one trifluoroacetic acid (31) 
 
A solution of tert-butyl ((3-bromo-7-(1-((tert-butoxycarbonyl)amino)-3-
azabicyclo[3.1.0]hexan-3-yl)-1-cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-dihydroquinolin-4-
yl)methyl)carbamate (27.0 mg, 0.04 mmol), methylboronic acid (13.0 mg, 0.22 mmol), 
PdCl2(dppf) CH2Cl2 adduct (7.10 mg, 8.69 µmol) and K3PO4 (18.4 mg, 0.09 mmol) in dioxane 
(0.9 mL) was stirred at 90 °C for 18 hours. Upon cooling to rt the mixture was diluted with water 
and extracted with EtOAc. The combined organic extracts were washed with brine, dried over 
Na2SO4, filtered and concentrated to give a dark brown oil. To a mixture of the protected bis-amine 
in DCM (0.5 mL) was added TFA (0.5 mL), followed by stirring at rt for 1 hour. The solution was 
concentrated and the crude material was purified by prep-HPLC, affording the desired product (9.3 
mg, 36% yield, 2 steps) as an off-white powder. LCMS (m/z): 357.4 [M+H]+. 1H NMR (400 MHz, 
CD3OD) δ 7.47 (d, J = 13.6 Hz, 1H), 4.38 (s, 2H), 3.83 (d, J = 8.8 Hz, 1H), 3.77 (dd, J = 9.4, 2.8 
Hz, 1H), 3.66 (d, J = 8.9 Hz, 1H), 3.62–3.53 (m, 1H), 3.37 (d, J = 9.5 Hz, 1H), 2.56 (s, 3H), 2.30 









Benzyloxyacetyl chloride (0.39 mL, 2.48 mmol) was added dropwise to a mixture of methyl 2-
(N-cyclopropylacetamido)-4-bromo-5-fluoro-3-methylbenzoate (150 mg, 0.50 mmol) and 
pyridine (0.20 mL, 2.48 mmol) in DCM (3 mL) at 0 °C. The solution was stirred at rt for 3 hours. 
The mixture was diluted with DCM and washed with saturated aqueous NH4Cl, saturated 
NaHCO3, and brine, then dried over MgSO4 and concentrated under reduced pressure. Purification 
by silica gel column chromatography (0-60% EtOAc/heptane) provided the desired product as a 




Methyl 2-(2-(benzyloxy)-N-cyclopropylacetamido)-4-bromo-5-fluoro-3-methylbenzoate (113 
mg, 0.25 mmol) was dissolved in THF (2.5 mL) and cooled to –78 °C. NaHMDS (1M in THF, 
0.75 mL, 0.75 mmol) was added dropwise and the reaction mixture was stirred at –78 °C for 30 
minutes. The reaction mixture was quenched with ice-water, acidified to pH 2 by the addition of 
1N HCl and extracted with EtOAc. The organic layer was washed with brine, dried over sodium 
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sulfate and concentrated to afford the desired heterocycle. The crude material was dissolved in 
DMF (1.25 mL) and cooled to 0 °C. Et3N (76.0 mg, 0.75 mmol) and PhNTf2 (107 mg, 0.30 mmol) 
were added and the reaction mixture was stirred at room temperature for 2 hours. The reaction 
mixture was quenched with cold water and extracted with EtOAc. The organic layer was washed 
with cold water, brine, dried over sodium sulfate and concentrated to afford a crude residue, which 
was purified by silica gel column chromatography (0-40% EtOAc/hexanes), providing the desired 
product (0.071 g, 52% yield). LCMS (m/z): 551.9 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 7.50 
(dd, J = 9.1, 7.3 Hz, 2H), 7.41–7.32 (m, 3H), 7.19 (d, J = 8.1 Hz, 1H), 5.54 (s, 2H), 3.55 (tt, J = 




A suspension of 3-(benzyloxy)-7-bromo-1-cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-
dihydroquinolin-4-yl trifluoromethanesulfonate (0.50 g, 0.90 mmol), K3PO4 (0.58 g, 2.70 mmol), 
potassium (((tert-butoxycarbonyl)amino)methyl)trifluoroborate (0.43 g, 1.81 mmol) in THF (5 
mL) and water (0.05 mL) was degassed with argon for 30 minutes. PdCl2(dppf)·DCM adduct (22.0 
mg, 0.03 mmol) was added and the reaction mixture was stirred at 90 °C for 7 hours. The reaction 
mixture was quenched with cold water and extracted with EtOAc. The combined organic layers 
were washed with brine, dried over sodium sulfate and concentrated to afford a crude residue, 
which was purified by silica gel column chromatography (0-25% EtOAc/hexanes), providing the 
desired product (0.14 g, 15% yield). LCMS (m/z): 431.4 [M–Boc+H]. 1H NMR (400 MHz, 
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DMSO-d6) δ 7.50–7.30 (m, 6H), 5.35 (s, 2H), 4.30 (d, J = 6.0 Hz, 2H), 3.81–3.79 (m, 1H), 3.61–





A suspension of tert-butyl ((3-(benzyloxy)-7-bromo-1-cyclopropyl-6-fluoro-8-methyl-2-oxo-
1,2-dihydroquinolin-4-yl)methyl)carbamate (130 mg, 0.24 mmol), Cs2CO3 (240 mg, 0.73 mmol), 
tert-butyl (azabicyclo[3.1.0]hexan-1-yl)carbamate (73.0 mg, 0.37 mmol) in toluene (5 mL) was 
degassed for 5 minutes. Pd2(dba)3 (11.0 mg, 0.01 mmol) and BINAP (15.0 mg, 0.02 mmol) were 
added and the reaction mixture was stirred at 100 °C for 15 hours. The reaction mixture was 
quenched with cold water and extracted with EtOAc. The organic layer was washed with brine, 
dried over sodium sulfate and concentrated to afford a crude residue, which was purified by silica 
gel column chromatography (50% EtOAc/hexanes), providing the desired product (55.0 mg, 35% 
yield). LCMS (m/z): 649.5 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 7.43–7.28 (m, 6H), 5.32 (s, 
2H), 4.28 (d, J = 5.6 Hz, 2H), 3.93–3.91 (m, 1H), 3.81–3.79 (m, 1H), 3.68–3.66 (m, 1H), 3.57–
3.55 (m, 1H), 3.26–3.23 (m 1H), 2.47 (s, 3H), 1.71–1.68 (m, 1H), 1.57 (s, 9H), 1.49 (s, 9H), 1.30–





hydroxy-8-methylquinolin-2(1H)-one trifluoroacetic acid (32) 
 
tert-Butyl (3-(3-(benzyloxy)-4-(((tert-butoxycarbonyl)amino)methyl)-1-cyclopropyl-6-fluoro-
8-methyl-2-oxo-1,2-dihydroquinolin-7-yl)-3-azabicyclo[3.1.0]hexan-1-yl)carbamate (55.0 mg, 
0.08 mmol) was dissolved in MeOH (0.5 mL). Pd/C (10%, 50% in water, 6.00 mg) was added and 
the reaction mixture was stirred at room temperature for 2 hours under a hydrogen atmosphere. 
The reaction mixture was filtered through Celite and the filtrate was concentrated to afford the 
deprotected hydroxyl. The protected bis-amine was dissolved in DCM (0.5 mL) and cooled to 0 
°C. HCl (4.0 M in dioxane, 0.3 mL) was added and the reaction mixture was stirred at room 
temperature for 2 hours. The reaction mixture was concentrated to afford a crude residue, which 
was purified by prep HPLC providing the desired product (3.50 mg, 15% yield, purity = 91%). 
LCMS (m/z): 359.4 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 7.38 (d, J = 13.2 Hz, 1H), 4.32 (s, 
2H), 3.82–3.57 (m 4H), 3.37 (s, 2H), 2.54 (s, 3H), 2.01–1.99 (m, 1H), 1.40–1.20 (m 4H), 0.57–













A suspension of 7-bromo-1-cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-dihydroquinoline-4-
carbonitrile (250 mg, 0.78 mmol), tert-butyl 3-azabicyclo[3.1.0]hexan-1-ylcarbamate (309 mg, 
1.56 mmol), BINAP (194 mg, 0.31 mmol), Pd2dba3 (143 mg, 0.16 mmol) and cesium carbonate 
(761 mg, 2.34 mmol) in toluene (7.8 mL) was heated to 100 °C for 5.5 hours. Upon cooling to 
room temperature the mixture was filtered and concentrated. The crude material was purified by 
silica gel column chromatography (0-100% EtOAc/heptane) to give the product (650 mg, 85% 
yield). LCMS (m/z): 439.4 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 7.32 (d, J = 12.1 Hz, 1H), 6.87 
(s, 1H), 3.94–3.82 (m, 1H), 3.75–3.67 (m, 1H), 3.59–3.52 (m, 1H), 3.52–3.44 (m, 1H), 3.40–3.30 
(m, 1H), 2.45 (s, 3H), 1.73 (s, 1H), 1.54 (s, 9H), 1.27–1.20 (m, 2H), 1.17–1.10 (m, 1H), 1.06–0.97 





A mixture of tert-butyl (3-(4-cyano-1-cyclopropyl-6-fluoro-8-methyl-2-oxo-1,2-
dihydroquinolin-7-yl)-3-azabicyclo[3.1.0]hexan-1-yl)carbamate (650 mg, 1.48 mmol) in 2M NH3 
in MeOH (60 mL) was treated with Pd/C (10%, 50% water, 947 mg, 0.45 mmol). The flask was 
partially evacuated and back-filled with H2 5 times, then stirred under a balloon of H2 for 1 hour. 
The reaction mixture was filtered through a plug of celite and concentrated under reduced pressure 
to give the desired primary amine as a yellow-brown oil. The amine was dissolved in THF (7.4 
mL) was treated with DIPEA (0.8 mL, 4.45 mmol) and Boc anhydride (0.45 mL, 1.93 mmol) 
followed by stirring at room temperature for 1 hour. The mixture was diluted with saturated 
aqueous NH4Cl and extracted with EtOAc. The combined organic extracts were washed with 
saturated brine, dried over MgSO4, filtered and concentrated under reduced pressure. Silica gel 
column chromatography (0-100% EtOAc/heptane) provided the title compound (448 mg, 50% 
yield, 2 steps) as a yellow foam. LCMS (m/z): 543.4 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 7.10 
(d, J = 13.2 Hz, 1H), 6.47 (s, 1H), 5.04 (s, 1H), 4.86–4.74 (m, 1H), 4.44–4.31 (m, 2H), 3.88–3.75 
(m, 1H), 3.67 (d, J = 8.6 Hz, 1H), 3.56–3.39 (m, 2H), 3.28 (d, J = 9.3 Hz, 1H), 2.45 (s, 3H), 1.69 







A mixture of tert-butyl (3-(4-(((tert-butoxycarbonyl)amino)methyl)-1-cyclopropyl-6-fluoro-8-
methyl-2-oxo-1,2-dihydroquinolin-7-yl)-3-azabicyclo[3.1.0]hexan-1-yl)carbamate (176 mg, 0.32 
mmol) in MeCN (1.6 mL) was treated with N-chlorosuccinimide (130 mg, 0.97 mmol) followed 
by stirring for 4 hours at room temperature. Volatiles were evaporated under reduced pressure. 
The residue was dissolved in EtOAc and washed with 10% aqueous citric acid, saturated aqueous 
NaHCO3 and brine, then dried over Na2SO4, filtered and concentrated under reduced pressure. 
Silica gel column chromatography (0-100% EtOAc/heptane) provided the title compound (127 
mg, 61% yield) as a pale yellow foam. LCMS (m/z): 577.3 [M+H]+. 1H NMR (400 MHz, CDCl3) 
δ 7.55–7.44 (m, 1H), 5.04 (br s, 1H), 4.83 (br s, 1H), 4.62 (d, J = 5.7 Hz, 2H), 3.83 (br s, 1H), 3.68 
(d, J = 8.7 Hz, 1H), 3.61–3.45 (m, 2H), 3.31 (d, J = 9.3 Hz, 1H), 2.44 (s, 3H), 1.70 (br s, 1H), 
1.55–1.38 (m, 18H), 1.22–1.14 (m, 3H), 1.04–0.96 (m, 1H), 0.56–0.48 (m, 2H). 
7-(1-Amino-3-azabicyclo[3.1.0]hexan-3-yl)-4-(aminomethyl)-3-chloro-1-cyclopropyl-6-
fluoro-8-methylquinolin-2(1H)-one trifluoroacetic acid (33) 
 
A mixture of tert-butyl (3-(4-(((tert-butoxycarbonyl)amino)methyl)-3-chloro-1-cyclopropyl-6-
fluoro-8-methyl-2-oxo-1,2-dihydroquinolin-7-yl)-3-azabicyclo[3.1.0]hexan-1-yl)carbamate (67 
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mg, 0.12 mmol) in DCM (0.6 mL) and TFA (0.6 mL) was stirred for 20 minutes at room 
temperature. Volatiles were evaporated under reduced pressure and the oily residue was 
concentrated twice from MeOH-toluene then subjected to preparative HPLC to give the product 
(22.8 mg, 32% yield). LCMS (m/z): 377.2 [M+H]+. 1H NMR (500 MHz, CD3OD) δ 7.55 (d, J = 
13.5 Hz, 1H), 4.52 (s, 2H), 3.87–3.82 (m, 1H), 3.82–3.76 (m, 1H), 3.74–3.69 (m, 1H), 3.69–3.63 
(m, 1H), 3.44–3.40 (m, 1H), 2.56 (s, 3H), 2.03–1.97 (m, 1H), 1.36–1.22 (m, 4H), 0.52–0.42 (m, 
2H). 
Preparation of 7-(1-Amino-3-azabicyclo[3.1.0]hexan-3-yl)-4-(aminomethyl)-1-
cyclopropyl-3,6-difluoro-8-methylquinolin-2(1H)-one hydrochloride (34) 
Methyl 4-bromo-2-(N-cyclopropyl-2-fluoroacetamido)-5-fluoro-3-methylbenzoate (75) 
 
Methyl 4-bromo-2-(cyclopropylamino)-5-fluoro-3-methylbenzoate (3.50 g, 11.6 mmol) was 
dissolved in toluene (15 mL) at 0 °C. 2-Fluoro acetyl chloride (1.11 g, 11.6 mmol) was added and 
the reaction mixture was stirred at 85 °C for 4 hours. The reaction mixture was quenched with 
water and extracted with EtOAc. The organic layer was washed with saturated NaHCO3 solution 
and brine, then dried over sodium sulfate and concentrated. The crude residue was purified by 
silica gel column chromatography (25-30% EtOAc/hexanes) to afford the desired product (3.00 g, 
62% yield). LCMS (m/z): 364.4 [M+2]+. 1H NMR (400 MHz, CDCl3) δ 7.71–7.55 (m, 1H), 5.40 
(ddd, J = 47.0, 37.4, 14.2 Hz, 1H), 4.53 (ddd, J = 76.7, 47.1, 13.5 Hz, 1H), 3.97–3.84 (m, 3H), 






Methyl 4-bromo-2-(N-cyclopropyl-2-fluoroacetamido)-5-fluoro-3-methylbenzoate (3.00 g, 8.20 
mmol) was dissolved in THF (20 mL) and cooled to –78 °C. NaHMDS (1M in THF, 24.9 mL, 
24.9 mmol) was added dropwise and the reaction mixture was stirred at –78 °C for 30 minutes. 
The reaction mixture was then stirred at room temperature for 1 hour. The reaction mixture was 
quenched with ice-water and washed with EtOAc. The aqueous layer was acidified with 1N HCl 
and extracted with EtOAc. The organic layer was washed with brine, dried over sodium sulfate 
and concentrated to afford a crude residue, which was purified by trituration with pentane, 
providing the desired product (2.50 g, 91% yield). LCMS (m/z): 332.3 [M+2]+. 1H NMR (400 
MHz, DMSO-d6) δ 12.03 (s, 1H), 7.59 (d, J = 8.7 Hz, 1H), 3.50 (s, 1H), 2.73 (s, 3H), 1.12 (d, J = 




7-Bromo-1-cyclopropyl-3,6-difluoro-4-hydroxy-8-methylquinolin-2(1H)-one (2.50 g, 7.50 
mmol) was dissolved in DMF (14 mL) at 0 °C. Triethylamine (2.29 g, 22.7 mmol) and PhNTf2 
(4.00 g, 11.4 mmol) in DMF (14 mL) were added at 0 °C and the reaction mixture was stirred at 
room temperature for 4 hours. The reaction mixture was quenched with ice-water and extracted 
with EtOAc. The organic layer was washed with cold water and brine, then dried over sodium 
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sulfate and concentrated to afford a crude residue, which was purified by silica gel column 
chromatography (0-5% EtOAc/hexanes), providing the desired product (3.00 g, 85% yield). LCMS 




A solution of 7-bromo-1-cyclopropyl-3,6-difluoro-8-methyl-2-oxo-1,2-dihydroquinolin-4-yl 
trifluoro methanesulfonate (1.50 g, 3.20 mmol), potassium (((tert-butoxycarbonyl)amino)methyl) 
trifluoroborate (1.53 g, 6.40 mmol) and Na2CO3 (0.86 g, 8.10 mmol) in toluene (45 mL) and water 
(0.15 mL) was degassed with nitrogen for 5 minutes. PdCl2(dppf) (0.12 g, 0.16 mmol) was added 
and the reaction mixture was stirred at 85 °C for 5 hours. The reaction mixture was diluted with 
water and extracted with EtOAc. The organic layer was washed with brine, dried over sodium 
sulfate and concentrated. The crude residue was purified by silica gel column chromatography (0-





A suspension of tert-butyl ((7-bromo-1-cyclopropyl-3,6-difluoro-8-methyl-2-oxo-1,2-dihydro 
quinolin-4-yl)methyl)carbamate (0.22 g, 0.50 mmol), tert-butyl (3-azabicyclo[3.1.0]hexan-1-
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yl)carbamate (0.20 g, 0.99 mmol), cesium carbonate (0.49 g, 1.49 mmol), Pd2dba3 (0.09 g, 0.10 
mmol) and BINAP (0.12 g, 0.20 mmol) in dioxane (3.6 mL) was stirred at 100 °C for 6 hours. The 
reaction mixture was quenched with water and extracted with EtOAc. The organic layer was 
washed with brine, dried over sodium sulfate and concentrated. The crude residue was purified by 
prep HPLC purification to afford the desired product (0.08 g, 40% yield). LCMS (m/z): 561.8 
[M+H]+. 1H NMR (400 MHz, MeOD) δ 7.47 (d, J = 13.2 Hz, 1H), 4.46 (s, 2H), 3.84 (s, 1H), 3.61 
(d, J = 20.3 Hz, 3H), 3.35 (s, 1H), 2.54 (s, 3H), 1.67 (s, 1H), 1.46 (s, 18H), 1.21 (d, J = 19.9 Hz, 
3H), 0.98 (s, 1H), 0.53 (s, 2H). 
7-(1-Amino-3-azabicyclo[3.1.0]hexan-3-yl)-4-(aminomethyl)-1-cyclopropyl-3,6-difluoro-8-
methylquinolin-2(1H)-one hydrochloride (34) 
 
tert-Butyl ((7-(1-((tert-butoxycarbonyl)amino)-3-azabicyclo[3.1.0]hexan-3-yl)-1-cyclopropyl-
3,6-difluoro-8-methyl-2-oxo-1,2-dihydroquinolin-4-yl)methyl)carbamate (50.0 mg, 0.01 mmol) 
was dissolved in dioxane (3 mL) at 0 °C. HCl (4M in dioxane, 3.0 mL) was added and the reaction 
mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated and 
the crude residue was triturated with diethyl ether to afford the desired product (35.0 mg, 90% 
yield). HRMS (ESI) calc’d for C19H23F2N4O [M+H]+ 361.1834, found 361.1832. 1H NMR (400 
MHz, MeOD) δ 7.54 (d, J = 13.2 Hz, 1H), 4.41 (s, 2H), 3.86 (d, J = 8.9 Hz, 1H), 3.80 (d, J = 9.9 




In vitro and in vivo Biology 
General: IC50 values obtained from the GyrA/B and ParC/E biochemical assays are reported as 
the geometric mean of 2 or more replicates, with the exception of compound 34 against E. coli 
GyrA/B (single replicate). For MIC data, the most frequently occurring value from three or more 
replicates is reported. In cases where only two replicates were available, or where two values 
occurred with identical frequency, the higher of the two values is reported. MIC data is based on 
two or more separate experiments with the exception of compounds 6-8, 11-14 and 18. 
Biochemical Assay 
Purification of E. coli GyrA, GyrB, ParC and ParE: Large scale expression cultures of E. 
coli cells carrying expression plasmid of recombinant full-length GyrA, GyrB, ParC and ParE (T7 
promoter C-terminal 6xHis tag) were grown separately using standard procedures (1-6 liters). 
When cultures reached late log-phase, incubation temperature was lowered to 18 ºC and protein 
expression was induced by adding IPTG to 1 mM with growth continuing overnight. Cells were 
collected by centrifugation, resuspended in 5x volume of IMAC buffer A (50 mM Tris-HCl pH7.5; 
300 mM NaCl;  2 mM MgCl2; 10% (v/v) glycerol; 1 mM TCEP) containing 15 mM imidazole, 
Benzonase endonuclease (EMD Millipore) and protease inhibitors (Roche cOmplete, EDTA-free), 
and lysed by sonication. The total lysate was centrifuged to obtain the soluble lysate, which was 
applied to a column of Ni Sepharose FF (GE Healthcare Life Sciences) equilibrated with 6% (v/v) 
IMAC buffer B (50 mM Tris-HCl pH 7.5; 300 mM NaCl; 2 mM MgCl; 10% (v/v) glycerol; 1 mM 
TCEP; 250 mM imidazole). The column was washed with the same buffer and developed with a 
linear gradient to 100% (v/v) IMAC buffer B over 20 column volumes. 
Fractions were analyzed by SDS-PAGE and pooled accordingly, concentrated and applied to a 
Superdex 200 (GE Healthcare Life Sciences) size-exclusion column equilibrated with 50 mM Tris-
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HCl pH7.5, 50 mM KCl, 2 mM MgCl2, 10% (v/v) glycerol; 1 mM TCEP. Fractions were pooled 
based on analysis by SDS-PAGE, made to 2 mM spermidine, quantified by Bradford assay, 
aliquoted, flash-frozen in liquid nitrogen, and stored at -80 ºC for reconstitution prior to 
biochemical assays.  
E. coli gyrase DNA supercoiling assay: Tetrameric E. coli GyrAB was prepared by incubation 
of 10 µM of each subunit in GyrAB assay buffer (50 mM Tris-HCl pH7.5, 10 mM MgCl2, 30 mM 
KCl, 10% glycerol, 0.005% BSA, 0.005% CHAP, 75 mM ammonium acetate , 0.5 mM EDTA and 
1 mM DTT) at room temperature for 60 minutes.  
10 nM tetramer of E. coli GyrAB was pre-incubated with compound for 30 minutes at room 
temperature before 40 µg/mL (final concentration) relaxed DNA (TopoGEN TG2035-3) and 1 
mM (final concentration) ATP in GyrAB assay buffer were added for a reaction time of 2 hours. 
The reaction was quenched with 0.1% (final) SDS. 
Supercoiled DNA generated by E. coli GyrAB was monitored by size exclusion 
chromatography. An Agilent 1100 HPLC containing a diode array detector was used to acquire 
data. The instrument was controlled using the Agilent Chemstation software. A 10 µL aliquot of 
each sample was injected onto a Waters Acquity BEH200 (1.7 µm particle, 4.6 x 300 mm) column. 
Separation occurred using an isocratic gradient with 100 mM sodium phosphate, pH 6.8, as mobile 
phase. Detection was by diode array at 260 nm. To increase assay throughput, the SEC analysis 
was multiplexed, by staggering injections of samples to effectively analyze four samples in one 
run. Samples were injected every 4 minutes using separate 4 min long isocratic gradient, with the 
fourth sample injected being subjected to a full 40 minute gradient to elute all peaks (see HPLC 
conditions below). Peak height was used to calculate percent inhibition. 
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To reduce column degradation and clogging, two 10 µL injections of Pierce universal nuclease 
(100 kU) were run through the column on a 120 minute isocratic gradient at a flow rate of 10 
µL/min, followed by 3 blank injections using the same gradient. 
Multiplexed HPLC pump and autosampler conditions for samples 1n-3n 
Sample 1n-3n pump parameters 
Time (min) Flow Rate (mL/min) 
0 0.1 
4 0.1 
NOTE: Injection overlap at 2.5 minutes 
Multiplexed HPLC pump and autosampler conditions for samples 4n 
Sample 4n pump parameters 








 E. coli Topoisomerase IV DNA decatenation assay: E. coli ParCE tetramer was prepared by 
incubation of 10 µM of each subunit in ParCE assay buffer (50 mM Tris-HCl pH7.5, 10 mM 
MgCl2, 50 mM KCl, 100 mM KGlu, 1 mM EDTA, 0.01% Tween 20, 4 mM DTT, 0.01% BSA) at 
room temperature for 60 minutes.  
 109 
1.25 nM E. coli ParCE tetramer was pre-incubated with compound for 30 minutes at room 
temperature before 10 µg/mL (final concentration) kinetoplast DNA (TopoGEN TG2013-3) and 1 
mM (final concentration) ATP in ParCE assay buffer were added for a reaction time of 1 hour. 
The reaction was quenched with 0.1% (final) SDS. 
Decatenated kinetoplast DNA generated by E coli ParCE was monitored by size exclusion 
chromatography. An Agilent 1200 capillary HPLC containing a variable wavelength detector was 
used to acquire data. The instrument was controlled using the Agilent MassHunter Acquisition 
software. An 8 µL aliquot of each sample was injected onto a Sepax Zenix size exclusion 
chromatography guard column (3 µm particle, 4.6 x 50 mm). The separation of the decatenated 
DNA from the UV sensitive buffer components was achieved on a 7 minute isocratic gradient at 
600µL per minute. 100 mM sodium phosphate pH 6.8 was used as the mobile phase. Diode array 
detector (DAD) detection was performed at 260 nm. 
Data were analyzed and LC peaks integrated using Agilent ChemStation software (Revision 
B.0.03.02-SR2). Manual integration was used to adjust integration in the event of additional peak 
integration. Area under the curve of decatenated kDNA was used to calculate percent inhibition. 
Antibacterial Susceptibility Testing 
Antibacterial Activity Testing: Antibacterial activity was assessed using a broth microdilution 
assay following the recommended methodology of the Clinical and Laboratories Institute (CLSI 
M07).93 Performance of the assay was monitored by testing ciprofloxacin against laboratory 
quality control strains in accordance with guidelines of the CLSI (CLSI M100).71 
Selection of single step spontaneous mutants. E. coli ATCC 25922 was used for selection 
experiments. Single-step selection was performed on cation-adjusted Mueller-Hinton agar plates 
containing test compounds at 2X, 4X and 8X multiples of the MIC. Dilutions of cell suspension 
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were also plated on drug-free medium to enumerate CFU/mL. Plates were incubated at 37 ºC for 
up to 72 hours and CFU were counted. Mutant frequencies were calculated by dividing the number 
of colonies on drug containing plates by the number of CFU plated. 
Bacterial strains: Wild type and laboratory engineered mutant strains are described in Table 9.  
In P. aeruginosa, a C248T mutation in gyrA (encoding T83I) together with a C260G mutation in 
parC (encoding S87L) imparts a 256-fold decrease in susceptibility to ciprofloxacin.94 These 
mutations were introduced onto the genome of the efflux deficient P. aeruginosa strain NB52023 
as follows: first, a 1 kb gyrA fragment encompassing the C248T mutation was amplified from a 
genome sequenced P. aeruginosa clinical isolate using primers SR73 (5′-
ggccagtgccaagctattgaacgaggcgactgga-3′) and SR75 (5′-acgaattcgagctcgggcagctcggtgatgataa-3′). 
This was inserted into the gene replacement vector pEX18Ap,95 that had been digested with 
HindIII/KpnI, using the In-Fusion HD cloning kit (Takara) according to the supplied instructions.  
The resulting vector was mobilized into strain NB52023 as described previously96 and 
merodiploids were selected on L-agar containing irgasan and carbenicillin. Merodiploids were 
resolved on L-agar containing sucrose and 0.125 µg/mL ciprofloxacin, and the presence of the 
gyrA C248T mutation was confirmed by PCR and sequencing. Next, a 1 kb parC fragment 
encompassing C260G was amplified from a genome sequenced P. aeruginosa clinical isolate using 
primers SR80 (5′-ggccagtgccaagcttgaccttcctgctcgatacc-3′) and SR82 (5′-
acgaattcgagctcgccggtctcgtagaccttctg-3′), which was inserted into pEXAp. The resulting suicide 
vector was used to introduce the mutation into NB52023 gyrA C248T as described above, except 
that merodiploids were resolved on L-agar containing sucrose and 2 µg/mL ciprofloxacin. The 
presence of parC C260G was confirmed by PCR and sequencing. The resulting gyrA parC double 
mutant was designated NB52023-CDK0006. 
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MIC50/90 Panel: A panel consisting of 126 Gram-negative clinical isolates, including 96 
Enterobacteriaceae and 30 P. aeruginosa, was assembled from the Novartis collection. The 
isolates were acquired between 2000 and 2016 from various geographic regions and included the 
following Enterobacteriaceae species: Citrobacter spp., Enterobacter spp., Escherichia coli, 
Klebsiella oxytoca, K. pneumoniae, Morganella morganii, Proteus mirabilis, and Serratia 
marcescens. 
Table 9.  Wild type and mutant bacterial strains used in this study 
Novartis 
Strain Code 
Referred to as Description Source or 
Reference 
E. coli    
NB27001 E. coli WT ATCC 25922 ATCC 
NB27178 E. coli-∆acrB BW25113 ΔacrB, JW0451-2 Ref97 
K. pneumoniae    
NB29002 K. pneumoniae WT ATCC 43816 ATCC 
P. aeruginosa    
NB52019 P. aeruginosa WT K767; PAO1, prototroph Ref98 
NB52023 P. aeruginosa ∆mexB 
∆mexXY 
K1542; K767 ∆mexB ∆mexXY Ref99 
   NB52023-   
   CDK0006 
P. aeruginosa 
∆mexB∆mexX FQ-R 





All studies were approved by the Institutional Animal Care and Use Committee of Novartis 
Institutes for BioMedical Research, Inc. (Emeryville, CA, USA). Female CD-1 mice (17–20 g; 
Envigo, Livermore, CA, USA) and male Wistar-Han rats (250-300 g, CRL, Raleigh, North 
Carolina, USA) were kept under controlled conditions with food and water ad libitum. 
Pharmacokinetic studies were performed in mice and rat with drug concentrations determined by 
LC-MS/MS. All analysis was performed using Phoenix WinNonLin 6.4 to generate PK 
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parameters. The AUC was obtained from the measured plasma concentrations versus time using 
the trapezoidal method. 
In Vivo PK Studies: All animal studies were conducted under a Novartis-Emeryville IACUC 
approved protocol in compliance with Animal Welfare Act regulations and the Guide for the Care 
and Use of Laboratory Animals. Animals were fasted overnight and dosed IV and PO at the 
targeted doses in a solution of 20% PEG300 and 5% Solutol in D5W or saline water. The whole 
blood was collected into vials containing EDTA at post-dose 0.083, 0.25, 0.5, 1, 2, 4, 6, 8 and 24 
hours, and immediately placed on dry ice until all samples were stored in –80 °C freezer. Prior to 
analysis, the samples were thawed on ice. Ten microliters of each blood sample were added to 80 
µL of acetonitrile containing Internal Standard (CHIRO73911) and centrifuged 3450 xg at 10 °C 
for 20 minutes. A 70 µL aliquot of the supernatant was transferred into a microtiter plate and dried 
down at 40 °C, and the residue was reconstituted with 100 µL of 0.1% FA in water. An aliquot of 
each sample was injected into the liquid chromatography/mass spectrometry/mass spectrometry 
(LC-MS/MS) system for analysis. Non-compartmental PK analysis was conducted using Phoenix 
WinNonLin 6.4 professional TM (6.4) (Certara, inc., Menlo Park, CA) to generate pharmacokinetic 
parameters. 
In Vivo Pharmacology Studies 
Inoculum preparation: An overnight culture of E. coli ATCC 25922 was prepared by 
inoculating 25 mL Mueller–Hinton Broth with 20 μL of bacterial strain from frozen stock. The 
culture was allowed to grow for 16–18 h at 37°C with agitation at 150 rpm (I2400 Incubator 
Shaker; New Brunswick Scientific). An aliquot was taken, centrifuged and the bacterial pellet 
resuspended in sterile saline (0.9% w/v). Using optical density: CFU correlations, the inoculum 
was prepared at 2 × 107 CFU/mL by diluting with sterile saline. 
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Neutropenic murine thigh infection: Animals (4 mice/group) were rendered neutropenic by 
intraperitoneal injections of 150 and 100 mg/kg cyclophosphamide (Sigma–Aldrich, St Louis, 
MO, USA), on days −4 and −1 respectively prior to infection. Two hours prior to treatment (−2 h), 
50 μL of bacterial inoculum was administered into the left gastrocnemius muscle via an 
intramuscular injection. At time 0 h, animals were treated via the subcutaneous (sc) route of 
administration  with doses from 2.5-120 mg/kg. At 0 h a cohort of animals was sacrificed via 
CO2 to determine the bacterial levels at the start of treatment. The remaining animals were 
euthanized 24 h after the start of therapy. The infected thighs were excised and homogenized in 
sterile saline (0.9% w/v) until the tissue was completely homogenized. The homogenates were 
serially diluted in sterile saline before dilutions were plated on TSA plates, incubated overnight at 
37°C, the colonies and. CFU/thigh determined. 
Calculation of static dose: The static dose (mg/kg/day) is that which is required to keep the 
bacterial load at the same level as when therapy was initiated. Dose/day was plotted against 
log10 CFU and analysed using a four parametric logistic curve (SigmaPlot 12.0; SyStat Software, 
San Jose, CA, USA). The static dose was calculated using the following equation: log10 static 
dose = {Log10 [E/(Emax − E)]/N} + log10 ED50, where E is the control growth (log10 change in CFU 
per thigh in untreated controls after the 24 h period of study), Emax is the maximum effect, ED50 is 
the dose required to achieve 50% of Emax, and N is the slope of the dose–effect curve.  
In vitro ADMET Assays 
LogD7.4 determination: Compound stock solutions (10 μL, 10 mM in DMSO) were placed in 
each well of a 96 well plate. 5 μL of 2 mM Halodipine (logD = 3.00) was added to each well as an 
internal standard (IS) and mixed. DMSO was removed using a lyophilizer (overnight). 250 μL of 
water (PBS, pH = 7.4)-saturated octanol was added to each well followed by 250 μL of octanol-
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saturated water (PBS, pH = 7.4) and the plate was vortexed overnight. 100 μL of the octanol phase 
was removed from each well, diluted 1:100 with DMSO and 1 uL was injected into a LC/UV/qTOF 
system (RP column). 100 μL of the water phase was removed from each well and 10 μL was 
injected into the LC/UV/qTOF system (RP column). Data was processed with ProfileLynx. Mass 
chromatograms were integrated, corrected for dilution and injection volumes and, finally, 
corrected using area ratio of internal standard. IS peak areas were adjusted to fit the theoretical 
concentration for aqueous and octanol phases for the known logD value.  
LogD was calculated according to the following: 
Analyte logD = log(Ratio_oct/Ratio_aq) 
Ratio_oct = (Undiluted analyte_peak area/Adjusted IS_peak area)oct 
Ratio_aq = (Undiluted analyte_peak area/Adjusted IS_peak area)aq 
Solubility determination: 20 µL of 10 mM DMSO compound stock solution was transferred 
into a 96 deep well “sample plate”. 5 µL of 10 mM DMSO stock solution was transferred to a 
second “compound standard plate”. The sample plate was placed in a Multi-Tainer MT-4 container 
(FTS Systems) and freeze-dried overnight to remove DMSO. 100 µL of PBS (pH 7.0) was added 
to the dried compound in the sample plate and 95 µL of DMSO to the standard plate. The sample 
plate was sonicated in a water bath for 10 min. The two plates were then placed onto a VWR orbital 
shaker to equilibrate for 24 hours at room temperature, then centrifuged at 4000 rpm for 30 min. 
10 µL aliquots of supernatant from the sample plate were removed and diluted 5-fold. Compound 
standard and sample were injected into a UPLC/UV/CLND/MS system to generate multi detector 
qualitative and quantitive analytical data. Data was processed with Xcalibur. CLND equimolar  
response was used for measuring compound concentration of DMSO solution and UV270 nm or 
MS relative ratio for was used for solubility determination.  
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pKa Measurements: pKa values were determined using the UV-metric method as described 
previously.101 UV-metric ionization constants were determined on the commercial Spectral 
Gradient Analyzer (SGA) or T3 instrument (Sirius Analytical Ltd., sirius-analytical.com) as 
described by Allen et al.102 Test compounds were diluted to 0.04 mM in a cosolvent mixture and 
titrated three times in 20–40% wt methanol. The titrations were performed at 25 °C and 0.15 M 
ionic strength, from pH 2 to 12 or 12 to 2 (with delta pH of 0.2) depending on the acidic or basic 
nature of the test compound. A linear buffer was added to allow fast pH stabilization after each 
titrant addition. Wavelengths from 230 to 450 nm were typically monitored for UV absorbance 
change due to the ionization state of the compound. Target factor analysis (TFA) was used to 
calculate apparent pKas from the multiwavelength absorption data at a given percent of cosolvent 
(psKa), followed by Yasuda–Shedlovsky extrapolation to 0% methanol to provide the aqueous 
pKa. Acid/base assignment was performed based on the slope of extrapolation.  
Metabolic stability in liver microsomes: Test compounds at 1 µM in duplicate were incubated 
at 37 oC in the presence of 0.5 mg/mL liver microsomal protein suspension, 1 mM NADPH, 1 mM 
UDPGA, 3 mM MgCl2, and 25 µg alamethicine per mg of microsomal protein. Sequential samples 
were collected at 0, 5, 15, and 30 minutes of the incubation. DMSO final concentration in the 
incubation was 0.01%. Bioanalysis was carried out using semi-quantitative LC-MS/MS method in 
MRM mode. Then compound concentration (Peak area ratio to internal standard) against time is 
plotted to obtain elimination rate constant (k) for intrinsic clearance estimation: Intrinsic Clearance 
= (-k) / [microsome protein]. 
Compounds were tested in the following number of individual experiments (replicates). For 
compounds with more than one replicate, data is presented as an average: compound 5: 4 
replicates; compound 10: 2 replicates; compound 34: 1 replicate. 
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In vitro plasma protein binding: Compounds were spiked into plasma of selected species (male 
CD-1 mouse, male Sprague Dawley rat or pooled human plasma, all in lithium heparin 
preparations, BioreclamationIVT) in the “plasma chamber” of a Rapid Equilibrium Device (RED, 
Thermo Scientific) plate at a final concentration of 10 µM (1% DMSO in the incubation), and 
allowed to reach equilibrium between the “plasma chamber” and “buffer chamber” (100 mM PBS) 
for four hours in a shaking incubator (37 oC, 800 rpm). Compounds were tested in duplicates. At 
the end of incubation, samples were collected from plasma and buffer chambers followed by 
bioanalysis using LC-MS/MS. The percent plasma protein binding of a test compound was 
estimated using the following equation: 
PPB (%) = 100 × (1 – Cbuffer / Cplasma)    
Where Cbuffer and Cplasma are compound concentrations in the buffer and plasma chambers at 
equilibrium, respectively. 
Recovery of a compound after the incubation was also calculated as % Recovery: 
Recovery (%) = 100 × (Cbuffer  × Vbuffer + Cplasma  × Vplasma) ∕ (C0 × Vplasma)     
Where Vbuffer and Vplasma are incubation volumes in buffer and plasma chambers, respectively.  
C0 is the initial compound concentration in plasma at the beginning of the incubation. 
The data presented for compounds 5 and 10 represents the results of a single experiment. Data 
for compound 34 represents the average of two individual experiments (replicates). 
CACO-2 Permeability: CACO-2 cells were cultured for 21 days on 96-well transwell plates. 
Test compound solutions were prepared by diluting 7 µL of 2 mM DMSO stock solution in 
transport buffer to a final volume of 1.4 mL (final compound concentration was 10 µM). Test 
compound solutions were transferred to either the apical or basolateral chambers of the 96-well 
transwell plates (the donor wells). Transport buffer was then added to the respective receiver wells. 
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Plates were then incubated for 2 hours at 37 °C with shaking/vortex. Donor wells were sampled at 
t = 0. Apical and basolateral wells were sampled at t = 2 hours. Samples were analyzed by LC-
MS-MS. Transport from A-B and B-A was measured in triplicate. Apparent compound 
permeability is calculated as follows: 
Papp = (∂Q/∂t)*(1/AC0) 
where ∂Q/∂t is the total amount of compound transported to the recipient chamber per unit time 
(e.g., nmol/sec); A is the surface area of the transport membrane (cm2) and C0 is the initial 
compound concentration in the donor chamber (e.g., nmol/mL). Papp is expressed as cm/sec. 
Compounds were tested in the following number of individual experiments (replicates). For 
compounds with more than one replicate, data is presented as an average: compound 5: 2 
replicates; compound 10: 2 replicates; compound 34: 1 replicate. 
hERG Manual Patch Clamp Electrophysiology: HEK293 cells stably transfected with the 
alpha-subunits of the hERG (University of Wisconsin, USA) were continuously maintained and 
passaged using standard cell culture media (Gibco-BRL, Switzerland). For experiments, the cells 
were plated onto sterile glass coverslips in 35 mm2 dishes at a density of 1.1-1.5 x 105 cells per 
dish. The dishes were stored in a humidified and gassed (5% CO2) incubator at 37ºC until use.  
The effect on hERG currents was assessed by means of the patch clamp technique in the whole-
cell configuration at 35  2°C. The corresponding vehicle for all superfusion concentrations was 
0.1% DMSO. The vehicle effect was investigated in 5 cells. The effect of the positive controls 100 
nM E-4031 (Calbiochem, Switzerland) was investigated in 2 cells. Cells were exposed to the test 
item for approximately 10 min. hERG tail currents were elicited by voltage jumps from -75 mV to 
+10 mV (500 ms) and then to -40 mV (500 ms) at 0.1 Hz. The composition of the extracellular 
solutions was [mM]: NaCl 137; KCl 4; CaCl2 1.8; MgCl2 1.0; D-glucose 10; N-2-
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hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES) 10; pH 7.4 (adjusted with 5 M NaOH).  
The composition of the pipette solutions was (mM): KCl 130; MgCl2 1.0; Ethylene glycol-bis(ß-
aminoethyl ether)-N,N,N’,N’-tetraacetic acid (EGTA) 5; Mg-ATP 5; HEPES 10; pH 7.2 (adjusted 
with 1 M KOH).  The compound effect on the currents was corrected by the mean vehicle rundown 
which was observed (n=5) by the treatment with extracellular solution containing 0.1 % DMSO. 
Data capturing and analysis was performed by using Pulse (Heka Electronics, Germany) and 
Excel. 
The data presented for compounds 5 represents the results of a single experiment.  
Automated Electrophysiology: hERG expressing cell lines were produced in-house at Novartis 
using CHO-K1 T-RexTM inducible plasmid system (Invitrogen) as described previously.103 Cell 
lines were maintained in Ham’s F12 Nutrient Mixture containing 10% FBS, blasticidin (10 
mg/mL; InvivoGen), hygromycin B (200 mg/mL; InvivoGen), Zeocin (200 mg/mL, Invitrogen) 
and neomycin (200 mg/mL, Invitrogen) using SelecT™ automated cell culture system (TAP 
Biosystems, Cambridge, UK). hERG and hCav1.2 channels expression was induced with 
tetracycline (0.25-1 µg/ml, Invitrogen) at least 24 hours prior to the experiment. 
hERG currents were recorded using the Qpatch automated patch clamp systems (Sophion 
Bioscience Inc., North Brunswick, NJ) in the whole (single) cell configuration. hERG expressing 
CHO-K1 cells were harvested with Detachin (Genlantis) and stored in the modified serum-free 
SFM-2 media (life Technologies) at room temperature. The extracellular solution contained (in 
mM) NaCl (145), KCl (4), MgCl2 (1), CaCl2 (2), and HEPES (10), pH 7.4 with NaOH. The 
intracellular solution contained KCl (135), MgCl2 (1.75), CaCl2 (5.4), EGTA (10), K2-ATP (4), 
and HEPES (10), pH 7.2 with KOH. After whole cell configuration was achieved, the cell was 
held at -90 mV, and a 0.1-sec pulse to -50 mV was delivered to measure the leaking current, which 
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was subtracted from the tail current on-line. Then the cell was depolarized to +20 mV for 4 seconds 
(pre-pulse), followed by a 4-sec test pulse to -50 mV to reveal hERG tail current. To monitor 
changes in the current amplitude, this voltage protocol was repeatedly applied every 20 sec. Test 
compounds were first diluted in DMSO for six dose-response experiments and then dissolved in 
the extracellular solution using Freedom EVO liquid handling robotic system (Tecan, Männedorf, 
Switzerland). The final DMSO concentration in samples was 0.3% v/v. Amitriptyline (Sigma) was 
tested as a positive control. Data were analyzed using in-house developed MatLab-based program 
(MathWorks, Natick, MA). 
hERG QPatch testing for compound 34 was performed using a long incubation protocol (10 
minutes per concentration point). To avoid current rundown during prolonged incubation, current 
was measured in duplicate ([11 and 100 µM] and [33 and 300 µM] concentration pairs) in different 
cells simultaneously. The results of these measurements were combined into one DR-plot. Data 
were analyzed manually using Sophion QPatch Assay software. 
The data presented for compounds 10 and 34 represents the results of a single experiment. 
Cytotoxicity assay: K562 (human leukemia cells), Molt-4 (T-lymphoblast derived from acute 
lymphoblastic leukemia) and HepG2 (human hepatocellular carcinoma cells) were used to 
determine compound cytotoxicity. Cell viability was quantified by using CellTiter-Glo®, which 
measures ATP release based on the mono-oxygenation of luciferin catalyzed by Mg2+, ATP and 
molecular oxygen. 
Cell line maintenance media - K562 cells were maintained in Iscove's Modification of 
Dulbecco's Modified Eagle's Medium (IMDM) supplemented with 1% penicillin/streptomycin and 
10% heat–inactivated fetal bovine serum (FBS). Molt-4 cells were maintained in Roswell Park 
Memorial Institute (RPMI 1640) culture medium supplemented with 1% penicillin/streptomycin 
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and 10% heat-inactivated FBS. HepG2 cells were maintained in Dulbecco's Modified Eagle's 
Medium (DMEM)-F12 supplemented with 1% penicillin/streptomycin and 10% heat–inactivated 
FBS. 
Cells were counted using a hemocytometer and diluted to 2x104 cells/mL for K562, 1x105 
cells/mL for Molt-4, and 5x104 cells/mL for HepG2 in the appropriate culture media. 50 µL of cell 
suspension were added to each well of the 384-well assay plate containing 1 µL of serial diluted 
compound (100 µM top concentration, 3.16x dilution factor) using the BioTek Multiflo-Stacker 
liquid dispenser. Plates were incubated 72 hours at 37 ºC, 5% CO2 and 90% humidity. 25 µLof 1X 
CellTiter-Glo® were then added to each well of the assay plate. Plates were incubated for 10 
minutes at room temperature before reading on the PolarStar-Omega plate reader using the 
Luminescence settings and a gain of 3300. The 50% cytotoxic concentrations (CC50) were 
determined. When multiple CC50 were determined for the same compound the average is reported. 
If one or more CC50 for the same compound showed a value > 100 µM (top concentration tested), 
100 µM was used as the value in the average calculation.  Compound 34 was tested in the following 
number of individual experiments (replicates): 3 (HepG2 and K562), 2 (MT4). 
In vitro 3T3 NRU phototoxicity test: In vitro phototoxicity assessment was conducted as 
described previously.58 Mouse Balb/c 3T3 fibroblast cells were treated with the test item for one 
hour and, subsequently, either irradiated with simulated sunlight for 50 minutes (normalized to 1.7 
± 0.1 mW/cm2 of UVA, resulting in a normalized radiation dose of 5.1 ± 0.3 J/cm2 UVA), or kept 
in the dark for 50 minutes. After medium replacement and approximately 24 hours recovery cell 
viability was assessed using the Neutral Red Uptake (NRU) endpoint. IC50 values were derived 
from the concentration-response curves obtained with and without irradiation and used to calculate 
the PIF (Photo Irritation Factor, PIF) as follows: 
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PIF = IC50 (-irr) / IC50 (+irr) 
In the case of compounds 15, 21 and 34, an IC50 was not achieved in the absence of irradiation. 
As a surrogate, the solubility limit during incubation was used (500 µM for 15, 316 µM for 21 and 
1000 µM for 34). In parallel, the known phototoxic compound chlorpromazine was tested as a 
positive control. 
X-ray Crystallography Studies 
Cloning, protein expression and purification: A K. pneumoniae Topoisomerase IV ParE-ParC 
fusion gene was made by fusing the C-terminal domain of parE (residues 390-631) and the N-
terminal domain of parC (residues 1-490) linked by a 2 amino acid Glu-Phe linker. The resulting 
construct (Kp ParEC) was inserted into a pETite vector (Lucigen) harboring a C- terminal 6 X-
histidine tag. OverExpress C41 (DE3) cells (Lucigen) were then transformed with this construct 
and grown at 37 °C in Terrific Broth. Protein expression was induced with 100 µM IPTG. Cells 
were pelleted and resuspended in 20 mM Tris pH 8.0, 200 mM NaCl, 10% glycerol, 2 mM TCEP, 
1 mM EDTA and Roche protease inhibitor and lysed in a pneumatic cell homogenizer. The cleared 
lysate was supplemented with imidazole and MgCl2 to final concentrations of 10 mM and 1.5 mM, 
respectively, and loaded on a immobilized metal chelate affinity column and eluted with increasing 
imidazole concentrations. The fusion protein was then further purified on a Q Sepharose ion 
exchange column equilibrated with 20 mM Tris pH 8.0, 10% glycerol and 2 mM TCEP and eluted 
with column equilibration buffer including 1 M NaCl. Protein containing fractions were pooled 
and further purified on a Superdex 200 SEC column equilibrated with 20 mM Tris pH 7.5, 100 
mM NaCl, and 2 mM TCEP. The fusion protein (MW ~84 kDa) was concentrated to 7.6 mg/mL, 
flash frozen in liquid nitrogen and stored in –80 °C for up to 6 months. A total of 22 mg of Kp 
ParEC with >95% purity was purified from 2 L of cell culture.  
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Crystallography: HPLC purified symmetric DNA oligo 5′-
TTACGTTGTATGATCATACAACGTAA-3′ was ordered from IDT and dissolved in 10 mM 
Tris-HCl pH 7.5 and 50 mM NaCl. The DNA was annealed by denaturing at 95 °C and slow 
cooling to room temperature in a thermos flask over 48 hours to form a 1 mM solution of 
symmetric duplex DNA. The protein-DNA-compound ternary complex was made by mixing 23 
uM (4 mg/mL) Kp ParEC dimer with 28 µM duplex DNA and 0.2 mM compound 34 and incubated 
overnight at 17 °C. Complex crystals were grown by the sitting drop vapor diffusion method at 18 
°C and appeared after 24 to 48 hours. 200 nL complex solution was mixed with 100 nL 
crystallization solution (20 mM MgCl2, 40 mM LiCl, 2 mM hexamine cobalt chloride, 40 mM 
sodium cacodylate trihydrate pH 5.5, and 30% MPD) and crystals were frozen in liquid nitrogen 
directly from the drop. Diffraction data were collected at the beamline 5.0.2 at the Advanced Light 
Source in Berkeley and processed with XDS. The structure was solved by molecular replacement 
using PDB 5EIX as starting model using Phaser.104 The model was improved to convergence by 
iterative rounds of model rebuilding in Coot105, 106 and refinement using phenix.refine of the Phenix 
suite.107, 108  
 
ASSOCIATED CONTENT 
Supporting Information  
The following files are available free of charge. 
Crystallographic data table for the structure of K. pneumoniae topoisomerase IV bound to 
compound 34; unbiased electron-density difference map (Fobs-Fcalc) for 34 bound to K. 
pneumoniae topoisomerase IV; interaction diagram of compound 34 bound to topoisomerase IV 
from K. pneumoniae; plot of CFU/thigh determined for each dose of compound 34 in the 
 123 
neutropenic murine thigh infection model; SEC chromatograms showing separation of 
supercoiled and relaxed DNA and detection of decatenated kDNA; LC/MS traces of all final 
compounds (PDF)  
Molecular Formula Strings (CSV) 
Accession Codes 
Structural coordinates for compound 34 have been deposited in the RCSB Protein Data Bank 
under the accession codes 6WAA. Authors will release the atomic coordinates and experimental 
data upon article publication.   
AUTHOR INFORMATION 
Corresponding Author 
*E-mail: colin.skepper@novartis.com. Phone: +1 510 879 9317 
Author Contributions 
Alexey Rivkin was the Project Team Leader for this drug discovery program. The manuscript 
was written through contributions of all authors. All authors have given approval to the final 
version of the manuscript.  
Funding Sources 
This work was funded by Novartis AG. 
ACKNOWLEDGMENTS 
The authors thank Haiying He, Zhigan Jiang and Jianhua Xia (WuXi AppTec) for synthesis of 
early compounds in this series including 4 and 5; Shengtian Yang for NMR structure elucidation 
support; Weiping Jia, Heidi Struble, Dazhi Tang and Alice Wan Wang for analytical and 
 124 
separations support; Linhong Yang for pKa determination; Colin Lorentzen, Kent Wong and 
Linda Xiao for in vitro ADME assays; Srijan Ranjitkar for construction of the bacterial strain P. 
aeruginosa ∆mexB∆mexX FQ-R. Johanne Blais is gratefully acknowledged for assistance in 
writing and editing this manuscript. 
ABBREVIATIONS 
ADMET: Absorption, Distribution, Metabolism, Excretion, Toxicity; BA: bioavailability; 
BINAP: 2,2′-Bis(diphenylphosphino)-1,1′-binaphthalene; Cmax: maximum plasma concentration; 
CDI: carbonyl diimidazole; CL: clearance; CLint: intrinsic clearance; DIPEA: N,N-
diisopropylethylamine; DPPF: 1,1′-ferrocenediyl-bis(diphenylphosphine); FQ: fluoroquinolone; 
FQ-R: fluoroquinolone resistant;  %F: percent orally bioavailable; fAUC: free (unbound) area 
under the curve; LiHMDS: lithium bis(trimethylsilyl)amide; MeCN: acetonitrile; NaHMDS: 
sodium bis(trimethylsilyl)amide; QRDR: quinolone resistance determining region; QT interval: 
the time that elapses between the beginning of the Q wave and the end of the T wave in an 
electrocardiogram; SAR: structure-activity relationship; SEMCl: 2-(Trimethylsilyl)ethoxymethyl 
chloride; Tmax: time at which maximum plasma concentration was reached; Vss: volume of 
distribution. 
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